VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 22 (1-12 octubre/2025)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el ojetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.
- Patentes más recientes en USPTO.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Noticias en la Web

Qdenga - A Promising Dengue Fever Vaccine

Oct 1. Dengue fever is transmitted through mosquito bites, and while mosquito control remains essential, vaccination offers an additional layer of protection. The World Health Organization (WHO) classifies dengue as one of the top 10 global health threats, with cases increasing tenfold from 500,000 in 2000 to over five million in 2019. In 2023 saw an unprecedented surge in dengue cases, with the first-ever global figures exceeding 6.5 million cases and over 6,800 deaths.Cases were reported in over 80 countries across Africa, the Americas, South-East Asia, the Western Pacific, and the Eastern Mediterranean regions. Asia recorded the highest case fatality ratio in 2023. In that year Bangladesh experienced its deadliest dengue outbreak in two decades, with 1,705 deaths out of 321,179 confirmed cases, a fatality rate of 0.53%.

In addition, spatial and temporal shifts in dengue patterns were observed in 2022 and continued in 2023. Nepal and Bangladesh experienced spikes in case numbers earlier than usual. Cases in Nepal shifted from the Kathmandu Valley in 2022 to the southeast Terai region and hill districts in Gandaki province in 2023. India, in 2023, experienced an increase in cases in Kerala and northeastern States bordering Bangladesh compared to the previous year. Vietnam has experienced dengue fever peaks approximately every 10 years between 1980 and 2018. However, the period from 2019 to 2023 saw two epidemic peaks in 2019 and 2022. In 2022, Vietnam reported over 367,000 dengue cases, second only to Brazil globally. WHO estimates about 390 million dengue infections occur worldwide annually, with 96 million symptomatic cases, 500,000 hospitalizations, and 40,000 deaths.

Vulnerable Populations and Treatment

Anyone can contract dengue fever, but children, pregnant women, and individuals with chronic diseases or obesity are at higher risk. Untreated dengue can lead to severe complications, including hypotension, heart failure, kidney failure, hemorrhagic shock, multiple organ failure, cerebral hemorrhage, and coma. Currently, treatment focuses on managing symptoms through blood filtration, plasma exchange, and anti-shock measures. The cost of treating a severe case can cross the economic ability of most of the people.

The approved dengue vaccines are Dengvaxia® and Qdenga® (TAK-003), with varying efficacies and recommended populations. Dengvaxia® has an efficacy of approximately 60–80% for preventing symptomatic dengue, but it is restricted to children aged 9-16 with a confirmed prior dengue infection due to an increased risk of severe disease in seronegative individuals. On the other hand Qdenga® shows higher overall efficacy, with around 80% protection against symptomatic dengue in both seropositive and seronegative individuals aged 4 and older.

Qdenga was invented by Takeda Pharmaceuticals, a Japanese company that developed the live, attenuated dengue vaccine (TAK-003) to protect against all four dengue virus serotypes. Regulatory

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

bodies that approved Qdenga include the European Medicines Agency (EMA) and the European Commission (EC) in 2022, followed by other countries like Indonesia, Great Britain, Brazil, and Argentina.

As of September 2025, QDENGA was authorized in 40 countries and available in 27 countries, including Indonesia (approved Aug 2022, available April 2023), Brazil (approved Mar 2023, available June 2023, Thailand (approved May 2023, available Aug 2023), Argentina (approved Apr 2023, available Oct 2023), (approved February 2024), and is also available in Vietnam.

Efficacy and Impact of Qdenga

The Qdenga vaccine has demonstrated an efficacy of up to 80% in protecting against all four dengue virus types. More importantly, it reduces the risk of hospitalization by up to 90%. This is particularly crucial in different countries like Bangladesh, where a significant portion of the population has been infected with dengue fever at least once. Subsequent infections tend to be more severe, making timely vaccination a vital preventive measure.

A vigorous consultation with all concern stakeholders early engagement with Takeda to secure a substantial supply of the vaccine may emphasis the commitment to reducing the annual burden of dengue fever.

Our people are frequent travelers to dengue-endemic areas and there is already a demand and questions on how and when to use the vaccine. Therefore, the Vaccine Expert group of the Swedish Society for Infectious Diseases Physicians have reviewed the literature to guide and formulate recommendations on the use of Qdenga® as a travel vaccine.

For travelers with previous known self-reported (hospitalized or policlinic testing) dengue fever, vaccination is recommended before travel to an endemic country.

For dengue naïve travelers vaccination may be considered in individuals aged 4–16 years old irrespective of travel duration.

For travelers aged 17–60 years old are recommended considering vaccination only for longer trips and related to travel destination. They also have suggested a trip for more than six weeks to South-East Asia, a region with among the highest global incidence of dengue fever, to be used as a reference.

Since Qdenga® has not yet been studied in individuals >60 years old, they clearly advise vaccination should be avoided in this group until data are available.

Travelling after only one vaccine dose should be avoided if possible, which is a challenge for most travelers coming with shorter notice for travel medicine advice. It can be considered, especially in individuals with previous dengue fever, given that they receive the second dose after return. As far as we know these recommendations are more cautious than in other non-endemic countries, especially regarding the upper age limit, and should be continuously revised when more information and experience become available. For safely travelling and living, management of aedes mosquitoes along with vaccination is essential.

Fuente: Daily Sun. Disponible en https://n9.cl/u1cg8

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

New research finds HPV vaccine delivers herd immunity, protecting unvaccinated women

Oct 1. A study spanning nearly two decades has found that vaccinating communities against human papillomavirus (HPV) doesn't just protect those who receive the shot, it also helps shield women who haven't been vaccinated.

A girl with a health worker during a HPV vaccination session in Eswatini. Credit: Gavi/2025/Svetlomir Slavchev

HPV is the main cause of cervical cancer – a leading cause of death among women, especially in low- and middle-income countries.

The HPV vaccine, if received in early adolescence, is known to be highly effective at preventing cervical cancer in later life.

Led by researchers at Albert Einstein College of Medicine and published in *JAMA Pediatrics*, the research analysed data on more than 2,300 adolescent and young adult women aged 13 to 26 years at enrolment, from 2006 to 2023.

The researchers found that HPV vaccination programmes offered significant protection through herd immunity: immunity conferred on unvaccinated people when enough people are vaccinated in a community.

Widespread vaccination would have lowered overall transmission of the virus, benefitting even those not immunised.

Dr Jessica Kahn, professor of paediatrics at the Albert Einstein College said that while randomised controlled studies had clearly shown the value of the HPV vaccine, the team wanted to "evaluate how the vaccine works in real-world settings that included young women who were at relatively high risk for HPV and had different levels of vaccine uptake".

Dramatic drops in HPV infections

Over the study period, HPV vaccination coverage in Cincinnati, USA, where the study data was taken from, rose from 0% to 82%.

During that time, HPV infections in vaccinated women fell steeply:

- In women covered by the bivalent vaccines against HPV types 16 and 18, infections dropped by 98.4%
- In women covered by the quadrivalent vaccines against HPV types 6, 11, 16 and 18, infections fell by 94.2%
- Infections of types addressed by the newer nonavalent vaccine dropped by 75.7%

Even among women who never received the vaccine, infection rates for HPV types covered by older vaccines declined dramatically.

- Infections with HPV types included in the bivalent vaccine decreased by 71.6%
- Infections with HPV types included in the quadrivalent vaccine dropped by 75.8%

Data for herd immunity from the nonavalent vaccines is still underway.

The decline is attributed to vaccination

"Our analysis of the data indicates that those reductions in infection rates were primarily due to the vaccine's introduction and not because of changes in sexual behavior or other factors," said Aislinn DeSieghardt, the

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

paper's first author and clinical research coordinator at the Cincinnati Children's Hospital Medical Center.

Because the study tracked trends over such a long span and included women at higher risk (for example many had multiple sexual partners or prior STIs) the results offer compelling "real-world" validation of the vaccine's broader population impact.

The study reinforces that strong vaccine uptake in a community can have important collateral benefits, reducing the burden of HPV even among those who are unvaccinated.

Dr Kahn concludes that "By expanding uptake of this highly safe and effective vaccine, and ensuring access to screening and treatment, we can achieve one of the greatest public health victories of our time: the elimination of cervical cancer worldwide."

Fuente: Gavi. Disponible en https://n9.cl/v7sag

New study shows all-in-one coronavirus vaccines could save millions of lives in future pandemics

Oct 2. A new study published in *Nature Communications* reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

The research, led by Imperial College London and supported by CEPI, modelled the potential impact of broadly protective sarbecovirus vaccines — innovative vaccines that could defend against multiple viruses including a novel sarbecovirus, referred to as SARS-X. Sarbecoviruses are types of coronaviruses that include both SARS-CoV-1, which caused the 2002–2004 SARS outbreak, and SARS-CoV-2, which continues to cause COVID-19.

Broadly protective sarbecovirus vaccines could be manufactured and stockpiled ahead of time and deployed as soon as a new coronavirus is detected, protecting the most vulnerable in the critical early months of a future outbreak while a new vaccine targeting the specific pathogen is being developed.

The modelling shows that, during a SARS-X outbreak, vaccinating high-risk populations aged 60 years and older with a broadly protective sarbecovirus vaccine could reduce mortality by more than half, while also cutting the need for disruptive non-pharmaceutical interventions, such as lockdowns, by more than 60 percent.

"COVID-19 showed us the catastrophic costs of facing a deadly new virus without a vaccine," said Dr Richard Hatchett, CEO of CEPI. "Broadly protective coronavirus vaccines could change the game. They would buy us valuable time in a future pandemic—saving lives, easing the burden on health systems, and helping societies to stay open—while scientists develop vaccines specifically targeting the new pathogen."

Vaccines to stay one step ahead of coronaviruses

The study explored multiple scenarios, from SARS-CoV-1-like outbreaks with limited transmission to highly transmissible SARS-CoV-2-like pandemics, and considered a range of assumptions about the size of the vaccine stockpile and the stringency of non-pharmaceutical interventions.

- Modelling shows that broadly protective sarbecovirus vaccines could halve the number of deaths in a future pandemic.
- Stockpiled vaccines would dramatically reduce the need for non-pharmaceutical interventions like lockdowns.
- If they had been available during the COVID-19 pandemic, as many as 65 percent of deaths could have been averted in the first year.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

It found that in outbreaks caused by slower-spreading viruses, using broadly protective sarbecovirus vaccines in ring vaccination strategies—where contacts of infected individuals are rapidly immunised—could help to contain transmission and bring an outbreak to an end. For fast-spreading viruses, like SARS-CoV-2, all-in-one shots would not contain outbreaks but could slow the spread of the disease and provide critical protection for those most at risk until a vaccine tailored to the new virus is developed.

In a scenario where it takes 250 days to create such a virus-specific vaccine, broadly protective vaccines could cut deaths in an average upper-middle-income country by more than half.

Even in a scenario in which CEPI's 100 Days Mission is achieved—a goal to develop new vaccines within 100 days of a pandemic pathogen being identified—and a virus-specific vaccine is available in just three months, all-in-one vaccines would provide a crucial safeguard against more transmissible pathogens. Faced with a pathogen with a reproduction rate of R0=3.5 – similar to that of smallpox, for example – broadly protective sarbecovirus vaccines could reduce deaths by 43 percent and the number of days under non-pharmaceutical interventions by almost 70 percent.

Dr Charlie Whittaker, Assistant Professor, Infectious Diseases & Vaccinology, University of California, Berkeley, who led the modelling study, said: "Our work highlights that a stockpiled broadly protective coronavirus vaccine could halve deaths in a future pandemic. Achieving this impact depends on more than just the vaccines alone though - it will require investment in manufacturing and delivery systems to ensure equitable global access, so that everyone, everywhere can benefit when the next pandemic arrives."

The researchers also looked back at the COVID-19 pandemic to assess the potential impact of broadly protective sarbecoviruses had they been available. They estimate that as many as 65 percent of deaths could have been averted during the pandemic's first year, depending on the size of the stockpile. For example, a moderate stockpile with enough doses to vaccinate 60 percent of older adults, could have saved 64,000 lives in Italy (52 percent of those who died), 56,000 lives in Iran (45 percent) and 89,000 lives in Bangladesh (69 percent) during that period.

CEPI's leadership in broadly protective vaccines

CEPI is a world leader in advancing broadly protective sarbecovirus vaccines, committing over US$200 million to date in a portfolio of vaccines spanning a diverse range of technologies. From RNA to protein-based candidates, the CEPI-supported vaccines each use different strategies for achieving broad protection.

Dr Hatchett added: "We cannot predict when or where the next coronavirus outbreak will emerge, but we can prepare. By investing in all-in-one vaccines now, CEPI is boosting the world's defences against future coronavirus pandemics."

The modelling study was conducted by a consortium of researchers from Imperial College London, the University of California, University of New South Wales, Duke-NUS Medical School, the London School of Hygiene & Tropical Medicine, National University of Singapore, National Centre for Infectious Diseases Singapore, Nanyang Technological University Singapore, and CEPI.

The full study is available open access in Nature Communications: Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemic | Nature Communications

Fuente: CEPI. Disponible en https://n9.cl/4zd7o

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Alerta mundial: la OMS confirma la nueva cepa de COVID-19 "Stratus" con un síntoma inesperado que la delata



3 oct. La Organización Mundial de la Salud emitió una advertencia sobre una nueva variante del coronavirus que está ganando terreno en los primeros compases del otoño.

Con la llegada de temperaturas más bajas y las primeras lluvias, los virus respiratorios encuentran su entorno ideal para propagarse, y esta nueva cepa denominada Stratus está demostrando una capacidad de transmisión preocupante.

Lo que distingue a esta variante del resto no son solo sus índices de contagio, sino un síntoma particular que está sirviendo como señal de alarma: la ronquera persistente.

Los datos más recientes indican que esta variante ya se detectó en 38 países y representa más del 20% de todos los casos de COVID-19 registrados actualmente a nivel mundial. Aunque las autoridades sanitarias califican el riesgo para la salud pública como bajo, la rapidez de su expansión puso en alerta a los sistemas de vigilancia epidemiológica de todo el planeta.

¿Qué es exactamente la variante Stratus y por qué preocupa a los expertos?

La cepa Stratus, identificada científicamente como XFG, pertenece a lo que los virólogos denominan combinaciones resultantes de la recombinación de dos o más cepas preexistentes. En este caso específico, Stratus es el resultado de la fusión entre las variantes LF.7 y LP.8.1.2, ambas circulantes anteriormente.

Este tipo de recombinaciones genéticas no son inusuales en virus ARN como el SARS-CoV-2, especialmente cuando múltiples variantes coexisten en la misma población. Lo que sí resulta destacable es la velocidad con la que Stratus logró posicionarse como una de las cepas dominantes en un período relativamente corto, superando ya el 20% de prevalencia en el mundo.

A pesar de su rápida propagación, la OMS mantiene una evaluación de riesgo bajo para la salud pública, sugiriendo que, si bien es más transmisible, no parece causar enfermedad más grave que sus predecesoras.

El síntoma revelador: ronquera persistente que marca la diferencia

La característica más llamativa de la variante Stratus es sin duda la ronquera o disfonía que están experimentando la mayoría de los pacientes infectados. Este síntoma, que implica una alteración en la calidad de la voz, va desde una ligera aspereza hasta la pérdida casi completa de la capacidad de hablar con normalidad.

Los especialistas explican que esta afectación vocal sugiere una predilección particular de esta variante por las vías respiratorias superiores, específicamente la laringe y las cuerdas vocales. Mientras que variantes anteriores también podían causar dolor de garganta, la ronquera marcada no había sido un síntoma tan predominante.

Además de la alteración vocal, los pacientes con Stratus continúan presentando el cuadro clínico habitual del COVID-19: congestión nasal, dolor de garganta y de cabeza, fiebre, fatiga extrema y en algunos casos, molestias digestivas.

Fuente: El Cronista. Disponible en https://n9.cl/swnehj

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

AI can strengthen pandemic preparedness

Oct 3. How to identify the next dangerous virus before it spreads among people is the central question in a new Comment in The Lancet Infectious Diseases. In it, researchers discuss how AI, combined with the One Health approach, can contribute to improved prediction and surveillance.

"Artificial intelligence cannot by itself prevent pandemics, but the technology can be a powerful supplement to the knowledge and methods we already use. The better we become at integrating data from humans, animals, and the environment, the better prepared we will be," says Professor Frank Møller Aarestrup from the DTU National Food Institute in Denmark, one of the authors of the Comment.

It was co-authored by Professor Marion Koopmans from the Erasmus Medical Center in the Netherlands. She warns that once a disease starts spreading, it is very hard to bring under control.

"The interventions required are drastic—as we saw during COVID-19. That is why it is crucial to detect new pathogens before they gain a foothold," says Koopmans, noting that once established, new diseases can become persistent challenges, as COVID-19 has also shown.

The team of authors, which also includes experts from Eötvös Loránd University (ELTE) in Hungary, the University of Bologna in Italy, and the UK Animal and Plant Health Agency, speaks from their experience as collaborators over years, focusing on One Health approaches to emerging disease preparedness in the VEO consortium—a European research initiative developing data-driven tools to detect and track emerging infectious diseases.

Pandemics often originate in animals

The outbreaks of diseases such as SARS-CoV-2, avian influenza, and mpox demonstrate the difficulty of controlling new potential epidemics. Many pathogens originate in animals, but when and where they will spill over into humans is unpredictable.

The authors of the Comment highlight how climate change, intensive animal production, and human encroachment into natural habitats increase the risk of so-called spillover events—situations in which pathogens cross from animals to humans and, in the worst case, develop into epidemics.

Spillovers have been likened to sparks: most extinguish, but some ignite fires that spread uncontrollably. Being able to detect such spillovers as early as possible is a challenge that the team has been studying using big data approaches.

AI can reveal patterns in complex datasets

Artificial intelligence can help to analyze such datasets from diverse sources—such as climate, land use, animal production, transport, population movements, and socio-economics. When these datasets are combined, AI can reveal patterns that would otherwise be difficult to discern.

"AI can help us identify where in the world surveillance should be intensified geographically, but also in specific animal species, in wastewater, or in humans. In this way, we can prioritize efforts where the risks are greatest, so-called hotspots," says Aarestrup.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Genetic signals as early warning

Once such hotspots are predicted, metagenomic sequencing can be added as a catch-all approach for detection of pathogens, both known and new ones. Metagenomic sequencing is the analysis of genetic material—in samples from wastewater, air, food, or the environment. It is increasingly used to provide insight into a vast diversity of known and unknown microorganisms. Many of the genetic fragments identified are not yet characterized.

"When we sequence a sample, we may find millions of genetic fragments. Most resemble something familiar and harmless, but we are left with thousands of unknowns. Here, AI can help detect patterns and point to what might be dangerous," explains Aarestrup.

Once it is clear there is a potential pathogen, questions can arise about how dangerous it is. The potential for viruses from animals to infect humans, spread and cause disease in part is embedded in the genetic code. AI-based tools can be used to predict how mutations might alter viral properties.

"We see huge developments in this area. AI-based protein models can provide an indication of what a mutation does to the structure of viruses, and how that then can be translated to risk of spread, or risk of severe disease. While challenging now, we see great potential for the use of AI to speed up risk assessment," says Koopmans.

AI as a co-scientist—opportunities and limitations

The comment also describes early prototypes of so-called AI "co-scientists," capable of conducting an entire research cycle—from hypothesis generation and literature review to data analysis and reporting.

"I envisage AI becoming a recognized competence at the table—on a par with different types of researchers. AI can deliver analyses or suggestions that we as scientists can evaluate. In that way, the technology becomes a supplement that can strengthen our decision-making processes," says Aarestrup.

"That also implies that we need to learn what our future role is as teachers and supervisors. How do we make sure that the novel ways of working provide trustworthy output? Will we be able to recognize mistakes with advancements of AI models? We also need to go back to the classroom. Really exciting," says Koopmans.

The authors conclude that artificial intelligence offers intriguing possibilities for enhancing pandemic preparedness. Still, it must be seen as a complement—not a replacement—to the classical surveillance and research approaches already in use.

Fuente: medicalxpress. Disponible en https://n9.cl/gvb77

Cuba vacunará a niñas de nueve años contra el VPH

3 oct. Autoridades sanitarias anunciaron la inclusión de la vacuna contra el Virus del Papiloma Humano (VPH) en el Programa Nacional de Inmunización, con la aplicación a todas las niñas de nueve años en Cuba.

Dagmar García, vicedirectora del Instituto Finlay de Vacunas, explicó que la decisión respondió a la relación comprobada entre la infección persistente por VPH y el cáncer de cuello uterino, una de las principales causas de muerte por cáncer en mujeres a nivel mundial, precisó el diario Granma.

La especialista acotó que se empleará la vacuna CECOLIN, de tipo bivalente, que protege contra los serotipos 16 y 18,

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

responsables de alrededor del 70 por ciento de los casos de esa enfermedad.

García señaló que la inmunización resulta más efectiva antes del inicio de la vida sexual, por lo cual se determinó aplicarla a niñas de nueve años, en correspondencia con las recomendaciones internacionales.

La vacuna CECOLIN, producida por la empresa china Innovax, cuenta con la precalificación de la Organización Mundial de la Salud y ha demostrado seguridad y eficacia en su uso.

El Programa Nacional de Inmunización, en funcionamiento desde 1962, administra cada año un promedio de 4 800 000 dosis de 13 tipos de vacunas, de las cuales ocho son de producción nacional.

Gracias a ese programa, Cuba eliminó seis enfermedades transmisibles, entre ellas la poliomielitis y el sarampión, y redujo complicaciones graves como el síndrome de rubéola congénita.

Con la incorporación de la vacuna contra el VPH, el país refuerza su estrategia de prevención y se adelanta en más de una década a la aparición de casos de cáncer cervicouterino en las nuevas generaciones.

Fuente: El Artemiseño. Disponible en https://n9.cl/14ywy

Europa compra la vacuna de Hipra contra la COVID-19 adaptada a LP.8.1

4 oct. La Autoridad de Preparación y Respuesta ante Emergencias Sanitarias de la Comisión Europea (HERA, por sus siglas en inglés) y la farmacéutica biotecnológica Hipra han firmado un contrato de compra de su vacuna Bimervax, de proteína recombinante monovalente con adyuvante adaptada a la variante LP.8.1 de la COVID-19. El acuerdo, con una duración de hasta dos años, permitirá a los países acceder a hasta 4 millones de dosis de la vacuna proteica de Hipra, sin que exista una obligación mínima de compra. Las entregas se realizarán a tiempo para la campaña de vacunación de este otoño, lo que refuerza la preparación de la Unión Europea frente al virus en los próximos meses.

La firma se ha llevado a cabo en Bruselas el viernes 3 de octubre entre David Nogareda, presidente y CEO de HIPRA, y Laurent Muschel, director de la Health Emergency Preparedness and Response Authority (HERA).

Hadja Lahbib, comisaria europea de Igualdad, Preparación y Gestión de Crisis, señaló que “con el aumento de casos de la variante conocida como ‘Frankenstein’, debemos garantizar que se mantiene la protección frente a esta enfermedad, especialmente para las personas más vulnerables. Con un portafolio diversificado de vacunas, que ahora incluye hasta 4 millones de dosis de esta vacuna proteica, reforzamos nuestra preparación y aseguramos el suministro de soluciones médicas necesarias frente a la amenaza constante de la Covid-19. La vacuna de Hipra sigue un enfoque integral, desde la investigación hasta la producción, íntegramente en Europa, lo que fortalece nuestra autonomía estratégica. Estamos comprometidos con reforzar nuestra seguridad sanitaria para una Europa más segura, saludable y mejor protegida”.

Aunque las vacunas de ARNm ya están disponibles, este contrato de adquisición conjunta diversifica el acceso para los ciudadanos europeos al incluir una vacuna de proteína recombinante. La vacuna de HIPRA, que ha recibido recientemente autorización de comercialización de la Comisión Europea tras demostrar que genera inmunidad frente a la variante LP.8.1 y protección cruzada frente a variantes emergentes como NB.1.8.1 y XFG, está lista para su distribución en viales monodosis y puede almacenarse entre 2 °C y 8 °C durante 12 meses.

Los estudios realizados con la vacuna original y con su adaptación han demostrado que es segura, con menos efectos secundarios que la comparativa de ARNm y genera una respuesta inmunitaria fuerte, duradera y con amplia reactividad cruzada frente a variantes emergentes.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Durante la firma, David Nogareda, presidente y consejero delegado de Hipra, subrayó que “este acuerdo es una muestra de confianza en la capacidad de Hipra para contribuir a la protección de la salud pública. Desde la investigación hasta la fabricación, todo el proceso tiene lugar en Europa, lo que nos permite garantizar calidad, seguridad e independencia estratégica. Con este contrato, reforzamos no solo la respuesta frente a la COVID-19, sino también la preparación de Europa ante futuros retos sanitarios”.

Fuente: DiarioFarma. Disponible en https://n9.cl/k03dpa

A next-generation vaccine technology has been developed that has a stronger immune effect than conventional injections

Oct 5. A next-generation vaccine technology has been developed that has a stronger immune effect than conventional injections just by applying it like a lotion without a syringe. It is predicted that it will not only dramatically increase the convenience of vaccination by eliminating pain and rejection, but also increase vaccine efficacy, which can emerge as a new alternative to the vaccine market in the future.

[Picture = Pixabay]

A joint research team from France's National Institute of Health and Medicine (INSERM) and King's College London in England has developed a new platform technology that delivers vaccines in a way that gently increases the skin with special devices, according to the international journal "Cell Reports."

The key to this technique is the gentle tension it puts on the skin. When the skin is relaxed for about 20 minutes with a device developed by the research team, collagen fibers in the skin are rearranged and hair follicles (fur holes) are temporarily opened. This is the principle that vaccine antigen particles penetrate deeply into the skin effectively through this gap.

The biggest finding of this study is that the act of increasing the skin itself, beyond simple drug injection, acts as a powerful 'immune promoter'. When the skin is relaxed, it has been confirmed that immune cells recognize the fine introduced skin bacteria as external invasion and operate the immediate defense system. In other words, the effectiveness of the vaccine can be maximized without a separate immunostimulator.

In fact, the research team administered the flu vaccine to mice in this way, and as a result, antibodies were formed at a much higher level than the general muscle injection method.

Dr. Stuart Jones, King's College London, UK, who led the study, said, "It has led to a more effective immune response just by increasing the skin than by needle inoculation. This is a practical achievement that can change the existing notion of vaccine delivery."

The research team expected that the technology developed this time could be widely used to deliver not only vaccines but also various biopharmaceuticals such as cell therapy and polymer drugs without pain in the future.

Fuente: MAEIL BUSINESS NEWSPAPER. Disponible en https://n9.cl/rgppux

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

CEPI backs new research into vaccines against multiple deadly filoviruses

Oct 6. CEPI will fund new research conducted by scientists at the Stanford School of Medicine to study whether new vaccines could offer broad protection against multiple deadly pathogens from the filovirus viral family.

Supported by up to $18 million in CEPI investment, researchers will design and test new vaccine constructs that could provide all-in-one protection against viruses including Zaire Ebolavirus, Marburg and Sudan Ebolavirus, and even filoviruses that we don't yet know about that could spill over from animals into humans in the future.

"A broadly protective filovirus vaccine could transform the world's defences against outbreaks of some of the world's most dangerous pathogens, for the benefit of all," explains CEPI's Executive Director of Research & Development Dr Kent Kester. "If we solve the scientific challenge of developing all-in-one filovirus vaccines now, we can ensure the world is ready to respond at speed to newly emerging filoviruses and potentially take the threat of future filovirus pandemics off the table."

The research will use cutting-edge artificial intelligence to design immunogens – the substance in a vaccine that provokes an immune response – that may be capable of protecting against more than one filovirus. These immunogens will be combined with a ferritin-based protein-nanoparticle vaccine platform to create a range of vaccine candidates that will be tested in preclinical studies to establish proof of concept. The most promising vaccine candidate will be advanced to the point where it is ready to rapidly enter Phase I clinical trials should an unknown filovirus outbreak emerge.

The ferritin nanoparticle vaccine platform is favourable for use in low- and middle-income countries as it does not require complex frozen storage that can impact access to doses in low-resource settings. It has previously been tested in Phase I clinical trials for influenza and COVID-19 vaccines, which generated positive safety data.

Professor Peter S. Kim, the Virginia & D.K. Ludwig Professor of Biochemistry, at the Stanford School of Medicine, and Principal Investigator on the project said: "We are excited to collaborate with CEPI to develop a globally effective broad-spectrum vaccine to protect against future filovirus pandemics."

Preparing for both known and unknown filovirus threats

Filoviruses such as Ebolavirus Zaire, Sudan Ebolavirus and Marburg cause frequent outbreaks in African countries, characterized by high fatality rates and significant societal and economic impacts. A single vaccine capable of combating all of these known threats could offer a cost-effective solution for proactively immunizing those who are most likely to be infected by one or more of the viruses.

Crucially, the project will also equip scientists with the tools they need to respond at pace if faced with an unknown pathogen – a so-called 'Disease X' - from the filovirus family. The scientific knowledge and immunogen designs generated by the research will be added to CEPI's 'Disease X Vaccine Library', a comprehensive collection of vaccine data and information about the most worrying viral families that can be rapidly adapted for use during outbreaks of novel viruses with pandemic potential.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

This approach to significantly accelerate vaccine development is central to the 100 Days Mission: a global goal, spearheaded by CEPI and embraced by G7 and G20 nations to develop pandemic-busting vaccines in just 100 days and make the world a safer place for all.

Committing to equitable access

CEPI is committed to enabling equitable access to the outputs of this project, in line with CEPI's Equitable Access Policy. This ultimately includes a commitment to vaccines being available first to populations at risk when and where they are needed, including specific obligations in the agreement related to affordable pricing and supply volumes for public health needs. It also includes sharing of any commercial benefits arising from CEPI's funding. Should the project be successful, CEPI has the option to explore providing further funding to the Stanford School of Medicine to develop its vaccine product and/or its immunogen designs, potentially combining them with other vaccine platforms via CEPI matchmaking for pandemic preparedness and response. Project results, including related data, will be published open access for the benefit of the global scientific community.

Fuente: CEPI. Disponible en https://n9.cl/7by7t

Pneumococcal Conjugate Vaccine Booster Maximizes Protection Against IPD

Oct 7. Pneumococcal conjugate vaccines (PCVs) were deemed highly effective in preventing invasive pneumococcal disease (IPD) among children, according to a study published in Vaccine: X. The study also revealed that PCV booster doses play a key role in maximizing vaccine type-IPD protection within the same population.

"Streptococcus pneumoniae is a bacterial pathogen responsible for a wide range of diseases, from mucosal infections, such as otitis media, sinusitis, and pneumonia, to IPD, which includes bacteremic pneumonia, sepsis, and meningitis," wrote the authors of the study. "High-risk populations include children under 5 years, adults over 65 years, individuals with immunocompromising conditions, those with chronic comorbidities, and individuals with lifestyle risk factors such as smoking, alcohol misuse, and being unhoused."

According to CDC data, IPD incidence falls at 8.3 cases per 100,000 patients. Further stratifying these statistics, the average mortality rate was 1 death per 100,000. Accounting just for children under the age of 18, this age group's incidence rate was 6.9 per 100,000. Finally, these data also showed a trend of greater risk for IPD complications as ages were reported to be lower.

Despite the continued prominence of IPD, especially among older adults and pediatric patients, its common occurrence has been significantly ameliorated through the introduction of PCVs.

Indeed, after the US' implementation of PCV7 in 2000, rates of pediatric IPD have decreased significantly. Because of vaccine protection against IPD, childhood rates of the disease decreased by 72% from 2002 to 2021. Since the introduction of all new PCVs following PCV7, researchers are still trying to determine the proper dosing and administration of PCVs to maximize protection against pediatric IPD.

"While previous research has evaluated overall [vaccine effectiveness (VE)], the impact of different pneumococcal dosing regimens remains unclear," they continued. "Given the importance of optimizing pneumococcal vaccination strategies, we aim to evaluate the effectiveness of PCV7 and PCV13 based on the number of vaccine doses received in this systematic review and meta-analysis."

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

To go about reassessing PCV7 and PCV13, researchers conducted a systematic review and meta-analysis of studies that explored the VE of each PCV valency among patients 18 years and younger.

More specifically, to determine VE among this population, researchers separated participating patients into 4 groups based on vaccination status at the onset of children's IPD. The 4 groups were a primary plus booster group (1 to 3 primary doses less than 12 months of age plus 1 booster dose 12 months or greater); the 1 primary dose group; 2 primary doses group; and 3 primary doses group (primary doses given <12 months of age and no booster).

With patients telling providers their vaccination status while also reporting IPD, the researchers were better able to determine how effective they were and what the ideal PCV dose should be.

After identifying 1982 studies on their initial search, study experts concluded their review with a total of 25.

"Pooled results showed that children receiving 2 or 3 primary doses without a booster had a higher risk of IPD compared with those completing a schedule with a booster dose (2 + 1 or 3 + 1 schedules)," wrote the authors. "Our findings reinforce the existing evidence supporting a vaccination schedule that includes a booster dose, as we found neither 2 nor 3 primary doses alone consistently achieved a pooled VE of >90% as with a schedule including a booster dose."

Previous evidence has shown that IPD can occur in vaccinated individuals due to PCV7 and PCV13's inability to protect against vaccine serotypes 3 and 19A. However, with the current finding of the booster's significant success over 1, 2, or even 3 doses of the primary vaccine alone, researchers uncovered an ideal PCV regimen for keeping children protected against IPD. As long as primary vaccine doses are accompanied by a subsequent booster, children 18 years and under can become even better protected against IPD.

"Our study reaffirms the high overall effectiveness of PCVs in preventing IPD in children and highlights the essential role of the booster dose in maximizing protection against [vaccine type]-IPD," concluded the authors. "As many countries transition to reduced dosing schedules to improve cost-effectiveness, streamline immunization programs, and address vaccine supply constraints, our findings emphasize the need for a full vaccination series that includes a booster to ensure optimal protection against IPD."

Fuente: Drug Topics. Disponible en https://goo.su/Hr3Dy7

New Vaccine Shows Promise Against Typhoid and Invasive Salmonella in First Human Trial

Oct 8. Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (CVD) have completed a successful Phase 1 clinical trial of a novel vaccine designed to protect against both typhoid fever and invasive non-typhoidal Salmonella--two major causes of illness and death among children in sub-Saharan Africa.

Results were published today in the journal *Nature Medicine*.

The investigational Trivalent Salmonella Conjugate Vaccine (TSCV) includes sugar molecules taken from the outer coating of the Salmonella typhi bacteria that cause typhoid and the two most common types of invasive Salmonella infections that are not associated with typhoid caused by Salmonella enterica. These sugars are attached to special proteins that help the body recognize and respond to the bacteria more effectively.

In the randomized, placebo-controlled Phase 1 trial, 22 healthy adults in the US received either a low dose (6.25 µg) or high dose (12.5 µg) of TSCV, or a placebo shot. The vaccine was found to be safe and well-tolerated, with only mild, short-lived injection site pain reported.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Importantly, 100 percent of the vaccine recipients developed strong immune responses to all three polysaccharide components, while none of the placebo recipients did.

"These results are highly encouraging," said study lead investigator Wilbur Chen, MD, MS, Professor of Medicine at UM School of Medicine and Chief of the Adult Clinical Studies section within CVD. "They show that TSCV has the potential to protect children in regions where both typhoid and salmonella are endemic and deadly."

The vaccine also has the potential to protect Americans against Salmonella infections, one of the leading causes of foodborne illness. Every year, bacteria from raw or undercooked chicken and eggs and contaminated produce cause 1.35 million Salmonella infections in the US and more than 26,000 hospitalizations, according to the Centers for Disease Control and Prevention. The serotypes targeted by the TSCV vaccine are among the most common in US infections.

In fact, some study participants showed pre-existing antibody responses, suggesting prior exposure to the bacteria via foodborne illness. Such priming might have led to stronger and longer-lasting immunity in the adult study volunteers, though researchers remain optimistic about the vaccine's effectiveness in infants and young children in endemic regions.

The vaccine triggered a strong and balanced immune response, including long-lasting antibodies—even at lower doses. It also activated a specific immune defense involving white blood cells that help clear infections, which hadn't been seen before with one of the vaccine's protein components. These findings suggest the vaccine could offer both gut-level and whole-body protection against Salmonella.

"These findings provide a strong foundation for future studies," said study co-author Myron Levine, MD, DTPH, professor emeritus at UM School of Medicine and CVD founding director. "We plan to explore broader functional assays to identify correlates of protection and evaluate TSCV's performance in young children—the population most vulnerable to these diseases."

The vaccine was developed in collaboration with Bharat Biotech International Limited (BBIL), building on their WHO-prequalified Typbar TCV™ platform.

"In 2017, sub-Saharan Africa saw over 420,000 cases of Salmonella disease and 66,000 deaths, primarily among children," said Mark T. Gladwin, MD, Dean of the UM School of Medicine. "Typhoid fever caused an additional 650,000 cases and nearly 9,000 deaths in the region. A single vaccine that protects against both could be a game-changer for global pediatric health."

Fuente: School of Medicine, University of Maryland. Disponible en https://goo.su/A4XiSiL

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Moderna opens Oxfordshire site for vaccine development

Oct 9. The new Moderna Innovation and Technology Centre, which will develop and manufacture mRNA vaccines, has been officially opened by Health and Social Care Secretary Wes Streeting.

Pioneering US biotech firm Moderna will be able to make millions of vaccines for seasonal viruses like COVID-19, create dozens of highly skilled jobs, and help Britain prepare for future pandemics thanks to its cutting-edge research centre in Harwell, Oxfordshire.

The new Moderna Innovation and Technology Centre is the latest addition to the UK's £100 billion life sciences sector to come out of Moderna's 10-year strategic partnership with the government. The partnership also includes an over £1 billion programme of investment in UK R&D being brought forward by the company, tapping into the UK's deep skills base, world-class academic institutions, and the power of the NHS as an engine for research and innovation.

The facility will support around 150 highly-skilled jobs, while enabling groundbreaking work on the use of mRNA vaccine technology to tackle cancer and seasonal infections like flu, RSV and COVID-19, subject to the usual regulatory processes. RNA technology is an emerging field of healthcare with the potential to overhaul how we tackle a wide range of diseases that currently cause ill-health and distress.

It could also be utilised to produce up to 250 million vaccine doses a year in the event of a pandemic, making a critical contribution to national resilience to future health emergencies, by building the UK's capacity to produce cutting-edge therapies at scale, at home, should they be needed.

To support further game-changing investments in life sciences R&D, the government is piloting the Life Sciences Transformational R&D Investment Fund. This new £50 million fund aims to bolster the UK's research and development infrastructure by supporting large-scale, capital-intensive projects in the life sciences sector worth over £100 million.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The fund is designed to attract substantial private investment in UK-based R&D, reinforcing the UK's position as the location of choice for life sciences innovation, and pulling in the investment that is a vital part of economic growth.

Science Minister Lord Vallance said: "The UK's life sciences sector is a fundamental part of our nation's health and economy, and will be critical to our ambitions going forward. The pioneering work Moderna will be doing, here in the UK, on mRNA is a prime example of the opportunity we want to grasp. It's the chance for new treatments that save lives, and new products that drive growth and job creation, all made possible thanks to our world-class institutions, skills, and the NHS. It is this unique mix that makes the UK a life sciences destination that punches well above its weight. The opening of this centre is proof of the brilliant things coming out of the deep and meaningful relationships we're determined to forge with companies like Moderna. This Innovation Centre will strengthen the UK's growth, health, and our resilience."

Professor Susan Hopkins, CEO, UK Health Security Agency (UKHSA) said: "The opening of this impressive state of the art facility in Harwell, alongside Moderna's substantial investment in UK research and development, will help ensure the NHS has rapid access to mRNA vaccines if needed in a future pandemic. It will also open doors to new vaccine products, helping support the government's 10 Year Health Plan and the focus on prevention. I'm delighted that UKHSA leads the partnership on behalf of government. It is an exemplar on how we and government can work closely with industry to prepare and respond to emerging health threats. It will support the UK's ambitions towards the 100 Days Mission, helping put the UK at the forefront of pandemic preparedness and new technologies whilst driving economic growth."

Moderna is best-known for developing one of the first COVID jabs put to use during the pandemic. These vaccines were based on messenger RNA technology: an emerging field of healthcare with enormous potential – ranging from cancer therapies currently being trialled on the NHS, to new vaccines for seasonal infections like flu and norovirus.

Moderna are also investing in UK R&D more broadly – ranging from clinical trials, to backing for postgraduate researchers. The company was one of the largest industry sponsors of clinical trials in the UK in 2024, and its investment is helping to get a larger number and broader range of volunteers involved in clinical trials, as part of the UK Vaccine Innovation Pathway. Moderna's 10-year strategic partnership with the government is managed by the UKHSA.

Fuente: PATHOLOGY IN PRACTICE. Disponible en https://goo.su/E2IivU

Five-Fold Shield: The Latest Advancements in Meningococcal Vaccine Technology

Oct 10. In the realm of public health, the continuous evolution of vaccines plays a pivotal role in safeguarding communities against various infectious diseases. One such groundbreaking development is the introduction of a new meningococcal vaccine that takes immunization to the next level. This vaccine targets not one or two, but an impressive five bacterial strains in a single shot, marking a significant stride in the fight against meningococcal disease. Understanding Meningococcal Disease: Meningococcal disease is a serious bacterial infection caused by Neisseria meningitidis. It can manifest as meningitis (inflammation of the membranes surrounding the brain and spinal cord) or septicemia (bloodstream infection). This disease can progress rapidly and lead to severe complications, making vaccination a crucial preventive measure. The Challenge of Multiple Strains: Traditionally, meningococcal vaccines have focused on specific strains, providing protection against the most prevalent ones. However, the emergence of new strains and the variability in regional

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

prevalence pose challenges in designing effective vaccines. The new breakthrough addresses this challenge by targeting five bacterial strains in a single vaccine, offering a more comprehensive defense against the diverse nature of meningococcal infections.

Key Features of the New Meningococcal Vaccine

1. Broad Spectrum Protection: Unlike previous vaccines that focused on individual strains, this new vaccine covers a spectrum of five bacterial strains, providing a more inclusive defense mechanism.
2. Reduced Dosage Frequency: The consolidation of multiple strains into one vaccine means fewer shots are needed for comprehensive protection. This not only simplifies vaccination schedules but also improves adherence to immunization programs.
3. Enhanced Immune Response: The formulation of the vaccine is designed to stimulate a robust immune response against each targeted strain, ensuring a higher level of protection compared to previous vaccines.
4. Global Impact: Given the vaccine's ability to target multiple strains, it holds promise for global vaccination campaigns, especially in regions where meningococcal disease is prevalent with varying strains.

Potential Challenges and Considerations: While the new meningococcal vaccine represents a significant leap forward, there are considerations to address. These may include:

- regulatory approvals
- distribution logistics
- ongoing surveillance

to monitor the long-term effectiveness and safety of the vaccine. Click here to see the full scientific article from Very Well Health. The development of a meningococcal vaccine targeting five bacterial strains in one shot is a remarkable achievement in the field of vaccinology. It not only addresses the challenges posed by diverse strains but also offers a more streamlined approach to immunization. As this breakthrough progresses through clinical trials and regulatory processes, it brings hope for a future where meningococcal disease can be more effectively controlled on a global scale, potentially saving countless lives.

Fuente: Asher Longevity Institute ALIVE. Disponible en https://goo.su/h9wu9b

Pfizer (PFE) Faces Challenges Amid Drug Pricing Push

Oct 11. Pfizer (PFE) experienced a significant drop last week, with its stock falling 9.41% as the company navigates challenges amid ongoing U.S. efforts to reform drug pricing. The pharmaceutical giant is part of a new direct-to-consumer platform, TrumpRx, which aims to offer sharp discounts on prescription medicines. Meanwhile, President Trump and Commerce Secretary Howard Lutnick's families could see financial gains from these initiatives, according to reports. The recent developments have sparked considerable movement within the healthcare sector.

Pfizer Inc, one of the world's largest pharmaceutical firms, generates annual sales of approximately $60 billion. Historically, the company sold a variety of healthcare products and chemicals, but now prescription

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

drugs and vaccines constitute the majority of its sales. Key products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer's global reach is significant, with international sales accounting for 40% of total sales, and emerging markets playing a crucial role.

With a market capitalization of $140.89 billion, Pfizer operates within the healthcare sector, specifically in the drug manufacturers industry. The company's current stock price is $24.78, reflecting recent market volatility.

Financial Health Analysis

Pfizer's financial metrics present a mixed picture:

- Revenue for the trailing twelve months stands at $63.83 billion, with a 3-year revenue growth rate of -7.8%, indicating a decline.
- Profitability remains robust with an operating margin of 25.93% and a net margin of 16.84%.
- The gross margin is 72.12%, although it has been in long-term decline at an average rate of -4% per year.
- On the balance sheet, Pfizer maintains a current ratio of 1.16 and a debt-to-equity ratio of 0.69, indicating moderate leverage. The Altman Z-Score of 2.08 places the company in a grey area, suggesting some financial stress.

Valuation & Market Sentiment

Pfizer's valuation metrics are as follows:

- The P/E ratio is 13.18, close to its 2-year low, suggesting potential undervaluation.
- The P/S ratio is 2.21, near a 10-year low, further indicating a favorable valuation.
- Analyst target price is $29.21, with a recommendation score of 2.5, reflecting a hold position.

Technical indicators show a 14-day RSI of 46.64, suggesting the stock is neither overbought nor oversold. Institutional ownership stands at 65.5%, with insider ownership at 0.28%.

Risk Assessment

Pfizer's financial health is supported by a Piotroski F-Score of 7, indicating a healthy situation. The Beneish M-Score of -2.52 suggests the company is unlikely to be a manipulator.

Sector-specific risks include regulatory changes in drug pricing and competitive pressures in the pharmaceutical industry. The stock's beta of 0.37 indicates lower volatility compared to the market.

Overall, while Pfizer faces challenges in revenue growth and regulatory pressures, its strong profitability and favorable valuation metrics provide a balanced outlook for investors.

- Pfizer (PFE, Financial) stock experienced a significant decline of 9.41% last week amid U.S. drug pricing reform efforts.
- The company is involved in TrumpRx, a new platform aimed at providing discounted prescription medicines.
- Pfizer's financial health shows mixed signals with strong profitability but declining revenue growth.

Fuente: GURU FOCUS. Disponible en https://n9.cl/20k6f

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2025/10/01"[Date - Publication] : "2025/10/12"[Date - Publication])) 741 records

Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis.

Hulscher N, Hodkinson R, Makis W, McCullough PA.ESC Heart Fail. 2025 Oct;12(5):3212-3225. doi: 10.1002/ehf2.14680. Epub 2024 Jan 14.PMID: 38221509

Vaccine Economics, Private Equity, And More.

Metz DE, The Editorial Staff.Health Aff (Millwood). 2025 Oct;44(10):1217. doi: 10.1377/hlthaff.2025.01299.PMID: 41052390

Effect of JYNNEOS vaccination on mpox clinical progression: a case-control study.

Granskog L, Saadeh K, Lorenz K, Quint J, Salih T, Lo T, Jacobson K, Ramos M, Chapman E, Snyder RE, Lewnard JA.Lancet Infect Dis. 2025 Oct;25(10):1106-1115. doi: 10.1016/S1473-3099(25)00180-X. Epub 2025 May 21.PMID: 40412423

Care-Vax: integrazione digitale ospedale-territorio per la tutela dei pazienti fragili e il potenziamento della copertura vaccinale secondo i principi della value-based healthcare.

Cocolicchio D, De Vita V, Cuoco F, Tona D, Porcelli M, Postorino D, Scaglioso F, Pascucci D, Regazzi L, Pastorino R, Laurenti P.Recenti Prog Med. 2025 Oct;116(10):617-618. doi: 10.1701/4573.45803.PMID: 41037387

Iron deficiency and vaccine efficacy: A mini-review of immunological interplay and evidence across vaccine types.

Mohammed J, Parveen A, Ubaid Chhapra H, Naaz Mashooq F, Shadan M.Hum Vaccin Immunother. 2025 Dec;21(1):2572195. doi: 10.1080/21645515.2025.2572195. Epub 2025 Oct 9.PMID: 41066388

Applying principles of vaccine development to oncomicrobial vaccines.

Despins CA, Viegas NJ, Holt RA.Blood Adv. 2025 Oct 1:bloodadvances.2024015610. doi: 10.1182/bloodadvances.2024015610. Online ahead of print.PMID: 41031833

Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles.

Neukirch L, Uhrig-Schmidt S, von Werthern K, Tuch A, Kraske JA, Lyu Y, Lenoir B, Eichmüller SB, Meyer M, Zörnig I, Jäger D, Schmidt P.Mol Ther. 2025 Oct 1;33(10):5003-5016. doi: 10.1016/j.ymthe.2025.07.014. Epub 2025 Jul 16.PMID: 40671675

Unscientific vaccine policy endangers vulnerable patients.

The Lancet Rheumatology.Lancet Rheumatol. 2025 Oct;7(10):e659. doi: 10.1016/S2665-9913(25)00262-0. Epub 2025 Sep 12.PMID: 40953576

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Varicella-zoster virus reactivation and the risk of dementia.

Polisky V, Littmann M, Triastcyn A, Horn M, Georgiou A, Widenmaier R, Anspach B, Tahrat H, Kumar S, Buser-Doepner C, Geldsetzer P, Van Duijn CM, Schwab P.Nat Med. 2025 Oct 6. doi: 10.1038/s41591-025-03972-5. Online ahead of print.PMID: 41053450

Dynamics of virus-specific CD8+ T cells in the human nasal cavity.

Lim JME, Ottolini S, Hang SK, Qui MD, Chia A, Low JGH, Le Bert N, Tan AT, Bertoletti A.Mucosal Immunol. 2025 Oct;18(5):1218-1227. doi: 10.1016/j.mucimm.2025.07.007. Epub 2025 Jul 22.PMID: 40706803

Targeting infection-specific peptides in immunopeptidomics studies for vaccine target discovery.

Leddy O, Yuki Y, Carrington M, Bryson BD, White FM.J Exp Med. 2025 Oct 6;222(10):e20250444. doi: 10.1084/jem.20250444. Epub 2025 Jul 21.PMID: 40689854

From Yesterday to Tomorrow: How Vaccine Platforms Have Shaped the Vaccine and Treatment Evaluation Units.

Dobrzynski DM, Graciaa DS, Babu TM, Coler RN, Paulsen GC, Hoft DF, Frey SE, Edwards KM, Jackson LA, Chen WH.Clin Infect Dis. 2025 Oct 10;81(Supplement_2):S125-S136. doi: 10.1093/cid/ciaf379.PMID: 41071740

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants.

Pichon S, Ullery GM, Cousin L, Sadarangani M, Ryu JH, Monfredo C, Mari K, Pandey A, Personnic S, Pouzet C, Manson C, Silhadi W, Minutello AM.Pediatr Infect Dis J. 2025 Oct 1;44(10):995-1008. doi: 10.1097/INF.0000000000004913. Epub 2025 Jul 31.PMID: 40833801

Operationalizing African self-reliance in vaccine manufacturing.

Mwila C, Ekström AM, Kampmann B, Swartling Peterson S, Alexander N, Dereje N, Genetu Bayih A, Kaseya J, Ottersen OP.Glob Health Action. 2025 Dec;18(1):2560209. doi: 10.1080/16549716.2025.2560209. Epub 2025 Oct 3.PMID: 41040058

Understanding COVID-19 Vaccine Uptake and Hesitancy in Latinx Sexual and Gender Minority People in North Texas.

Ali S, Griner SB, Neelamegam M, Webb N, Kline N.Int J Behav Med. 2025 Oct 3. doi: 10.1007/s12529-025-10395-6. Online ahead of print.PMID: 41044446

Personalized 3D Vaccine Integrates Immunotherapy and Antiangiogenic Therapy to Prevent Oral Squamous Cell Carcinoma Recurrence.

Ren J, Chu T, Li B, Wu S, Yang Z, Sun G, Lu Z, Qi F, Wu F, Peng Y, Li M, Zhao Y, Nie G, Wang Y, Li S.Adv Mater. 2025 Oct;37(39):e2417708. doi: 10.1002/adma.202417708. Epub 2025 Jul 24.PMID: 40708335

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes.

Gristick HB, Hartweger H, Nishimura Y, Gavor E, Nagashima K, Koranda NS, Gnanapragasam PNP, Kakutani LM, Segovia LN, Donau OK, Keeffe JR, West AP Jr, Martin MA, Nussenzweig MC, Bjorkman PJ.J Exp Med. 2025 Oct 6;222(10):e20250693. doi: 10.1084/jem.20250693. Epub 2025 Aug 12.PMID: 40794027

A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4).

Scott P, Ukkonen B, Caraco Y, Perez SN, Alpizar SA, Cardona JF, Greenberg D, Grijalva CG, Orenstein W, Wiedmann RT, Fernsler D, Cheon K, Li J, Platt HL.Med. 2025 Oct 10;6(10):100748. doi: 10.1016/j.medj.2025.100748. Epub 2025 Jun 20.PMID: 40543503

Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023-2024 Season, United States.

Tenforde MW, Reeves EL, Weber ZA, Tartof SY, Klein NP, Dascomb K, DeSilva MB, Yang DH, Grannis SJ, Irving SA, Ong TC, Link-Gelles R, Salas SB, Sy LS, Lewin B, Contreras R, Zerbo O, Fireman B, Hansen J, Timbol J, Sheffield T, Bride D, Arndorfer J, VanOtterloo J, McEvoy CE, Akinsete OO, Essien IJ, Dixon BE, Rogerson C, Fadel WF, Duszynski T, Naleway AL, Barron MA, Rao S, Mayer D, Chavez C, Ball SW, Payne AB, Ray C, Dickerson M, Neelam V, Adams K, Flannery B, DeCuir J, Garg S.Clin Infect Dis. 2025 Oct 6;81(3):667-678. doi: 10.1093/cid/ciae597.PMID: 39656838

Highly conserved Betacoronavirus sequences are broadly recognized by human T cells.

Pereira Neto TA, Zmasek C, Avalos L, Sidney J, Trevizani R, Phillips E, Mallal S, Frazier A, Tan GS, Scheuermann RH, Sette A, Grifoni A.Cell. 2025 Oct 2;188(20):5653-5665.e12. doi: 10.1016/j.cell.2025.07.015. Epub 2025 Aug 6.PMID: 40774254

Synergistic anti-tumor effects of mRNA vaccine and PERK inhibitor combination in melanoma treatment.

Li X, Ma L, Guo J, Wei Y, Ma S, Mai Y, Gou G, Zuo W, Yang J.Colloids Surf B Biointerfaces. 2025 Oct;254:114808. doi: 10.1016/j.colsurfb.2025.114808. Epub 2025 May 16.PMID: 40383023

What's Old is New Again: Pertussis.

Naureckas Li C, Edwards KM, Kaplan SL, Marshall GS, Parker S, Healy CM.Pediatrics. 2025 Oct 3:e2025072868. doi: 10.1542/peds.2025-072868. Online ahead of print.PMID: 41038623

Antibody response and safety through 12 months after booster vaccination with an investigational Lyme disease vaccine in adults: a plain language summary.

Messier M, Stark JH, Wagner L, Lamberth E.Curr Med Res Opin. 2025 Oct 6:1-2. doi: 10.1080/03007995.2025.2564929. Online ahead of print.PMID: 41051995

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Pneumococcal carriage prevalence, serotype distribution, and vaccine coverage in Ethiopia 12 years after pneumococcal vaccine introduction.

Bizuayehu HY, Kebede Y, Deressa M, Solomon E, Marami D, Karani A, Gardiner E, Dessie Y, Scott JAG, Gallagher KE.Vaccine. 2025 Oct 3;64:127762. doi: 10.1016/j.vaccine.2025.127762. Epub 2025 Sep 17.PMID: 40966977

Stapling of β-Glucans Increases Antibody Binding.

Ledvinka J, Kullmann R, Reuber EE, Weikl T, Ricardo MG, Seeberger PH.J Am Chem Soc. 2025 Oct 7. doi: 10.1021/jacs.5c12690. Online ahead of print.PMID: 41054343

From hesitancy to confidence: Shaping the future of vaccine messaging.

Dube E, Gagnon D.Hum Vaccin Immunother. 2025 Dec;21(1):2570584. doi: 10.1080/21645515.2025.2570584. Epub 2025 Oct 8.PMID: 41060260

Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.

McDaniel JR, Voss WN, Bowyer G, Rush SA, Spencer AJ, Bellamy D, Ulaszewska M, Goike J, Gregory S, King CR, McLellan JS, Hill AVS, Georgiou G, Ewer KJ, Ippolito GC.J Exp Med. 2025 Oct 6;222(10):e20241908. doi: 10.1084/jem.20241908. Epub 2025 Jul 28.PMID: 40719751

Vaccine value profile for schistosomiasis.

Yamey G, McDade KK, Anderson RM, Bartsch SM, Bottazzi ME, Diemert D, Hotez PJ, Lee BY, McManus D, Molehin AJ, Roestenberg M, Rollinson D, Siddiqui AA, Tendler M, Webster JP, You H, Zellweger RM, Marshall C.Vaccine. 2025 Oct 3;64:126020. doi: 10.1016/j.vaccine.2024.05.068. Epub 2024 Jul 23.PMID: 39592316

The relationships among psychosocial impact, professional type, and vaccine hesitancy among healthcare workers during the COVID-19 pandemic.

Huang JJ, Chou FH, Hsu ST, Hsieh KY, Lin GG, Wu PJ, Liu CL, Wu HC, Wang WC, Li DJ.BMC Psychol. 2025 Oct 6;13(1):1109. doi: 10.1186/s40359-025-03452-y.PMID: 41053821

Vaccine acceptance and refusal in Western and Central and Eastern European countries: An analysis based on the European Social Survey data from 23 countries, using a classification and regression tree.

Wróblewski M, Meler A.Vaccine. 2025 Oct 2;65:127807. doi: 10.1016/j.vaccine.2025.127807. Online ahead of print.PMID: 41043305

Mn and Zn-Doped Multivariate Metal-Organic Framework as a Metalloimmunological Adjuvant to Promote Protection Against Tuberculosis Infection.

Howlett TS, Kumari S, Ehrman RN, Masson J, Izzo L, Wang T, Gull H, Trashi I, Tang W, Trashi O, Satish N, Wijesundara YH, Herbert FC, Izzo AA, Gassensmith JJ.Adv Healthc Mater. 2025 Oct;14(26):e2402358. doi: 10.1002/adhm.202402358. Epub 2024 Dec 8.PMID: 39648542

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Protecting koalas from chlamydial disease.

Loeb J.Vet Rec. 2025 Oct 4;197(7):262-263. doi: 10.1002/vetr.6036.PMID: 41042572

Anti-vaccination of Turkish parents in forums: a qualitative study.

Gümüşay M, Sahin N.BMC Public Health. 2025 Oct 8;25(1):3374. doi: 10.1186/s12889-025-23034-2.PMID: 41063023

Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian Cancer.

Cudmore AO, Rodriguez GM, Maranda V, Farokhi Boroujeni S, Murshed H, Macdonald EA, Grondin M, Garson K, Matuszewska K, Diallo JS, Petrik JJ, Vanderhyden BC.Mol Cancer Ther. 2025 Oct 1;24(10):1626-1639. doi: 10.1158/1535-7163.MCT-24-0906.PMID: 40062380

A Synthetic Liposome Nanoparticle Vaccine Platform for Broad-Spectrum Vaccine Design.

Zhang M, Gao Z, Feng S, Wang X, Wang H, Yang C, Lin X, Xu Z, Zhang N, Li Y, Tian H, Jin N, Yu B, Wang P, Li C, Yu X.Nano Lett. 2025 Oct 1. doi: 10.1021/acs.nanolett.5c03021. Online ahead of print.PMID: 41032408

Single dose of foot-and-mouth disease peptide vaccine fully protects swine and achieves intraserotype crossed neutralization.

Blanco E, Torres E, de León P, Forner M, Bustos MJ, Hammer SE, Sobrino F, Andreu D, Defaus S.NPJ Vaccines. 2025 Oct 6;10(1):216. doi: 10.1038/s41541-025-01274-y.PMID: 41053087

Influenza vaccine effectiveness and genetic diversity: insights from end-of-season community surveillance, France, 2024-2025.

Clercq A, Blanquart F, Vieillefond V, Visseaux B, Chakra CNA, Nunes MC, Jacques A, Haim-Boukobza S, Wehrle V, Deleglise G, Duret T, Bernard-Stoecklin S, Bercoff DP, Lina B, Rameix-Welti MA, Josset L, Enouf V, Bal A; RELAB study group.Emerg Microbes Infect. 2025 Dec;14(1):2562045. doi: 10.1080/22221751.2025.2562045. Epub 2025 Oct 11.PMID: 40955037

Determinants and Motivations of Vaccination Hesitancy and Uptake in Nurses: A Systematic Review and Meta-Analysis.

Locatelli G, Luciani M, Fabrizi D, Albanesi B, Conti A, Clari M, Renzi E, Massimi A, Ausili D.J Clin Nurs. 2025 Oct;34(10):4005-4037. doi: 10.1111/jocn.17852. Epub 2025 Jun 25.PMID: 40563208

Vaccine-preventable diseases in migrants in Europe: a systematic review.

Halliday R, Morais B, Bouaddi O, Deal A, Faijue D, Bojang S, Hargreaves S.Vaccine. 2025 Oct 6;65:127788. doi: 10.1016/j.vaccine.2025.127788. Online ahead of print.PMID: 41056757

Chagas disease: host responses, parasite evasion and vaccine advances.

Serrano-Coll H.Trans R Soc Trop Med Hyg. 2025 Oct 6:traf109. doi: 10.1093/trstmh/traf109. Online ahead of print.PMID: 41048042

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Serotyping, molecular typing, and vaccine protein screening for Riemerella anatipestifer: Overcoming challenges in prevention and treatment.

Li Y, Huang Z, Zhu X, Liu C, Cao S, Li Y.Vet Microbiol. 2025 Oct;309:110663. doi: 10.1016/j.vetmic.2025.110663. Epub 2025 Aug 8.PMID: 40818300

Research hotspots and trends in tumor vaccine adjuvants: A bibliometric analysis from 2010 to 2024.

Gong L, Lu W, Chang L, Cui Y, Zhao S.Hum Vaccin Immunother. 2025 Dec;21(1):2527450. doi: 10.1080/21645515.2025.2527450. Epub 2025 Oct 8.PMID: 41063530

COVID-19 vaccination around the time of conception and risk of placenta-mediated adverse pregnancy outcomes.

Regan AK, Bruce L, Lavin Venegas C, Török E, Platt RW, Gravel CA, Alton GD, Dimanlig-Cruz S, Shah PS, Barrett J, Walker MC, El-Chaâr D, Wilson K, Sprague AE, Buchan SA, Kwong JC, Wilson SE, Håberg SE, Okun N, Dhinsa T, Dunn S, Fell DB.Acta Obstet Gynecol Scand. 2025 Oct;104(10):1883-1896. doi: 10.1111/aogs.70025. Epub 2025 Aug 1.PMID: 40747952

Norway rat hepacivirus resembles hepatitis C virus in terms of intra-host evolution and escape from neutralizing antibodies.

Thorselius CE, Wolfisberg R, Fahnøe U, Scheel TKH, Holmbeck K, Bukh J.J Hepatol. 2025 Oct;83(4):870-880. doi: 10.1016/j.jhep.2025.02.044. Epub 2025 Mar 15.PMID: 40096950

HPV Workshop for Underserved High School Students.

Delavary D, Evans L, Tamamian C, Nicolas L, Wooten C, Liu C, Agarwal N, Townson M, Rhymer A, Ashendouek M, John MS.J Cancer Educ. 2025 Oct 6. doi: 10.1007/s13187-025-02746-4. Online ahead of print.PMID: 41051417

Longitudinal patterns and predictors of COVID-19 vaccine confidence from pre-vaccine rollout to mass vaccination: A population-based cohort study.

Wang Y, Ni Y, Leung CMC, Ning K, Lun P, Flores FP, Xiao X, Wong CSM, Lin L, Ni MY.Vaccine. 2025 Oct 3;64:127736. doi: 10.1016/j.vaccine.2025.127736. Epub 2025 Sep 9.PMID: 40930038

Cellular and humoral immunogenicity of respiratory syncytial virus vaccination in solid organ transplant recipients.

Bronder S, Abu-Omar A, Lennartz S, Tschausowsky D, Radun R, Fliser D, Schmidt T, Wilkens H, Schmit D, Sester M.Am J Transplant. 2025 Oct 6:S1600-6135(25)03003-5. doi: 10.1016/j.ajt.2025.09.023. Online ahead of print.PMID: 41062073

Future Goals and Long-term Vision of the Infectious Diseases Clinical Research Consortium/Vaccine and Treatment Evaluation Unit Network.

Whitaker JA, Collins MH, Rebolledo PA, Dobrzynski D, Samanovic MI, Hoft D, Stephens DS, Rostad CA.Clin Infect Dis. 2025 Oct 10;81(Supplement_2):S137-S146. doi: 10.1093/cid/ciaf412.PMID: 41071739

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Influenza vaccine hesitancy in the elderly: Where do we stand?

Pires C.Vaccine. 2025 Oct 11;66:127831. doi: 10.1016/j.vaccine.2025.127831. Online ahead of print.PMID: 41076809

Plant- and microalgae-made fish vaccines.

Angulo C, Reyes-Becerril M, Bañuelos-Hernández B, Ramos-Vega A, Trujillo E, Angulo M, Cisneros-Geraldo A, Monreal-Escalante E.Fish Shellfish Immunol. 2025 Oct;165:110539. doi: 10.1016/j.fsi.2025.110539. Epub 2025 Jul 2.PMID: 40614947

Lipid nanoparticle encapsulated membrane-anchored E2 mRNA vaccine elicits cross-protective immune responses against bovine viral diarrhoea virus infection in calves.

Le T, Jia B, Sun C, Zhou Y, Qi Y, Liu H, Bian H, Tian C, Wang J, Xue F, Zhu Y, Chang J, Luan Y, Zhang Z, Li Z, Tai W, Jiang Z, Yin X.Vaccine. 2025 Oct 9;66:127841. doi: 10.1016/j.vaccine.2025.127841. Online ahead of print.PMID: 41072279

Religious Service Attendance, COVID-19 Vaccine Attitudes, and COVID-19 Vaccination Status: A Vaccine Safety Datalink Member Survey, 2022-2023.

Williams JTB, Kurlandsky K, Breslin K, Cruz H, Stein A, Shoup JA, Reifler LM, Daley MF, Lewin B, Goddard K, Henninger ML, Nelson JC, Vazquez-Benitez G, Hanson KE, Fuller CC, Hambidge SJ.AJPM Focus. 2025 Jul 30;4(5):100404. doi: 10.1016/j.focus.2025.100404. eCollection 2025 Oct.PMID: 40977997

Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine.

Pfranger M, Krause N, Asbach B, Meier J, Carnell G, Scheer L, Kalender A, Brenner D, Tonks P, Frost S, Wright E, Jordan I, Kennedy E, Hewson R, Blacklaws B, Chan A, Parthasarathy S, Dowall S, Carroll M, Sandig V, Fedosyuk S, Kinsley R, Heeney J, Wagner R.J Gen Virol. 2025 Oct;106(10):002157. doi: 10.1099/jgv.0.002157.PMID: 41051941

Temporal trends in COVID-19 vaccine uptake among social housing residents compared to the general population in Ontario, Canada: A population-based panel study.

Agarwal G, Keshavarz H, Angeles R, Pirrie M, Marzanek F, Nguyen F, Brar J, Michael Paterson J.Ann Epidemiol. 2025 Oct;110:154-159. doi: 10.1016/j.annepidem.2025.08.024. Epub 2025 Aug 19.PMID: 40840571

Dual-targeting exosome vaccine confers efficient protection against CVB3-induced myocarditis.

Cao Q, Ge Y, Wang T, Lin K, Xiong S, Yue Y.Nanomedicine. 2025 Oct 2;70:102865. doi: 10.1016/j.nano.2025.102865. Online ahead of print.PMID: 41046097

Evaluation of enterovirus A71 vaccine effectiveness against pediatric hand, foot, and mouth disease caused by enterovirus A71 virus in Tianjin, China, 2016-2023: A test-negative design case-control study.

Gao L, Cheng S, Li L.Hum Vaccin Immunother. 2025 Dec;21(1):2572181. doi: 10.1080/21645515.2025.2572181. Epub 2025 Oct 10.PMID: 41070884

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Vaccine hesitancy among legal guardians of children with chronic neurological disorders: a cross-sectional study in Saudi Arabia.

Almutairi AM, Alanezi AA, Almahmoud KA, Aljuhni AM, Alluhidan WA, Abahussain TA, Alzaraa K.BMC Public Health. 2025 Oct 9;25(1):3429. doi: 10.1186/s12889-025-24269-9.PMID: 41068648

A safe, T cell-inducing heterologous vaccine against elephant endotheliotropic herpesvirus in a proof-of-concept study.

Maehr T, Lopez J, Drake G, Ferreira FM, Fraser R, Mckown R, Kailath R, Morris S, Chambers A, Graves LP, Walker SL, Dastjerdi A, Edwards KL, Nakaya HI, Steinbach F.Nat Commun. 2025 Oct 3;16(1):8374. doi: 10.1038/s41467-025-64004-x.PMID: 41044129

Global Estimates of the HPV-related, Noncervical Cancer Burden in People With HIV and AIDS and the Potential Effect of Improved HPV Vaccine Coverage in This Population: A Systematic Review, Meta-analysis and Modeling Study.

Wongkalasin N, Pilkington V, Levi J, Pepperrell T, Garratt A, Fairhead C, Hill A.Open Forum Infect Dis. 2025 Sep 16;12(10):ofaf577. doi: 10.1093/ofid/ofaf577. eCollection 2025 Oct.PMID: 41069589

Australian vaccine preventable disease epidemiological review series: mumps, 2013-2021.

Nadeeka S, Jackson J, Dey A, Bag S, Lambert S, Beard F.Commun Dis Intell (2018). 2025 Oct 1;49. doi: 10.33321/cdi.2025.49.033.PMID: 41027414

Efficacy and Safety of EGF/EGFR Vaccines in EGFR-Driven Solid Tumors: A Systematic Review and Meta-Analysis of Controlled and Single-Arm Studies.

Chen F, Bai L, Cui J.Cancer Med. 2025 Oct;14(19):e71295. doi: 10.1002/cam4.71295.PMID: 41069015

Comparison of Adverse Events in Pregnant Persons Receiving COVID-19 and Influenza Vaccines: A Disproportionality Analysis Using Combined Data from US VAERS and EudraVigilance Spontaneous Report Databases.

Roque-Pereira L, Sisay MM, Ogar CK, Durán CE, van Puijenbroek E, Weibel D, Verhamme K, Sturkenboom M.Drug Saf. 2025 Oct;48(10):1127-1139. doi: 10.1007/s40264-025-01561-6. Epub 2025 Jun 10.PMID: 40495022

Vaccination in Multiple Myeloma: Challenges and Strategies.

Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Caserta S, Mendicino F, Morabito F, Gentile M.Eur J Haematol. 2025 Oct;115(4):334-343. doi: 10.1111/ejh.70013. Epub 2025 Jul 26.PMID: 40716013

Protecting travellers from vaccine-preventable diseases.

McGuinness SL, Leder K, Starr M.Aust J Gen Pract. 2025 Oct;54(10):691-697. doi: 10.31128/AJGP-05-25-7685.PMID: 41038691

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

DNA Vaccine Encoding Trypanosoma brucei MSP-B Elicited IgG and IFN-gamma Responses and Partial Protection in Immunised Mice.

Yusuf AB, Gouegni EF, Habila AJ, Umar IA, Ibrahim S, Kabir J, Hirayama K, Kato K, Velasquez CV, Inaoka DK, Mamman M, Balogun EO, Shuaibu MN.Parasite Immunol. 2025 Oct;47(10):e70033. doi: 10.1111/pim.70033.PMID: 41064873

Understanding influenza vaccination attitudes and behaviors: An assessment of health decision-making preferences.

Anderson KM, Nowak GJ, Cacciatore MA, Rohani P, Drake JM.Vaccine. 2025 Oct 3;65:127804. doi: 10.1016/j.vaccine.2025.127804. Online ahead of print.PMID: 41045633

The social lives of the SARS-CoV-2 vaccines: A qualitative study of vaccine understandings and decision-making among people of Black ethnicities in London, UK.

Nicholls EJ, Onyango D, Kolodin V, Ottaway Z, Carter A, Campbell L, Post F, Tariq S.Vaccine. 2025 Oct 10;66:127802. doi: 10.1016/j.vaccine.2025.127802. Online ahead of print.PMID: 41076806

Uptake of Pneumococcal Vaccines Among U.S. Adults After 2022 Update to Recommendations.

Averin A, Vietri J, Mohs AA, Willis SJ, Lonshteyn A, Weycker D.AJPM Focus. 2025 Jun 25;4(5):100384. doi: 10.1016/j.focus.2025.100384. eCollection 2025 Oct.PMID: 40791952

Novel Oral papaya-based preventive and therapeutic vaccine for controlling different zoonotic Taeniid parasites: Current advances.

Hernández M, Caltempa AO, Villalobos N, Elisondo MC, Guzmán C, Hernández-Aceves JA, Aguilar L, Flores-Pérez I, Martínez JJ, Elguea Zarate SD, Prieto MJP, Meneses G, Chea RH, Sifontes-Rodríguez S, Sako Y, Cardoso-Taketa A, Villarreal ML, Bobes RJ, Rosas G, Fragoso G, Sciutto E.Vaccine. 2025 Oct 8;66:127818. doi: 10.1016/j.vaccine.2025.127818. Online ahead of print.PMID: 41066986

Design Strategies for Novel Lipid Nanoparticle for mRNA Vaccine and Therapeutics: Current Understandings and Future Perspectives.

Li X, Li J, Wei J, Du W, Su C, Shen X, Zhao A, Xu M.MedComm (2020). 2025 Oct 5;6(10):e70414. doi: 10.1002/mco2.70414. eCollection 2025 Oct.PMID: 41059491

PV-10 enhances immune responses in hepatitis B vaccination through STING pathway.

Sipila P, Zhao Y, Thakur S, Malhotra M, Zhang C, Willetts L, Murguia-Favela L, Narendran A.Hum Vaccin Immunother. 2025 Dec;21(1):2567703. doi: 10.1080/21645515.2025.2567703. Epub 2025 Oct 7.PMID: 41055008

Did COVID-19 vaccine enforcement work? Evidence from northwestern and northern Uganda.

Parker M, Okello B, Kermundu P, Ozunga BE, Baluku M, Akello G, MacGregor H, Leach M, Allen T.Soc Sci Med. 2025 Oct;382:118273. doi: 10.1016/j.socscimed.2025.118273. Epub 2025 May 30.PMID: 40633404

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

A Novel Abeta B-cell epitope Vaccine, Abeta1-10 with carrier protein OVA and KLH reduce Abeta-induced neuroinflammation mediated neuropathology in mouse model of Alzheimer's disease.

Park JS, Choe K, Ahmad R, Park HY, Kang MH, Park TJ, Kim MO.Brain Behav Immun. 2025 Oct;129:196-205. doi: 10.1016/j.bbi.2025.06.001. Epub 2025 Jun 6.PMID: 40484150

A commentary on measles vaccine in the context of outbreaks: Viral evolution, waning immunity and public trust.

Equils O, Kuliyev T, Hoang A, Tafuri S.Hum Vaccin Immunother. 2025 Dec;21(1):2570582. doi: 10.1080/21645515.2025.2570582. Epub 2025 Oct 8.PMID: 41063497

Oral adjuvanted Vibrio vaccine enhances antibody production and lysozyme activity in the serum and mucus of marine-cultured red hybrid tilapia (Oreochromis sp.) against V. harveyi and V. alginolyticus.

Manchanayake T, Mohamad A, Amir-Danial Z, Nor NA, Yong-Kit C, Nazarudin MF, Nor RM, Hasnan Q, Zamri-Saad M, Azmai Amal MN, Ina-Salwany MY, Salleh A.Fish Shellfish Immunol. 2025 Oct;165:110503. doi: 10.1016/j.fsi.2025.110503. Epub 2025 Jun 16.PMID: 40532752

A Multilevel Analysis of School-Level Human Papillomavirus Vaccination Coverage in Virginia.

McNally K, Weinstein A, Lindley L, Wallin R, Roess A.J Sch Nurs. 2025 Oct;41(5):557-569. doi: 10.1177/10598405231214981. Epub 2023 Nov 29.PMID: 38031333

The Sweet Aspects of Orthoflavivirus Treatment Design and Vaccine Development.

Alcalá AC, Gutiérrez M, Ludert JE.J Med Virol. 2025 Oct;97(10):e70637. doi: 10.1002/jmv.70637.PMID: 41065131

Enhancing vaccine immunogenicity through heterologous prime-boost regimen with multiple nasal boosting with liposomal TLR7 ligand.

Hayashi T, Yao S, Sato-Kaneko F, Cozza R, Baba H, Jin J, Mclaughlin I, Gil F, Quiroz PA, Shukla NM, Chan M, Cottam HB, Carson DA.Vaccine. 2025 Oct 8;65:127778. doi: 10.1016/j.vaccine.2025.127778. Online ahead of print.PMID: 41067087

The gonococcal vaccine candidate antigen NGO1701 is a N. gonorrhoeae periplasmic copper storage protein.

Roe SK, Mazgaj R, Zhu T, Esmaeeli M, Lewis LA, Genco C, Waldron KJ, Massari P.PLoS Pathog. 2025 Oct 9;21(10):e1013559. doi: 10.1371/journal.ppat.1013559. eCollection 2025 Oct.PMID: 41066371

Neutralizing antibody durability and SARS-CoV-2 infection in older adults six months after XBB-containing vaccine booster.

Chen RR, Cao GP, Song XD, Lu M, Wang MM, Wang XJ, Wang MF, Wang SQ, Wan S, Yang GJ, Lv L, Ma YM, Cheng YM, Kong M, He XJ, Yang HY, Zhan BD, Ma MJ.Signal Transduct Target Ther. 2025 Oct 9;10(1):336. doi: 10.1038/s41392-025-02437-y.PMID: 41062464

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Africa is an Essential Partner in the Research and Development of an HIV Vaccine.

Gray G, Williamson C, Bekker LG, Daniels B, Smidt W, Garrett N, Kityo Mutuluuza C, Mwesigwa B, Stranix-Chibanda L, Akimbu A, Obuku A, Johnson T, Naluyima P, Sawe F, Burgers W, Ntiginya N, Morar N, Takalani A, Hendricks S, Woeber K, Abrahams F, Tholanah M, Mugamba S, Mulder M, Moore P.Curr HIV Res. 2025 Oct 2. doi: 10.2174/011570162X361496250627004203. Online ahead of print.PMID: 41047688

Resurgence of pertussis: whopping the '100-day cough'.

Christie CDC.Curr Opin Pediatr. 2025 Oct 1;37(5):508-516. doi: 10.1097/MOP.0000000000001486. Epub 2025 Aug 21.PMID: 40842393

Development of a novel safety assessment method for quality control of mRNA vaccines based on lung biomarker gene expression.

Hiraga K, Momose H, Kuribayashi W, Uemura M, Sakuragi S, Nojima K, Ishii M, Imai K, Maeyama JI, Nakano K, Seki Y, Tezuka K, Kuramitsu M, Mizukami T.Vaccine. 2025 Oct 4;65:127805. doi: 10.1016/j.vaccine.2025.127805. Online ahead of print.PMID: 41046838

Immunoinformatics design and experimental expression of a multi-epitope vaccine simultaneously targeting AAV2 and HAdV-F41 against acute hepatitis of unknown etiology.

Zeng F, Liu Q, Wang X, Zhong P, Wu P, Yang M, Wei P.Virology. 2025 Oct;611:110653. doi: 10.1016/j.virol.2025.110653. Epub 2025 Aug 18.PMID: 40850180

Resilience, perceived control, and intention to receive additional vaccines for COVID-19 among healthcare university students: Mediating role of knowledge of vaccine and infection-preventive behaviors.

Kondo A, Abuliezi R, Ota E, Oki T, Naruse K.Jpn J Nurs Sci. 2025 Oct;22(4):e70016. doi: 10.1111/jjns.70016.PMID: 40761162

Testing Theory-Enhanced Messaging to Promote COVID-19 Vaccination Among Adults: Randomized Controlled Trial.

Piltch-Loeb R, Shen Y, Fleary S, Robertson M, Nuñez Sahr J, Penrose K, Sanborn J, Yadav S, Srivastava A, Nash D, Parcesepe A.J Med Internet Res. 2025 Oct 7;27:e79228. doi: 10.2196/79228.PMID: 41057045

Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations.

Pan Z, Jiang L, Chen Y, Peng H, Liu Y, Zheng X, He Y, Liu Y, Wang Y, Zhang X, Qi Z, Ding C, Xu J, Zhao P.J Virol. 2025 Oct 3:e0109925. doi: 10.1128/jvi.01099-25. Online ahead of print.PMID: 41042059

Revealing dynamic transcriptomic and immune cell signatures underlying heterogeneous responses to influenza vaccination.

Hui S, He R, Li H, Li Y, Lu Y, Zhou H, Yu R, Huang P.Vaccine. 2025 Oct 3;64:127777. doi: 10.1016/j.vaccine.2025.127777. Epub 2025 Sep 21.PMID: 40983023

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

West Nile virus vaccine candidates attenuated by dinucleotide enrichment are immunogenic and protective against lethal infection.

Le NPK, Singh PP, Trus I, Karniychuk U.PLoS Pathog. 2025 Oct 3;21(10):e1013560. doi: 10.1371/journal.ppat.1013560. eCollection 2025 Oct.PMID: 41042818

A rat hepacivirus model to aid hepatitis C viral vaccine development?

Houghton M.J Hepatol. 2025 Oct;83(4):828-829. doi: 10.1016/j.jhep.2025.04.016. Epub 2025 Apr 17.PMID: 40250765

Innate immune mechanisms underlying the efficacy of a next-generation nanoparticle-based vaccine against opioid use disorders.

Hamid FA, Rostamizadeh K, Skiados N, Le NN, Walter DL, Hannon B, Marecki C, Bian Y, Luengas D, Zhang C, Pravetoni M.J Control Release. 2025 Oct 6:114294. doi: 10.1016/j.jconrel.2025.114294. Online ahead of print.PMID: 41061858

Post-pandemic questions in vaccination counseling: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines.

Shamsrizi P, Eitze S, Heinemeier D, Tänzer AS, Jenny MA.Vaccine. 2025 Oct 8;66:127823. doi: 10.1016/j.vaccine.2025.127823. Online ahead of print.PMID: 41066985

Factors associated with healthcare personnel uptake of updated COVID-19 vaccine doses in the United States.

Kontowicz E, Harland KK, Stubbs A, Beiser D, Plumb I, Krishnadasan A, Talan DA, Mohr NM.Prev Med Rep. 2025 Sep 8;58:103233. doi: 10.1016/j.pmedr.2025.103233. eCollection 2025 Oct.PMID: 41050854

Development and reproductive safety of AdCLD-CoV19, an adenoviral vector-based COVID-19 vaccine, in female Sprague-Dawley rats and their offspring.

Park SJ, Kim S, Kim S, Shin KS, Kang CY, Hong EJ, Im WJ, Jeong JS, Yu WJ, Ko KC, Kim YB.Toxicol Appl Pharmacol. 2025 Oct;503:117503. doi: 10.1016/j.taap.2025.117503. Epub 2025 Aug 6.PMID: 40780534

Mutations of two amino acids in VP5 mediate the attenuation of human rotavirus vaccine: evidence from in vitro and in vivo studies.

Bessey TK, Wang Y, Moon S-S, Sanchez-Tacuba L, Jaïs PH, Greenberg HB, Jiang B.J Virol. 2025 Oct 8:e0106725. doi: 10.1128/jvi.01067-25. Online ahead of print.PMID: 41060027

Examining the contributions of demographic variables to vaccination uptake among the U.S. aged 50.

Balmuth A, Brennan T, Ashebir S, D'Ambrosio L.Vaccine. 2025 Oct 3;64:127711. doi: 10.1016/j.vaccine.2025.127711. Epub 2025 Sep 9.PMID: 40930039

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Durability of effectiveness of a booster dose of COVID-19 bivalent (ancestral/BA.4-5) vaccine against all-cause mortality in older adults in Japan, October 2022 to September 2023.

Ogata T, Hattori S, Kawachi K, Ishikane M, Tanaka H.Vaccine. 2025 Oct 4;65:127796. doi: 10.1016/j.vaccine.2025.127796. Online ahead of print.PMID: 41046837

Identification of age-group reservoirs for persistent vaccine-type pneumococcal carriage in rural Gambia.

Osei I, Mendy E, van Zandvoort K, Jobe O, Sarwar G, Mohammed NI, Bruce J, Barjo O, Molfa M, Salaudeen R, Greenwood B, Flasche S, Mackenzie GA.Pneumonia (Nathan). 2025 Oct 5;17(1):22. doi: 10.1186/s41479-025-00176-w.PMID: 41046301

Understanding COVID-19 vaccination disparity among Black adults in North America: A two-study motivational approach.

Fang X, Holding AC, Audet ÉC, Thai H, Koestner R.Vaccine. 2025 Oct 2;65:127803. doi: 10.1016/j.vaccine.2025.127803. Online ahead of print.PMID: 41043306

Mansonella perstans - the forgotten filaria.

Ritter M, Hsu HY, Lenz B, Kien CA, Gandjui NVT, Hübner MP, Hoerauf A, Wanji S.Trends Parasitol. 2025 Oct;41(10):909-921. doi: 10.1016/j.pt.2025.08.003. Epub 2025 Sep 3.PMID: 40908246

Sex Differences in Adverse Event Reporting Rates Following COVID-19 Vaccination in South Korea During the Pandemic.

Kim JA, Park S, Cho H, Jeong NY, Choi NK.Int J Infect Dis. 2025 Oct 6:108107. doi: 10.1016/j.ijid.2025.108107. Online ahead of print.PMID: 41061848

Rare but Severe Cardiovascular Complications of SARS-CoV-2 Vaccination: A Call for Awareness.

Marchetta M, Golino M, Markley JD, Abbate A.J Cardiovasc Pharmacol. 2025 Oct 1;86(4):317-320. doi: 10.1097/FJC.0000000000001740.PMID: 40705503

Recording vaccine doses administered: A global analysis of tally sheet design for infant and child immunizations.

Higgins-Steele A, Shendale S, Grevendonk J, Gacic-Dobo M, Danovaro-Holliday MC.PLOS Glob Public Health. 2025 Oct 6;5(10):e0004973. doi: 10.1371/journal.pgph.0004973. eCollection 2025.PMID: 41052098

A rationally designed multi-epitope vaccine candidate targeting conserved FiuA for broad Pseudomonas aeruginosa protection.

Hessami A, Moosavi M, Rahim F, Mogharari Z, Heidari M, Farzam F, Rahbar MR.Comput Biol Med. 2025 Oct 2;198(Pt A):111170. doi: 10.1016/j.compbiomed.2025.111170. Online ahead of print.PMID: 41043247

Rational Design of DNA Nanostructures as TLR9 Agonists.

Chen C, Tian C, Jin Z, Wen Y, Xia X, Ren Q, Huang CZ, Zuo H.Biomacromolecules. 2025 Oct 8. doi: 10.1021/acs.biomac.5c00919. Online ahead of print.PMID: 41060642

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Assessing the effect of social contact structure on the impact of pneumococcal conjugate vaccines.

Wong A, Kramer SC, Weinberger DM, Domenech de Cellès M.Sci Rep. 2025 Oct 7;15(1):35012. doi: 10.1038/s41598-025-20255-8.PMID: 41057458

A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.

Chen WH, Barnes RS, Sikorski MJ, Datar R, Sukhavasi R, Liang Y, Rapaka RR, Pasetti MF, Sztein MB, Wahid R, Tennant SM, Simon R, Baliban SM, Galen JE, Lees A, Bernshtein B, Alter G, Ella R, Mohan K, Naidu MG, Rao DY, Ella KM, Levine MM.Nat Med. 2025 Oct 8. doi: 10.1038/s41591-025-04003-z. Online ahead of print.PMID: 41062830

Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations.

Belongia EA, Nguyen HQ, McClure DL, Lewis N, Ellington S, Flannery B, Petrie JG.Clin Infect Dis. 2025 Oct 9:ciaf563. doi: 10.1093/cid/ciaf563. Online ahead of print.PMID: 41062090

Current status of BCG and OPV vaccination in children with primary immunodeficiency in Chongqing, China.

Liu Y, Zhang Y, Ning Y, Zhang Z, Wang Q, Xie W, Yang H, Chen L, Zhao H, Xu J.Medicine (Baltimore). 2025 Oct 3;104(40):e44935. doi: 10.1097/MD.0000000000044935.PMID: 41054950

Effective strategies for typhoid conjugate vaccine delivery: Health and economic insights from the 2015 Kampala outbreak.

Lee Y, Salonga PKN, Son C, Jang G, Koh DH, Kim JH, Lee H.PLoS Negl Trop Dis. 2025 Oct 7;19(10):e0013566. doi: 10.1371/journal.pntd.0013566. Online ahead of print.PMID: 41056354

Mucous Membrane Pemphigoid After SARS-CoV-2 Vaccine.

Oteiza-Rius I, Hashimoto T, Ishii N, España A.Actas Dermosifiliogr. 2025 Oct;116(9):T1029-T1032. doi: 10.1016/j.ad.2025.07.003. Epub 2025 Jul 14.PMID: 40669667

Mucous Membrane Pemphigoid After SARS-CoV-2 Vaccine.

Oteiza-Rius I, Hashimoto T, Ishii N, España A.Actas Dermosifiliogr. 2025 Oct;116(9):1029-1032. doi: 10.1016/j.ad.2023.11.027. Epub 2025 May 19.PMID: 40398742

America's Vaccine Policy Whiplash-Finding the Way Forward.

Navin MC, Ross LF.JAMA. 2025 Oct 1. doi: 10.1001/jama.2025.19088. Online ahead of print.PMID: 41032401

Unveiling the Immunostimulatory Potential of the HSPA1A Mini-Chaperones Compared to the HSPA1A and HSP27 Chaperones: In Silico and In Vitro Insights for Vaccine Development.

Heidarnejad F, Ekhlasi F, Moradi Pordanjani P, Nemati F, Bolhassani A.Protein J. 2025 Oct;44(5):611-638. doi: 10.1007/s10930-025-10285-6. Epub 2025 Aug 14.PMID: 40813535

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

High-throughput flow cytometry-based titration of a live attenuated rotavirus vaccine.

Dias MM, Carvalho SB, Matheise JP, Van Beersel G, Knott I, Gomes-Alves P, Alves PM.J Biotechnol. 2025 Oct;406:91-98. doi: 10.1016/j.jbiotec.2025.07.004. Epub 2025 Jul 3.PMID: 40617258

Development of an indirect ELISA for Duck circovirus detection based on prokaryotically expressed antigen.

Wu M, Zhu Y, Mao M, Li B, Liang S, Li H, Lu C, Lu M, Ma H, Cui X, Han Q, Wang D, Zhang H, Luo G, Diao Y, Li J, Tang Y.BMC Vet Res. 2025 Oct 6;21(1):585. doi: 10.1186/s12917-025-05002-5.PMID: 41053733

Prolonged Monkeypox Virus Infections, California, USA, May 2022-August 2024.

Schildhauer S, Saadeh K, Snyder RE, Tang EC, Chapman E, Sykes DA, Peters P, Jacobson K, Watson J, Johnson KA.Emerg Infect Dis. 2025 Oct;31(10):1935-1941. doi: 10.3201/eid3110.250507. Epub 2025 Sep 12.PMID: 40936180

Detection of pathogens and vaccine design strategies for Streptococcus pneumoniae.

Zhang J, Ma H, Liu F, Zhao Z, Zhao X, Xie Y, Wang B, Li X, Li R, Sima J, Zhang B, Li X.Microb Pathog. 2025 Oct;207:107896. doi: 10.1016/j.micpath.2025.107896. Epub 2025 Jul 15.PMID: 40669214

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.

Mkhize NN, Zhang B, Brackett C, Elyanu PJ, Tapley A, Dadabhai S, Hu J, Do BTN, Schuster DJ, Heptinstall J, Sawant S, Seaton K, Sarzotti-Kelsoe M, Hudson A, Jin Y, Bhebhe S, Kaldine H, Kgagudi P, Modise T, Mgodi NM, Andriesen J, Randhawa AK, Fisher LH, Kee JJ, Magaret CA, Peng J, Kenny A, Carpp LN, Chen Z, Heng S, Villaran M, Takalani A, Le Roux B, Wilkinson E, Odhiambo J, Shah P, Polakowski L, Yacovone M, Samandari T, Chirenje Z, Makhema J, Kamuti E, Njekwa K, Nuwagaba-Biribonwoha H, Baguma A, Badal-Faesen S, Brumskine W, Coetzer S, Dawson R, Delany-Moretlwe S, Diacon AH, Fry S, Gill K, Madikida A, Hoosain ZAE, Hosseinipour MC, Inambao M, Innes C, Innes S, Kalonji D, Mwape H, Kassim P, Kamanga MC, Kilembe W, Laher F, Malahleha M, Maluleke VL, Mboya G, Madiega PA, McHarry K, Mitha E, Duki Y, Mda P, Moerane M, Moloantoa T, Nuwamanya S, Mahomed S, Naicker V, Nana A, Nanvubya A, Kawoozo B, Nchabeleng M, Otieno W, Potgieter EL, Potloane D, Punt Z, Said J, Singh Y, Kassim S, van der Vendt D, Tayob MS, Vahed Y, Wabwire DO, Kublin JG, Bekker LG, Corey L, Gray GE, Huang Y, Kotze P, Garrett N, Hural J, Ferrari G, Andersen-Nissen E, Montefiori D, Moore PL, McElrath MJ, Tomaras GD, Gilbert PB…See abstract for full author list ➔Nat Commun. 2025 Oct 6;16(1):8876. doi: 10.1038/s41467-025-63948-4.PMID: 41053137

Targeting HIV-1 immune escape mechanisms: Key advances and challenges in HIV-1 vaccine design.

Fang Z, Jiang W, Liu P, Xia N, Li S, Gu Y.Microbiol Res. 2025 Oct;299:128229. doi: 10.1016/j.micres.2025.128229. Epub 2025 May 21.PMID: 40460810

Acceptance of chikungunya vaccination: a rapid survey in Reunion island during an epidemic.

Manaquin R, Desmoulin A, Luong Nguyen LB, Kornblum D, Deparis X, Ferdynus C, Bertolotti A, Verger P, D'Ortenzio E, Pasquet A, Eldin C, Gérardin P, Mosnier E.Vaccine. 2025 Oct 3;64:127720. doi: 10.1016/j.vaccine.2025.127720. Epub 2025 Sep 13.PMID: 40946352

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Perceived Risk and HPV Vaccination Awareness Among Women in Rural and Underserved Communities in the State of Louisiana.

Smith DG, Dantes EM, Beyl R, de Koter YXA, Bourg M, Smith CD, Jackson G, Brown J, McLarty JW.J Community Health. 2025 Oct;50(5):826-832. doi: 10.1007/s10900-025-01465-7. Epub 2025 Apr 5.PMID: 40186838

Vaccine for pancreatic and colorectal cancer: phase I AMPLIFY-201 trial.

Hindson J.Nat Rev Gastroenterol Hepatol. 2025 Oct;22(10):672. doi: 10.1038/s41575-025-01123-2.PMID: 40926033

Nanotechnology-driven enhancement and modulation of immune responses in monkeypox and respiratory syncytial virus nanovaccine research.

Niculescu AG, Dumitrascu AM, Koçer AT, Arayıcı PP, Yuka SA, Koçer S, Üstündağ CB, Grumezescu AM, Vrancianu CO, Mihai MM, Paun M, Chifiriuc MC.Colloids Surf B Biointerfaces. 2025 Oct;254:114829. doi: 10.1016/j.colsurfb.2025.114829. Epub 2025 May 29.PMID: 40450846

The Uptake of Influenza, Pneumococcal, Shingles, and COVID-19 Vaccines Among US Adults With and Without Kidney Disease: Findings From the Behavioral Risk Factor Surveillance System 2018-2022.

Yeboah E, Lin W, Ishigami J.Kidney Med. 2025 Aug 5;7(10):101074. doi: 10.1016/j.xkme.2025.101074. eCollection 2025 Oct.PMID: 41050123

Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.

Batmunkh T, Neal EFG, Amraa O, Mazarakis N, Altangerel B, Avaa N, Batbayar L, Batsukh K, Bright K, Burentogtokh T, Do LAH, Dorj G, Hart JD, Jamiyandorj O, Javkhlantugs K, Jigjidsuren S, Justice F, Li S, Mashbaatar K, Moore KA, Namjil N, Nguyen CD, Ochirbat B, Surenjav U, Thomson H, Tsolmon B, Licciardi PV, von Mollendorf C, Mulholland K.Vaccine. 2025 Oct 9;66:127840. doi: 10.1016/j.vaccine.2025.127840. Online ahead of print.PMID: 41072276

Optimizing Influenza Vaccine Protection in India.

Vashishtha VM, Kumar P.Indian Pediatr. 2025 Oct;62(10):769-774. doi: 10.1007/s13312-025-00119-0. Epub 2025 Jul 22.PMID: 40694287

A therapeutic multi-epitope protein vaccine targeting HPV16 E6 E7 elicits potent tumor regression and cytotoxic immune responses.

Zhu L, Pu J, Tao Y, Shi L, Liu S, Zhang X, Liu W, Sun M, Yao Y, Shi L.Cancer Biol Med. 2025 Oct 6;22(9):1102-26. doi: 10.20892/j.issn.2095-3941.2025.0370.PMID: 41054971

Factors influencing influenza vaccination among childcare and education professionals: A nationwide survey (2023-2024).

Okubo Y, Honjo R, Uda K, Miyairi I, Sakamoto M.J Infect Chemother. 2025 Oct;31(10):102808. doi: 10.1016/j.jiac.2025.102808. Epub 2025 Sep 8.PMID: 40930417

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Association between Perceived Ethnic Discrimination and Receipt of COVID-19 Vaccine in Pregnancy or Postpartum.

Jaeke E, Anguzu R, Greenberg R, Palatnik A.J Racial Ethn Health Disparities. 2025 Oct;12(5):3442-3450. doi: 10.1007/s40615-024-02147-1. Epub 2025 Feb 20.PMID: 39979695

Gamma-irradiated Salmonella Gallinarum oral vaccine elicits robust cellular and humoral immune responses in a chicken model.

Ashraf M, Ghafoor A, Suleman M, Mukhtar M, Farooq MU, Zahoor UB, Mushtaq MH.Vaccine. 2025 Oct 4;65:127833. doi: 10.1016/j.vaccine.2025.127833. Online ahead of print.PMID: 41046833

A Thermostable nasal spray dried COVID vaccine candidate.

Aisenstat M, Duong K, Renshaw C, Kinsey R, Kaufman K, Ordoubadi M, Chen J, Wang H, McClary WD, Gerhardt A, Alvim RGF, Lima TM, Castilho LR, Martin AR, Fox CB, Vehring R.Int J Pharm. 2025 Oct 5:126240. doi: 10.1016/j.ijpharm.2025.126240. Online ahead of print.PMID: 41057059

Corrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naive Japanese adults 65 years of age" [Vaccine 62 (2025) 127456].

Kishino H, Inoue S, Matsuoka O, Yagi M, Igarashi R, Oshima N, Sawata M, Platt HL.Vaccine. 2025 Oct 3;64:127688. doi: 10.1016/j.vaccine.2025.127688. Epub 2025 Sep 6.PMID: 40916264

Chitosan-based Oral DNA vaccine elicits mucosal immunity and reduces Helicobacter pylori colonization in mice.

Chan YL, Chao YP, Li TL, Liao KW.Vaccine. 2025 Oct 3;64:127692. doi: 10.1016/j.vaccine.2025.127692. Epub 2025 Sep 9.PMID: 40930041

Design-of-experiments based development and in vitro evaluation of a cationic lipid-based triple adjuvanted subunit pertussis vaccine.

Mandava TT, Gerdts V, Ejlali M, Wasan EK.Eur J Pharm Biopharm. 2025 Oct 3:114890. doi: 10.1016/j.ejpb.2025.114890. Online ahead of print.PMID: 41047086

Duration of the serological response and effectiveness of the inactivated influenza vaccine in healthy adults aged 18-65 years: a systematic review and meta-analysis.

Nazareth J, Veli N, Pan D, Martin CA, Kekere-Ekun A, Hassan FA, Divall P, Al-Oraibi A, Teece L, Stephenson I, Wiselka MJ, Tang JW, Nellums L, Pareek M.Lancet Microbe. 2025 Oct 6:101136. doi: 10.1016/j.lanmic.2025.101136. Online ahead of print.PMID: 41067240

Heat-inactivated Mycobacterium marinum as a vaccine adjuvant and a trained immunity inducer in rainbow trout (Oncorhynchus mykiss).

Lee KM, Kim KH.Fish Shellfish Immunol. 2025 Oct;165:110521. doi: 10.1016/j.fsi.2025.110521. Epub 2025 Jun 25.PMID: 40578585

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Respiratory syncytial virus (RSV) vaccine effectiveness and antibody correlates of protection among older adults in the Community Vaccine Effectiveness (CoVE) observational study.

Godonou ET, Callear AP, Juntila-Raymond CL, Raji D, Smith M, Rumfelt KE, Midgley CM, Feldstein LR, Jones JM, Hagen MB, Eisenberg MC, Lauring AS, Monto AS, Wagner AL, Martin ET.EBioMedicine. 2025 Oct 11;121:105961. doi: 10.1016/j.ebiom.2025.105961. Online ahead of print.PMID: 41076991

National Pharmacovigilance Assessment of Oral Adverse Events Following COVID-19 Vaccination in Germany (2020-2023).

Riad A.Int Dent J. 2025 Oct;75(5):100906. doi: 10.1016/j.identj.2025.100906. Epub 2025 Jul 19.PMID: 40684682

Prevalence of candidate vaccine targets and genomic features of pediatric invasive Streptococcus agalactiae in Japan.

Kasai M, Nakano S, Koide S, Otake S, Shibata M, Ishida-Kuroki K, Sugawara Y, Akeda Y, Nozu K, Sugai M.J Infect Dis. 2025 Oct 9:jiaf491. doi: 10.1093/infdis/jiaf491. Online ahead of print.PMID: 41065369

Maternal antibodies to Bartha-K61 vaccine did not protect newborn piglets from challenge with novel recombinant pseudorabies virus.

Liu YY, Zhang TT, Zhao Y, Li NW, Malhi KK, Yao X, Li JL.Vet J. 2025 Oct 3;314:106463. doi: 10.1016/j.tvjl.2025.106463. Online ahead of print.PMID: 41047069

Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, non-randomised extension of a phase 1/2 trial.

Song JY, Choi WS, Heo JY, Kim YR, Lee JS, Jung DS, Kim SW, Park KH, Eom JS, Jeong SJ, Lee J, Kwon KT, Choi HJ, Sohn JW, Kim YK, Lee Y, Park HK, Ryu JH, Lee SJ, Park YW, Kim H, Solmi F, Ceregido MA, Koutsoukos M, King N, Veesler D, Cheong HJ.Int J Infect Dis. 2025 Oct 8:108108. doi: 10.1016/j.ijid.2025.108108. Online ahead of print.PMID: 41072855

The Current and Future State of Vaccines for Lyme Disease.

Plotkin SA, Shapiro ED.Clin Infect Dis. 2025 Oct 6;81(3):687-692. doi: 10.1093/cid/ciae639.PMID: 39711074

β-Propiolactone, its application and assay methods.

Mirjalili SZ, Sabourian R, Chavoshi F, Shirangi M, Tamiji Z, Kobarfard F, Amini M.Anal Methods. 2025 Oct 2;17(38):7608-7617. doi: 10.1039/d5ay00024f.PMID: 40977330

Constructing protective mechanism by analysis of vaccine impact based on hybrid model of dynamic DEA and cluster tendency.

Hung TJ, Kuo CY, Dai HD, Chen YT, Su EC.BMC Public Health. 2025 Oct 8;25(1):3392. doi: 10.1186/s12889-025-24277-9.PMID: 41062991

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Area-related sociodemographic factors and the risk of severe COVID-19: a longitudinal study of the total adult population in Sweden.

Mellström Dahlgren H, Li H, Dotevall L, Nyberg F.Infect Dis (Lond). 2025 Oct;57(10):933-947. doi: 10.1080/23744235.2025.2503466. Epub 2025 May 15.PMID: 40372946

Pneumococcal colonization rates in children and adults in two developing countries: A prospective cross-sectional hospital-based study.

Leakhena PC, Awasthi S, Rabilloud M, Daw R, Verma N, Yib S, Elsensohn MH, Vanhems P, Pradel F, Saadatian-Elahi M, Picot VS.Vaccine. 2025 Oct 3;64:127697. doi: 10.1016/j.vaccine.2025.127697. Epub 2025 Sep 9.PMID: 40930040

Comparison of major, minor and junctional circumsporozoite protein epitopes for malaria vaccine design.

Ryan E, Brown D, Harrison W, Foor S, Ashraf K, Bolton JS, Flores-Garcia Y, MacGill RS, Locke E, Bergmann-Leitner E, Roth AE, Robben PM, Matyas G, Soisson L, Miller R, Batchelor AH, Zavala F, Dutta S.NPJ Vaccines. 2025 Oct 3;10(1):215. doi: 10.1038/s41541-025-01264-0.PMID: 41044073

Cocoon Vaccination Among Mothers of Very Preterm Infants.

James D, Joy A, Pournami F, Prabhakar J, Jain N.Indian Pediatr. 2025 Oct;62(10):738-741. doi: 10.1007/s13312-025-00131-4. Epub 2025 Jul 25.PMID: 40711508

Respiratory syncytial virus (RSV) vaccination recommendations in older adults: An update.

El-Hussein M, Bal RS.Nurse Pract. 2025 Oct 1;50(10):e26-e33. doi: 10.1097/01.NPR.0000000000000364. Epub 2025 Sep 25.PMID: 40996846

The European Vaccination Challenge: Stemming the Resurgence of Vaccine-Preventable Diseases.

Somekh E, Haddad J, Bali D, Giardino I, Vural M, Sevketoglu E, Pop TL, Pastore M, Pettoello-Mantovani M.J Pediatr. 2025 Oct 9:114844. doi: 10.1016/j.jpeds.2025.114844. Online ahead of print.PMID: 41075973

Humoral immunity to current variants of SARS-CoV-2 in exposed adults, September 2023 to September 2024.

Jeworowski LM, Mühlemann B, Walper F, Schmidt ML, Jansen J, Krumbholz A, Jones TC, Corman VM, Drosten C.mBio. 2025 Oct 8;16(10):e0161825. doi: 10.1128/mbio.01618-25. Epub 2025 Sep 12.PMID: 40937853

Protective efficacy of the UniFluVec influenza vaccine vector against the highly pathogenic influenza A/Indonesia/5/2005 (H5N1) strain in ferrets.

Romanova J, Krokhin A, Ferko B, Pleimes D, Vareckova E, Kostolansky F, Egorov A.Vaccine. 2025 Oct 4;65:127795. doi: 10.1016/j.vaccine.2025.127795. Online ahead of print.PMID: 41046834

Unlocking Hope: Paving the Way for a Cutting-Edge Multi-Epitope Dengue Virus Vaccine.

Wajeeha AW, Mukhtar M, Zaidi NUSS.Mol Biotechnol. 2025 Oct;67(10):3874-3897. doi: 10.1007/s12033-024-01294-4. Epub 2024 Oct 10.PMID: 39388049

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Immune responses of multi-epitope recombinant vaccine candidate strains against Fusobacterium nucleatum in mice.

Xu HW, Li P, Zhu SL.Microb Pathog. 2025 Oct;207:107824. doi: 10.1016/j.micpath.2025.107824. Epub 2025 Jun 30.PMID: 40602442

Human Papillomavirus Vaccine Effectiveness by Age, Age at Vaccination, and Timing of Vaccination Relative to Age at First Sex Among Men Who Have Sex With Men-Seattle, Washington, 2018 to 2020.

Buchbinder SA, Lin J, Markowitz LE, Hughes JP, Querec TD, Unger ER, Dada D, Iqbal A, Golden MR, Meites E, DeSisto CL, Winer RL.Sex Transm Dis. 2025 Oct 1;52(10):631-640. doi: 10.1097/OLQ.0000000000002192. Epub 2025 Jun 2.PMID: 40454692

Effectiveness of the 2023 Southern Hemisphere Influenza Vaccine Against Outpatient Influenza-Like Illness: A Multi-Country Test-Negative Design Study.

Regan AK, Gharpure R, Chilver M, Stocks N, St George S, Walaza S, von Gottberg A, Wolter N, Cohen C, Samuels AM, Prasert K, Praphasiri P, Davis WW, Pittayawonganon C, Sullivan SG, Azziz-Baumgartner E.Open Forum Infect Dis. 2025 Sep 17;12(10):ofaf560. doi: 10.1093/ofid/ofaf560. eCollection 2025 Oct.PMID: 41041150

B-EPIC: A Transformer-Based Language Model for Decoding B Cell Immunodominance Patterns.

Liang JZ, Wang Y, Sun C, Liu T, Wu Z, Chen L, Chen L, Li P, Li Z, Zhang C, Lu B, Chen Y, Gu B, Zhong Q, Wang XW, Zeng MS, Liu J.Adv Sci (Weinh). 2025 Oct 7:e08896. doi: 10.1002/advs.202508896. Online ahead of print.PMID: 41054859

Costs, delivery strategies and implementation challenges for malaria vaccines: a rapid review of literature.

Isah A, Obi C, Okeke I, Gwe M, Onwujekwe O.Trop Dis Travel Med Vaccines. 2025 Oct 7;11(1):34. doi: 10.1186/s40794-025-00268-x.PMID: 41057897

A Latent Class Analysis of COVID-19 Vaccine Attitudes and Beliefs: Results from a Community Survey Conducted Via the Chicagoland Community Engagement Alliance (CEAL) Program.

Vu M, Yeom J, Trinh D, Gou J, Hong T, Zaheeruddin M, Bishop-Royse J, Hartstein M, Spring B, Moskowitz D, Doan A, Martin M.J Community Health. 2025 Oct;50(5):883-895. doi: 10.1007/s10900-025-01472-8. Epub 2025 May 7.PMID: 40335867

Advances and challenges in Helicobacter pylori subunit vaccine development: antigen candidates and immunization strategies.

Liu Z, Li H, Huang X, Liu Q.J Appl Microbiol. 2025 Oct 6;136(10):lxaf236. doi: 10.1093/jambio/lxaf236.PMID: 40982232

Bimetallic nanoadjuvants for cancer vaccines.

Luo J, Wang Y, Yu C, Yang Y.Trends Pharmacol Sci. 2025 Oct;46(10):958-974. doi: 10.1016/j.tips.2025.08.007. Epub 2025 Sep 18.PMID: 40973570

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

How did Ontario healthcare institutions implement and legitimize Covid-19 vaccine mandates? A qualitative multi-method study protocol.

Chaufan C.PLoS One. 2025 Oct 3;20(10):e0332589. doi: 10.1371/journal.pone.0332589. eCollection 2025.PMID: 41042782

Characterization of patients with Candida (Candidozyma) auris before and during the COVID-19 pandemic in New York, 2017-2022.

Meek HC, Konkle S, Ostrowsky B, Rosenberg ES, Southwick K, Kogut S, Quinn M, Clement EJ, Lutterloh E.Am J Infect Control. 2025 Oct;53(10):1034-1042. doi: 10.1016/j.ajic.2025.06.016. Epub 2025 Jun 25.PMID: 40578439

Pilot Testing Digital Stories to Influence College Men's Intentions to Vaccinate Against HPV.

Koskan A, Venetis MK, Kim SW.J Cancer Educ. 2025 Oct;40(5):694-699. doi: 10.1007/s13187-024-02563-1. Epub 2025 Jan 9.PMID: 39779643

General knowledge and attitude of healthcare professionals and infrastructural readiness prior to implementation of malaria vaccine in selected hospitals in Tororo district, Uganda: a cross-sectional study.

Asio L, Besigye I, Puleh SS, Nazziwa N, Ocan M.BMC Public Health. 2025 Oct 9;25(1):3437. doi: 10.1186/s12889-025-24545-8.PMID: 41068667

Research note: Comparison of live attenuated and non-attenuated Eimeria vaccines on safety following overdose administration using the European pharmacopoeia monograph model.

Pagès M, Albó A, Bech-Sàbat G, Morató R, Molist-Badiola J, Dardi M.Poult Sci. 2025 Oct;104(10):105610. doi: 10.1016/j.psj.2025.105610. Epub 2025 Jul 25.PMID: 40752196

Alpha hemolysin enhances the immune response by modulating dendritic cell differentiation via ADAM10-Notch signaling.

Wang K, Liao J, Yuan Y, Chen Z, Gou Q, Jing H, Liang M, Tang Y, Yan P, Yu X, Zhao Z, Sun T, Xia Z, Yu T, Liao Y, Zeng H, Zhang X, Zou Q, Zhang J.Signal Transduct Target Ther. 2025 Oct 8;10(1):334. doi: 10.1038/s41392-025-02432-3.PMID: 41062455

A replicating RNA vaccine protects cynomolgus macaques against lethal clade 2.3.4.4b influenza A H5N1 virus challenge.

Hawman DW, Griffin A, McCarthy N, Okumura A, Leventhal SS, Agumamidi M, Chorabik M Jr, Altynova E, Lewis M, Hinkley T, Stone ET, Warner N, Park S, Lovaglio J, Smith BJ, Hanley P, Saturday G, Shaia C, Clancy C, Rosenke K, Erasmus JH, Feldmann H.Sci Transl Med. 2025 Oct 8;17(819):eadw4646. doi: 10.1126/scitranslmed.adw4646. Epub 2025 Oct 8.PMID: 41061043

What is the relationship between viral prospecting in animals and medical countermeasure development?

Aatresh AV, Lipsitch M.mBio. 2025 Oct 8;16(10):e0203325. doi: 10.1128/mbio.02033-25. Epub 2025 Aug 25.PMID: 40852983

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Hepatitis B vaccination status, knowledge and associated factors among healthcare professionals in Dongola, Sudan, 2024: a cross-sectional study.

Mohamed Awad M, Altalib S, Shaaban KM.BMC Infect Dis. 2025 Oct 10;25(1):1279. doi: 10.1186/s12879-025-11703-x.PMID: 41073930

Dual roles of GM-CSF in breast cancer: Immunomodulation and therapeutic implications.

Guo Y, Hu Y, Huang D, Yang J, Fu S, Deng X, Long J, Wang J, Wang Y.Crit Rev Oncol Hematol. 2025 Oct;214:104804. doi: 10.1016/j.critrevonc.2025.104804. Epub 2025 Jun 16.PMID: 40516637

The mutual cyclical influence of internet information and vaccination intention on post-dissemination vaccination: A longitudinal study during the availability period of COVID-19 booster shots.

Inoue S, Fuji K.Vaccine. 2025 Oct 3;64:127741. doi: 10.1016/j.vaccine.2025.127741. Epub 2025 Sep 16.PMID: 40961799

Factors influencing COVID-19 vaccine decision: What attitudes can we expect from young Poles in the future? A cross-sectional, representative survey.

Tomaszewska A, Bałan B, Sobeczek K, Rakocy K, Furmańczyk K, Chrzanowska M, Samel-Kowalik P, Raciborski F, Samoliński B.Int J Occup Med Environ Health. 2025 Oct 1:209538. doi: 10.13075/ijomeh.1896.02595. Online ahead of print.PMID: 41035420

Engineering of mRNA vaccine platform with reduced lipids and enhanced efficacy.

Ma X, Liu S, Zhang S, Liu Z, Wang H, Luo W, Zu M, Qin H, Li Z, Zhong J, Li J, Chen Q, Lin J, Liu A, Zhang X, Li H, Lu X, Shi X, Li L, Gu Z, Nie G, Ji T.Nat Commun. 2025 Oct 7;16(1):8913. doi: 10.1038/s41467-025-63965-3.PMID: 41057328

Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma.

Frey A, Clulo K, Fei Y, Dumit TC, Scallo F, Williams JA, Chang E, Perry CJ, Wirth LV, Jacobs D, Braun DA, Bosenberg MW, Tran TT, Clune J, Kluger HM, Olino K, Ishizuka JJ.Cell Rep. 2025 Oct 1;44(10):116359. doi: 10.1016/j.celrep.2025.116359. Online ahead of print.PMID: 41042672

TeenVac.org: A Mobile Web App to Improve Human Papillomavirus Vaccine Uptake for Adolescent Boys.

Woodall WG, Buller D, Zimet G, Kong AS, Reither J, Chilton L, Martinez L, Brooks M, Chirico N, Ginossar T.J Adolesc Health. 2025 Oct;77(4):749-755. doi: 10.1016/j.jadohealth.2025.06.015. Epub 2025 Aug 18.PMID: 40824226

High-resolution antibody dynamics following influenza vaccination reveal predominantly weak responses as well as infrequent but durable immunity across the 2014-2022 seasons.

Lane A, Quach HQ, Ovsyannikova IG, Kennedy RB, Ross TM, Einav T.Vaccine. 2025 Oct 3;64:127677. doi: 10.1016/j.vaccine.2025.127677. Epub 2025 Sep 12.PMID: 40946064

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Exploring the predictors for the uptake of Respiratory Syncytial Virus (RSV) vaccine under the immunization programme in India.

Hora R, Ray A, Kumari A, Dutta M, Mehra R, Kaur A, Quadri SF, Koshal SS, Singh SK, Sultana A, Roy AD.Vaccine. 2025 Oct 9;66:127827. doi: 10.1016/j.vaccine.2025.127827. Online ahead of print.PMID: 41072278

Maternal antibody transfer efficiency: The impact of M. bovis-BoHV-1 combined vaccine.

Zhang S, Liu G, Guo A, Chen Y.Virology. 2025 Oct;611:110656. doi: 10.1016/j.virol.2025.110656. Epub 2025 Aug 12.PMID: 40819481

Disparities and temporal trends in pneumococcal vaccination uptake among older adults in the Israeli population: A population-based retrospective cohort study.

Turjeman A, Shochat T, Drozdinsky G, Leibovici L.Vaccine. 2025 Oct 3;64:127765. doi: 10.1016/j.vaccine.2025.127765. Epub 2025 Sep 16.PMID: 40957306

Evolving strategies to optimize immunization and protection of pediatric transplantation recipients.

Danino D, Ardura MI.Curr Opin Infect Dis. 2025 Oct 1;38(5):458-467. doi: 10.1097/QCO.0000000000001125. Epub 2025 Jul 23.PMID: 40699566

Anterior Uveitis Associated with ASIA Syndrome: A Distinct Clinical Entity?

Barman Kakil Ş, Pekdiker M, Akikol T.Ocul Immunol Inflamm. 2025 Oct;33(8):1712-1718. doi: 10.1080/09273948.2025.2530131. Epub 2025 Jul 10.PMID: 40638894

Individual vs societal perspectives: implications on quantitative benefit-risk assessment of vaccination.

Kitano T, Salmon DA, Dudley MZ, Saldanha IJ, Levy JF, Austin JM, Thompson DA, Engineer L.Expert Rev Pharmacoecon Outcomes Res. 2025 Oct 10:1-9. doi: 10.1080/14737167.2025.2572319. Online ahead of print.PMID: 41054401

PhenoAge acceleration predicts antibody persistence and breakthrough infection after SARS-CoV-2 vaccination and infection.

Yang JH, Lee CL, Chiu YF, Chiu SY, Wang LJ, Sheng TW, Wang SC, Huang SC, Huang SH, Lin CM, Wei KC, Hsieh JC.J Infect Public Health. 2025 Oct 10;18(12):102989. doi: 10.1016/j.jiph.2025.102989. Online ahead of print.PMID: 41076847

The impact of viral evolution on vaccine development for SARS-CoV-2.

Bachmann MF, Mohsen MO, Speiser DE.Curr Opin Immunol. 2025 Oct;96:102612. doi: 10.1016/j.coi.2025.102612. Epub 2025 Jul 18.PMID: 40684673

Yonder: Access and quality of life, vaccine hesitancy, SABAs and acute cardiovascular events, and air quality.

Burrell A.Br J Gen Pract. 2025 Sep 25;75(759):472. doi: 10.3399/bjgp25X743337. Print 2025 Oct 1.PMID: 40998715

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Association of 2024-2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans.

Cai M, Xie Y, Al-Aly Z.N Engl J Med. 2025 Oct 8. doi: 10.1056/NEJMoa2510226. Online ahead of print.PMID: 41061231

Economic evaluation of the second booster dose of diphtheria-tetanus-acellular pertussis vaccine for children aged 6 years in Zhejiang Province: A cost-utility analysis.

Su Y, Zhou Y, Luo F, Zheng S, He H, Zhu Y, Tang X.Hum Vaccin Immunother. 2025 Dec;21(1):2563447. doi: 10.1080/21645515.2025.2563447. Epub 2025 Oct 8.PMID: 41060213

Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial.

Diemert DJ, Graciaa DS, Zhang B, Rouphael NG, Branche AR, Martin TCS, Jackson LA, Presti RM, Kamidani S, Mahgoub SM, Babu TM, Magaret CA, Simon V, van Bakel H, Roberts PC, Beigel JH, Gilbert PB, Follmann D; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team.Vaccine. 2025 Oct 3;64:127718. doi: 10.1016/j.vaccine.2025.127718. Epub 2025 Sep 9.PMID: 40930044

Class switch toward IgG2 and IgG4 is more pronounced in BNT162b2 compared to mRNA-1273 COVID-19 vaccinees.

Siebner AS, Griesbaum J, Huus KE, Flügge J, Hopfensperger K, Michel T, Schneiderhan-Marra N, Sauter D, Kremsner PG, Ley RE, Dulovic A, Esen M.Int J Infect Dis. 2025 Oct;159:107990. doi: 10.1016/j.ijid.2025.107990. Epub 2025 Jul 17.PMID: 40681092

Evaluating the effect of vaccination on the impact of BTV-3 in Dutch sheep flocks in 2024.

Dijkstra E, Santman-Berends IMGA, Stegeman A, van den Brink KMJA, van Schaik G, van den Brom R.Vet Microbiol. 2025 Oct;309:110652. doi: 10.1016/j.vetmic.2025.110652. Epub 2025 Jul 24.PMID: 40819644

The silent surge: the under-recognised burden of respiratory syncytial virus, human metapneumovirus, and parainfluenza viruses in adults.

Davido B, Loubet P.Int J Infect Dis. 2025 Oct;159:108006. doi: 10.1016/j.ijid.2025.108006. Epub 2025 Aug 5.PMID: 40752767

Predictors of hepatitis B vaccination uptake among healthcare workers in Benadir region, Somalia: a multicenter study.

Mohamoud JH, Mohamed AMS, Adam MH, Garba B, Halane SA, Mahamud MA.Sci Rep. 2025 Oct 8;15(1):35202. doi: 10.1038/s41598-025-19165-6.PMID: 41062744

Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine.

El Hindi T, Anugulruengkitt S, Lapphra K, Limkittikul K, Tangsathapornpong A, Galindo CM, Hellwig M, Roubinis N, Schuring R, Biswal S, Folschweiller N.Vaccine. 2025 Oct 6:127786. doi: 10.1016/j.vaccine.2025.127786. Online ahead of print.PMID: 41058426

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Human Metapneumovirus (HMPV): Current insights and future perspectives.

Garg A, Singh R, Gupta D, Nayak S, Gambhir RS.Przegl Epidemiol. 2025 Oct 3;79(2):178-186. doi: 10.32394/pe/206000. Epub 2025 Jul 2.PMID: 41042954

Overview of the tuberculosis vaccine development landscape.

Velayutham B.Indian J Tuberc. 2025 Oct;72(4):517-520. doi: 10.1016/j.ijtb.2025.01.004. Epub 2025 Jan 19.PMID: 40975584

Adopting the estimand framework in prophylactic vaccine trials.

Beckers F, Karkada N, Yang Y, Scott J, Huang L, Klinglmüller F, Fay MP, Englert S, Spiessens B, Van Dromme I, Shekar T, Zhou H, Deng Q, Casula D, Janes H, Moulton LH.Vaccine. 2025 Oct 3;64:127645. doi: 10.1016/j.vaccine.2025.127645. Epub 2025 Sep 3.PMID: 40907068

Neutralizing antibodies induced by IpaB and IpaC mRNA vaccines inhibit *Shigella flexneri* invasion.

Moon Y-E, An T, Park P-G, Hong K-J.Microbiol Spectr. 2025 Oct 7;13(10):e0099325. doi: 10.1128/spectrum.00993-25. Epub 2025 Sep 2.PMID: 40891984

Vaccination models of delivery for refugees and migrants: a global scoping review.

Aghajafari F, Guzek D, Kamal H, Ness A, Wall L, McClurg C, Pooladi-Darvish A, Weightman AM, Coakley A.BMC Public Health. 2025 Oct 8;25(1):3396. doi: 10.1186/s12889-025-24315-6.PMID: 41063068

Vaccination models of delivery for refugees and migrants: a global scoping review.

Aghajafari F, Guzek D, Kamal H, Ness A, Wall L, McClurg C, Pooladi-Darvish A, Weightman AM, Coakley A.BMC Public Health. 2025 Oct 8;25(1):3396. doi: 10.1186/s12889-025-24315-6.PMID: 41063068

Vaccination equity: a warning from the COVID-19 pandemic.

Alford S.Brain Behav Immun. 2025 Oct;129:294-295. doi: 10.1016/j.bbi.2025.06.022. Epub 2025 Jun 14.PMID: 40523536

Utilization of population-wide digital contact tracing to estimate real-world vaccine effectiveness in a pandemic setting.

Chan JWQ, Wee LE, Abdul Malek MIB, Chiew C, Ho ZJM, Ong B, Heng D, Lee V, Lye D, Tan KB.Clin Microbiol Infect. 2025 Oct;31(10):1713-1719. doi: 10.1016/j.cmi.2025.06.014. Epub 2025 Jun 16.PMID: 40532758

Enhancing vaccine stability in transdermal microneedle platforms.

Pahal S, Huang F, Singh P, Sharma N, Pham HP, Tran TBT, Sakhrie A, Akbaba H, Duc Nguyen T.Drug Deliv Transl Res. 2025 Oct;15(10):3414-3438. doi: 10.1007/s13346-025-01854-4. Epub 2025 Apr 16.PMID: 40240731

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Using machine learning models to predict vaccine hesitancy: a showcase of COVID-19 vaccine hesitancy in rural populations during the pandemic.

Ge Y, Zahid A, Kuchur R, Martinez L, Wang B, Zhang L, Aras S, Raynee P, Dike A, Navarro C, Lawrick C, Greer T, Twum F, Shen Y, Gipson J, Lemacks J.Vaccine. 2025 Oct 10;66:127799. doi: 10.1016/j.vaccine.2025.127799. Online ahead of print.PMID: 41075400

Pneumonia Vaccines: Indications for Use and Current Safety Data in Pregnancy.

Dutra K, Berry H, Lazenby GB.Am J Perinatol. 2025 Oct;42(14):1809-1818. doi: 10.1055/a-2505-5434. Epub 2024 Dec 19.PMID: 39701146

Detection of initial intra-cellular functional, structural and ultra-structural changes in virus-inoculated cells: A pilot study.

Sainova I, Hadjiolova R, Petrov A, Dimitrova-Dikanarova D, Markova T.Infect Genet Evol. 2025 Oct;134:105801. doi: 10.1016/j.meegid.2025.105801. Epub 2025 Jul 21.PMID: 40701489

Safety and immunogenicity of a single booster dose of the group B streptococcus AlpN candidate vaccine (GBS-AlpN) in previously vaccinated healthy women compared with a single dose in previously unvaccinated women.

Johansson-Lindbom B, Kitson G, Oostvogels L, Darsley M, Fischer PB.Vaccine. 2025 Oct 4;65:127820. doi: 10.1016/j.vaccine.2025.127820. Online ahead of print.PMID: 41046840

The IFPMA IVS seasonal influenza vaccine dose distribution survey 2022-2023: evidence of the need for committed national investment in and uptake of seasonal influenza vaccination.

Palache B, Fyyaz H, Thomson D, Taylor B, Copping E, Barbosa P; IFPMA Influenza Vaccine Supply (IFPMA IVS) task force.Vaccine. 2025 Oct 3;64:127747. doi: 10.1016/j.vaccine.2025.127747. Epub 2025 Sep 21.PMID: 40983024

Potential predictors of COVID-19 booster vaccine confidence among adult people: a cross-sectional analysis amid the Omicron surge in Southern Bangladesh.

Roy DN, Rashid M, Aktar A, Parvin MS, Islam ME.Vaccine. 2025 Oct 3;64:127693. doi: 10.1016/j.vaccine.2025.127693. Epub 2025 Sep 5.PMID: 40913815

Changes in the Streptococcus pneumoniae population responsible for invasive disease of young children after the implementation of conjugated vaccines in the National Immunization Program in Poland.

Wróbel-Pawelczyk I, Gołębiewska A, Ronkiewicz P, Kiedrowska M, Błaszczyk K, Kuch A, Sadowy E, Hryniewicz W, Litt D, Groves N, Skoczyńska A.Vaccine. 2025 Oct 3;64:127759. doi: 10.1016/j.vaccine.2025.127759. Epub 2025 Sep 19.PMID: 40974736

Conserved domains of flagellin as adjuvants for an inactivated vaccine against porcine epidemic diarrhea virus.

Afzal H, Hoa NT, Murtaza A, Doan TD, Chung YC, Ke GM, Cheng LT.Vet J. 2025 Oct;313:106393. doi: 10.1016/j.tvjl.2025.106393. Epub 2025 Jun 16.PMID: 40532846

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Monitoring for classical swine fever virus persistence and seropositivity in vaccinated pig farms using on-farm sentinel pigs during the pre-elimination phase toward a CSF-free status.

Tsai KJ, Chen HY, Wang C, Hung CS, Hsu WC, Chen TH, Deng MC, Tsai CT, Lin NN, Hsu JP, Chang CY, Huang YL.Prev Vet Med. 2025 Oct;243:106610. doi: 10.1016/j.prevetmed.2025.106610. Epub 2025 Jul 1.PMID: 40614530

Incorporating meningeal immunity into vaccine development.

Menon M, Haile CN, Dowling DJ.Nat Commun. 2025 Oct 9;16(1):8981. doi: 10.1038/s41467-025-64476-x.PMID: 41068115

An O-Specific Polysaccharide Shigella flexneri 3a Conjugate Vaccine is Immunogenic and Protective against Virulent Keratoconjunctival Challenge in Guinea Pigs.

Janardhanan J, Wagh C, Yang J, Charles RC, Pansuriya RK, Chowdhury F, Kaminski RW, Khan AI, Bhuiyan TR, Qadri F, Kováč P, Xu P, Ryan ET.Am J Trop Med Hyg. 2025 Aug 5;113(4):737-743. doi: 10.4269/ajtmh.25-0269. Print 2025 Oct 1.PMID: 40763727

Differentiating COVID-19 vaccine-related adverse events from long COVID: A comprehensive review of clinical manifestations, pathophysiology, and diagnostic approaches.

Domingo JL.Vaccine. 2025 Oct 11;66:127842. doi: 10.1016/j.vaccine.2025.127842. Online ahead of print.PMID: 41076807

Influence of eHealth literacy on acceptance of healthcare services with risks in China: chain-mediating effect of general risk propensity and self-efficacy.

Chen J, Chen X, Tang Z, Lei L, Zhan Y, Liu S, Zhou H, Wan J, Chen Z, Wu Y, Luo Z.Public Health. 2025 Oct;247:105891. doi: 10.1016/j.puhe.2025.105891. Epub 2025 Aug 14.PMID: 40816112

A Scientometric Analysis of the Global Epidemiology of Childhood Vaccine Hesitancy Among Turkish Parents.

Yılmazel G, Keleş E.Public Health Nurs. 2025 Oct 10. doi: 10.1111/phn.70022. Online ahead of print.PMID: 41070937

No disproportionate reporting of inflammatory arthritis following COVID-19 vaccination: a pharmacovigilance study using VAERS data.

Ciaffi J, Torrigiani G, Ruscitti P, Zambon A, Ursini F.Semin Arthritis Rheum. 2025 Oct;74:152827. doi: 10.1016/j.semarthrit.2025.152827. Epub 2025 Sep 4.PMID: 40939515

Expanded CD16^{+}CD56^{+}Granzyme B^{+} NK like CD8^{+} T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia.

Hastak P, Phetsouphanh C, Zhang ZH, Bull RA, Shrestha LB, Klemm V, Louie R, Luciani F, Munier CML, Hoppé AC, Keoshkerian E, Beaton B, Rankin K, Wong A, Trotman J, Kelleher AD, Sasson SC.Sci Rep. 2025 Oct 5;15(1):34641. doi: 10.1038/s41598-025-18450-8.PMID: 41047388

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Unlocking the potential of blood-stage vaccines for malaria elimination.

Nema S, Rathore S, Mohmmed A, Malhotra P.Trans R Soc Trop Med Hyg. 2025 Oct 1;119(10):1200-1203. doi: 10.1093/trstmh/traf013.PMID: 39921411

Risk of Highly Pathogenic Avian Influenza A/H5N1 Virus in Pediatrics.

Healy CM.J Pediatric Infect Dis Soc. 2025 Oct 2;14(10):piaf035. doi: 10.1093/jpids/piaf035.PMID: 40289622

Recombinant Orf viral vectors: A novel vaccine platform.

Penaloza-MacMaster P.Mol Ther. 2025 Oct 2:S1525-0016(25)00768-3. doi: 10.1016/j.ymthe.2025.09.039. Online ahead of print.PMID: 41043425

Vaccine-Induced Specific Cellular and Humoral Immunity after MRNA-Based COVID-19 Vaccination in Athletes and Controls.

Klemis V, Schmidt T, Venhorst A, Halmans L, Marx S, Hielscher F, Urschel R, Guckelmus C, GREIß F, Sester U, Gärtner BC, Meyer T, Sester M.Med Sci Sports Exerc. 2025 Oct 1;57(10):2119-2128. doi: 10.1249/MSS.0000000000003757. Epub 2025 May 14.PMID: 40367509

Gut microbiota as a regulator of vaccine efficacy: implications for personalized vaccination.

Lu Q, Feng Y, Wang H, Zhu K, Teng L, Yue M, Li Y.Gut Microbes. 2025 Dec 31;17(1):2563709. doi: 10.1080/19490976.2025.2563709. Epub 2025 Oct 6.PMID: 41047820

Nanoadjuvant-Mediated EV-Derived Artificial APC to Trigger Protective Immunity Against Virus Infection.

Pan X, Lv Y, Zheng Z, Li C, Hu L, Lin J, Tang R, Wang X.Small. 2025 Oct;21(40):e01291. doi: 10.1002/smll.202501291. Epub 2025 Aug 13.PMID: 40801246

Immune cell transcriptional profiles from pre-vaccination peripheral blood predict immune response to preventative MUC1 cancer vaccine.

Yuan DY, McKeague ML, Raghu VK, Schoen RE, Finn OJ, Benos PV.Eur J Cancer. 2025 Oct 1;228:115685. doi: 10.1016/j.ejca.2025.115685. Epub 2025 Aug 5.PMID: 40815873

Vaccine Treatment and Evaluation Units: Why Support a "Ready Base" of Clinical Trial Sites?

Erbelding EJ, Marrazzo JM.Clin Infect Dis. 2025 Oct 10;81(Supplement_2):S55-S58. doi: 10.1093/cid/ciaf376.PMID: 41071735

Volunteer scientists work 'nights and weekends' to guide vaccine advice in US.

Lenharo M.Nature. 2025 Oct 6. doi: 10.1038/d41586-025-03181-7. Online ahead of print.PMID: 41057701

Herpes zoster reactivation in a cohort of people living with HIV vaccinated with recombinant vaccine.

Arsuffi S, Rossi L, Colombo FR, Inverardi M, Mirovic E, Laurenda D, Izzo I, Rapino S, Castelli D, Gaffurini F, Polesini I, Castelli F, Calza S, Quiros-Roldan E, Focà E.Vaccine. 2025 Oct 3;64:127723. doi: 10.1016/j.vaccine.2025.127723. Epub 2025 Sep 9.PMID: 40930046

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

"Life as We Knew It": Continued Challenges in Getting Up-to-Date COVID-19 Vaccinations Amongst Black and Latinx Michigan Residents.

Cross FL, Esqueda AP, Ku CP, Hunt R, Lucio J, Williams CE 2nd, Bailey S, Williamson S, Marsh EE, Resnicow K.J Racial Ethn Health Disparities. 2025 Oct;12(5):3556-3567. doi: 10.1007/s40615-024-02157-z. Epub 2024 Sep 3.PMID: 39227548

Comparison of total IgG and neutralizing antibody responses to a novel trivalent recombinant Mannheimia haemolytica vaccine containing serotype 6.

Balevi A, İlban A, Uslu A, Toslak EE, Sayın Z, Gölen GS, Karyeyen Y, Gök A, Kebabcıoglu C, Erganis O.Microb Pathog. 2025 Oct;207:107875. doi: 10.1016/j.micpath.2025.107875. Epub 2025 Jul 5.PMID: 40623483

Preferences and willingness-to-pay for human papillomavirus vaccination among men who have sex with men in China: a discrete choice experiment.

Zou Z, Hu Y, Yang H, Zhao M, Cao Y, Tieosapjaroen W, Soe NN, Latt PM, Ong JJ, Zhuang G, Zhang L.Vaccine. 2025 Oct 4;65:127806. doi: 10.1016/j.vaccine.2025.127806. Online ahead of print.PMID: 41046841

Temporal stability of preferences: The case of COVID-19 vaccines in Australia and New Zealand.

Tran M, Maris R, Hess S, Dorner Z, Huynh E, Glass K, Lancsar E.Soc Sci Med. 2025 Oct;383:118417. doi: 10.1016/j.socscimed.2025.118417. Epub 2025 Jul 25.PMID: 40784147

Building and Sustaining Flu Vaccine Acceptance and Trust in the Black Community through Partnerships with Churches, Salons, and Barbershops.

Nuss H, Privor-Dumm L, Ukachukwu C, Hall LL.J Racial Ethn Health Disparities. 2025 Oct;12(5):3365-3374. doi: 10.1007/s40615-024-02141-7. Epub 2024 Sep 6.PMID: 39240452

Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination.

Purcell RA, Koutsakos M, Kedzierski L, Allen LF, Lloyd Williams OH, Wang JD, Cavic G, Wheatley AK, Lee WS, Wines BD, Mark Hogarth P, Eriksson EM, Mueller I, Bond KA, Williamson DA, Trevillyan JM, Trubiano JA, Nguyen THO, Ramanathan P, Rogerson SJ, Arnold KB, Subbarao K, Lee A, Hudson AL, Yuile A, Wheeler HR, Kent SJ, Selva KJ, Mahanty S, Kedzierska K, Fahrer AM, Kanjanapan Y, Chung AW.NPJ Vaccines. 2025 Oct 6;10(1):217. doi: 10.1038/s41541-025-01268-w.PMID: 41053135

Validation and evaluation of the rapid fluorescent focus inhibition test (RFFIT) for the quantification of neutralizing antibodies as an indirect measure of rabies vaccine relative potency: An alternative to the NIH test.

Tibavija SS, Almario MP, Jaramillo V, Rivera J, Chaparro CY, Paramo C, García DF, Ladino L, Suarez ZR.Vaccine. 2025 Oct 3;64:127724. doi: 10.1016/j.vaccine.2025.127724. Epub 2025 Sep 10.PMID: 40934733

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Mpox infection: A state-of-the-art overview of epidemiological, molecular, and clinical aspects following the 2024 public health emergency.

Zamani S, Noroozi E, Hasanzadeh A, Zamani E, Trinidad JC, Firooz A.J Infect Public Health. 2025 Oct;18(10):102940. doi: 10.1016/j.jiph.2025.102940. Epub 2025 Aug 28.PMID: 40885131

Comparing the immunogenicity of intradermal and intramuscular vaccination of elderly with BNT162b2 XBB.1.5: An equivalent dose study.

van Beek LF, He X, Koks MS, van der Gaast-de Jongh CE, Roukens AHE, Visser LG, Diavatopoulos DA, de Graaf H, de Jonge MI.Vaccine. 2025 Oct 3;64:127749. doi: 10.1016/j.vaccine.2025.127749. Epub 2025 Sep 15.PMID: 40957304

A simulation-based policy analysis of anticipatory action for cholera outbreaks, Democratic Republic of the Congo.

Loo PS, Rajah JK, de Leon HJH, Kopainsky B, Milano L.Bull World Health Organ. 2025 Oct 1;103(10):607-618. doi: 10.2471/BLT.25.293226. Epub 2025 Sep 3.PMID: 41035558

Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19.

Almeida GG, Pinto JA, Pinto PM, da Silva LB, Andrade LAF, Valiate BVS, Zini N, Bagno FF, Rivelli GG, Lourenço KL, Souza JPC, Gomes IP, de Castro NS, Maia ALC, de Carvalho AF, Alves JC, de Castro JT, Li G, da Rocha Fernandes G, Alves PA, Diniz RC, Daher AB, de Souza RP, Teixeira SMR, Fernandes APSM, Gazzinelli RT, da Costa Santiago H.Vaccine. 2025 Oct 3;64:127756. doi: 10.1016/j.vaccine.2025.127756. Epub 2025 Sep 19.PMID: 40974737

In silico design and assessment of a multiepitope and multiantigen potential vaccine candidate against Leishmania donovani.

Saha S, Laskar S, Gunalan S, Kothandan G, Kumar D.In Silico Pharmacol. 2025 Oct 3;13(3):140. doi: 10.1007/s40203-025-00433-2. eCollection 2025.PMID: 41048573

Longitudinal study on changes in COVID-19 vaccination intentions in Benin and Senegal: Insights from Generalized Estimating Equations (GEE).

Gaye I, Faye A, Avahoundje EM, Ba MF, Ridde V.Hum Vaccin Immunother. 2025 Dec;21(1):2565927. doi: 10.1080/21645515.2025.2565927. Epub 2025 Oct 7.PMID: 41054838

Vaccination with a novel quadrivalent fusion protein protects chickens against necrotic enteritis lesions caused by Clostridium perfringens.

Manohar MM, Campbell BE, Keyburn AL, Walduck AK, Moore RJ.Poult Sci. 2025 Oct 3;104(12):105936. doi: 10.1016/j.psj.2025.105936. Online ahead of print.PMID: 41072087

Testing Psychological Correlates of Ambiguity Aversion in the Context of COVID-19 Vaccination: Evidence for Motivated Reasoning and the Appraisal-Tendency Framework.

Simonovic N, Gesser-Edelsburg A, Taber JM.Behav Med. 2025 Oct-Dec;51(4):332-346. doi: 10.1080/08964289.2025.2497808. Epub 2025 May 23.PMID: 40407143

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Interplay of host and viral genetic variations in modulating antibody responses to genotype 3a hepatitis C virus: Implications for vaccine design.

Wang Z, Humphreys I, Quistrebert J, Chai H, Stass R, Dhir J, Nisioi A, Radford P; STOP-HCV consortium; Ball JK, Irving WL, Bowden TA, Klenerman P, Barnes E, McKeating JA, Tarr AW, Ansari MA.Cell Rep. 2025 Oct 10;44(10):116418. doi: 10.1016/j.celrep.2025.116418. Online ahead of print.PMID: 41076628

Influences and Implications of Medical Mistrust on Healthcare Behaviors in a Low Health Outcomes County in the State of New Jersey.

Johnson D, Javed A, Byrnes NJ, Jones AC, Bertsch KN.J Community Health. 2025 Oct;50(5):939-947. doi: 10.1007/s10900-025-01483-5. Epub 2025 May 27.PMID: 40425979

The efficacy and effectiveness of COVID-19 vaccines in Iran: a systematic review and meta-analysis.

Mousavi SM, Younesian S, Yunesian M, Fotouhi A.BMC Infect Dis. 2025 Oct 7;25(1):1245. doi: 10.1186/s12879-025-11716-6.PMID: 41057795

A Qualitative Study of Social Processes, HPV Vaccine Attitudes, and Vaccination Behavior Among Hesitant Adopter Parents.

Moore R, Purvis RS, Willis DE, Li J, Sorrell S, Lee SC, Finley EP, Sexton K, Kraleti S, James C, McElfish PA.Clin Pediatr (Phila). 2025 Oct;64(10):1388-1399. doi: 10.1177/00099228251335851. Epub 2025 May 4.PMID: 40319367

Comparative Epidemiology of Salmonella enterica Serovers Paratyphi A and Typhi Causing Enteric Fever, Bangladesh, 2018-2020.

Rahman SIA, Firoj MG, Park SE, Khanam F, Agampodi S, Haile K, Mesfin E, Ahmmed F, Islam MT, Khan AI, Chowdhury F, Akter A, Mwebia MB, Im J, Rickett NY, Mbae CK, Aziz AB, Ongadi B, Mwangi M, Ngugi B, Behute MG, Kering K, Kanungo S, Liu X, Kim DR, Pollard AJ, Zaman K, Kariuki S, Qadri F, Clemens JD.Emerg Infect Dis. 2025 Oct;31(10):1922-1934. doi: 10.3201/eid3110.241601.PMID: 41017031

Nanobody-based epitope mapping and establishment of a blocking ELISA for S protein of porcine epidemic diarrhea virus.

Yang X, Yang J, Su X, Fang R, Xu Z, Shen Y, Qi W, Xiao Z, Wang H.Int J Biol Macromol. 2025 Oct 9:148110. doi: 10.1016/j.ijbiomac.2025.148110. Online ahead of print.PMID: 41075890

Peri-Conception Human Papillomavirus Vaccination Exposure and Risk of Birth Defects: A Population-Based Retrospective Cohort Study.

Guo J, Zhao P, Liu C, Liao M, Chen J, Ren Y, Yao G, Qian Y, Rong B, Qi H, Chen M, Zou K, Xiong Y, Sun X, Tan J.Pharmacoepidemiol Drug Saf. 2025 Oct;34(10):e70222. doi: 10.1002/pds.70222.PMID: 40984047

Epstein-Barr virus (EBV) infection and its sequelae in the immunocompetent host.

Meirhaeghe MR, Balfour HH Jr.J Clin Virol. 2025 Oct;180:105854. doi: 10.1016/j.jcv.2025.105854. Epub 2025 Aug 8.PMID: 40816194

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Noninferiority Study of Purified Vero Rabies Vaccine-Serum Free in 3-dose and 2-dose Preexposure Prophylaxis Regimens in Comparison With Licensed Rabies Vaccines.

Chokephaibulkit K, Huoi C, Tantawichien T, Mootsikapun P, Kosalaraksa P, Kiertiburanakul S, Ratanasuwan W, Vangelisti M, Laot T, Huang Y, Petit C, Pineda-Peña AC, Frago C.Clin Infect Dis. 2025 Oct 6;81(3):654-666. doi: 10.1093/cid/ciae581.PMID: 39587931

Sex-dependent impairment of antibody responses to tick-borne encephalitis virus vaccination and infection in obese mice.

Dvorak M, Arbon D, Salat J, Fortova A, Pajuelo Reguera D, Frckova T, Holoubek J, Balounova J, Prochazka J, Sedlacek R, Ruzek D.J Gen Virol. 2025 Oct;106(10):002161. doi: 10.1099/jgv.0.002161.PMID: 41051946

Salvia miltiorrhiza polysaccharide-Mn2+-PLGA as an adjuvant in H9N2 vaccine: Immunomodulatory effects in chickens.

Zhu Y, Gu P, Bao Y, Song B, Zhang J, Wang X, Shi W.Poult Sci. 2025 Oct;104(10):105599. doi: 10.1016/j.psj.2025.105599. Epub 2025 Jul 26.PMID: 40753653

Development of a Multiple Epitopes-Based Dengue Vaccine: An Immunoinformatics Approach and Insights From Pakistani Population Genetics.

Hassan A, Mahmood MS, Idrees M, Afzal S.Microbiol Immunol. 2025 Oct 8. doi: 10.1111/1348-0421.70015. Online ahead of print.PMID: 41063484

Exploring Attitudes and Obstacles Around Digital Public Health Tools: Insights From a Statewide Cross-Sectional Survey on Washington's Vaccine Verification System.

Molino AR, Revere D, Hills RA, Elder AS, West LM, Karras BT, Baumgartner C, Baseman JG.J Med Internet Res. 2025 Oct 3;27:e66550. doi: 10.2196/66550.PMID: 41042596

Effects of immersion vaccination in striped catfish (Pangasianodon hypophthalmus) using a cationic lipid-based mucoadhesive nanovaccine against Edwardsiella ictaluri.

Kitiyodom S, Kamble MT, Yostawonkul J, Sukkarun P, Thompson KD, Pirarat N.Fish Shellfish Immunol. 2025 Oct;165:110540. doi: 10.1016/j.fsi.2025.110540. Epub 2025 Jul 2.PMID: 40614946

Evaluating Now I Know mHealth intervention promoting HPV vaccine completion among young women attending federally supported clinics.

Kim SK, Duncan R, Chittams J, Teitelman AM.Cancer Causes Control. 2025 Oct 11. doi: 10.1007/s10552-025-02046-8. Online ahead of print.PMID: 41075078

Barriers and enablers to childhood immunization in high zero-dose burden communities in Kano and Lagos states, Nigeria.

Bolarinwa OA, Salaudeen GA, Lar L, Alhaffar M, Abdelmagid N, McGowan CR, Adesoro O, Valentine P, Ahmed T, Clarke A, Makunja S, Akande TM.Vaccine. 2025 Oct 3;64:127754. doi: 10.1016/j.vaccine.2025.127754. Epub 2025 Sep 13.PMID: 40946351

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Assessment of influenza vaccine effectiveness among the elderly in Taiwan using population-based registry data for the 2023-2024 season.

Huang YT, Tsou TP, Kuo SH, Huang YT.Vaccine. 2025 Oct 3;64:127690. doi: 10.1016/j.vaccine.2025.127690. Epub 2025 Sep 5.PMID: 40913816

Small bowel obstruction secondary to peritoneal tuberculosis: A case report.

Renshaw MJ, Webster PJ.Surgeon. 2025 Oct;23(5):313-315. doi: 10.1016/j.surge.2025.04.027. Epub 2025 May 23.PMID: 40413096

Randomised controlled field trial to assess the safety and efficacy of a killed autologous vaccine against Streptococcus dysgalactiae subspecies dysgalactiae in a sheep flock.

Angell JW, Ahmed N, Jackson LP, Kasiora K, Ballingall K, Duncan JS.Vet Rec. 2025 Oct 10:e5667. doi: 10.1002/vetr.5667. Online ahead of print.PMID: 41071169

Bacterial outer membrane vesicles in immune modulation: from mechanisms to applications.

Wang Y, Yang R, Luo J, Li J, Huang B, Yang J.J Mater Chem B. 2025 Oct 8. doi: 10.1039/d5tb01708d. Online ahead of print.PMID: 41058591

Time intervals from vaccine administration to reimbursement for an updated Advisory Committee on Immunization Practices (ACIP) recommendation: Evidence from pneumococcal conjugate vaccinations among privately insured adults, 2021-2022.

Rosenblum HG, Carpenter CM, Trosclair T, Kaul R, Cho BH, Kobayashi M, Leidner AJ.Vaccine. 2025 Oct 3;64:127665. doi: 10.1016/j.vaccine.2025.127665. Epub 2025 Sep 26.PMID: 41014761

Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials.

White RG, Churchyard GJ, Horton KC, Fiore-Gartland A, Behr MA, Clark RA, Cobelens F, Ernst JD, Esmail H, Garcia-Basteiro AL, Hadinegoro SR, Hanekom WA, Hatherill M, Hill PC, Muloiwa R, Pelzer PT, Rangaka L, Rees H, Schrager L, Stanley M, Tufet M, Wong EB, Houben RMGJ.Lancet Respir Med. 2025 Oct;13(10):933-942. doi: 10.1016/S2213-2600(25)00164-X. Epub 2025 Jul 3.PMID: 40618773

Superior Effectiveness and Estimated Public Health Impact of Cell- Versus Egg-Based Influenza Vaccines in Children and Adults During the US 2023-2024 Season.

Stein AN, Thanataveerat A, McDermott K, Dean A, Wall S, Pack C, McGovern I, Sullivan SG, Haag M.Infect Dis Ther. 2025 Oct 3. doi: 10.1007/s40121-025-01230-2. Online ahead of print.PMID: 41042449

Motivators and Barriers to COVID-19 Vaccination Intentions Across U.S. County-Level Barriers in the COVID-19 Vaccine Coverage Index.

Fernandez JR, Richmond J, Strassle PD, Cunningham-Erves J, Forde AT.J Racial Ethn Health Disparities. 2025 Oct;12(5):2882-2895. doi: 10.1007/s40615-024-02096-9. Epub 2024 Aug 2.PMID: 39093376

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Application of a novel virus-like particle platform to the development of Neisseria vaccines.

Tornaletti LB, Alabbad AF, Thistlethwaite A, Rashmi S, Derrick JP.J Biotechnol. 2025 Oct;406:190-197. doi: 10.1016/j.jbiotec.2025.07.012. Epub 2025 Jul 16.PMID: 40680861

Temperature stability of rabies neutralizing antibodies.

Jones NJ, Appler KA, Jarvis JJ, Keyel AC, Davis AD.J Immunol Methods. 2025 Oct 8:113982. doi: 10.1016/j.jim.2025.113982. Online ahead of print.PMID: 41072607

Emerging nano-vaccine technologies to overcome anti-microbial resistance.

Choi H, Son S.J Control Release. 2025 Oct 10;386:114076. doi: 10.1016/j.jconrel.2025.114076. Epub 2025 Jul 29.PMID: 40744147

Recombinant Lactococcus lactis-based oral vaccine expressing non-toxic alpha toxin domains of Clostridium septicum can offer protection against Clostridial dermatitis in turkeys.

John FA, Criollo V, Gaghan C, Armwood AR, Boodhoo N, Thachil AJ, O'Flaherty S, Kulkarni RR.Vaccine. 2025 Oct 3;65:127801. doi: 10.1016/j.vaccine.2025.127801. Online ahead of print.PMID: 41046832

Designing a "Deep End" childhood immunisation intervention: a pre-implementation qualitative study.

Sacre A, Todd A, Bambra C, Sowden S.BJGP Open. 2025 Oct 8:BJGPO.2025.0110. doi: 10.3399/BJGPO.2025.0110. Online ahead of print.PMID: 41062251

Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation.

Jano K, Babu TM, Kottkamp AC, Rebolledo PA, Parameswaran L, Wiley Z, Branche AR, Kotloff K.Clin Infect Dis. 2025 Oct 10;81(Supplement_2):S117-S124. doi: 10.1093/cid/ciaf377.PMID: 41071742

One Action and Multiple Results: Influenza A Virus and SARS-CoV-2 Poly-Epitope-Based Hybrid Vaccine Exploration by Reverse Vaccinology and Immunoinformatic Methods.

Razmjooei F, Izadi M, Dehghanian A, Hassani S, Mir H, Mofazzal Jahromi MA, Bagherzadeh MA.Hum Immunol. 2025 Oct 4;86(6):111588. doi: 10.1016/j.humimm.2025.111588. Online ahead of print.PMID: 41046591

Genetic diversity and natural selection of cell-traversal protein for ookinetes and sporozoites (CelTOS) in Plasmodium falciparum isolates from Vietnam.

Võ TC, Lê HG, Kang JM, Minh Trinh NT, Cho M, Goo YK, Quang HH, Na BK.Gene. 2025 Oct 10;968:149731. doi: 10.1016/j.gene.2025.149731. Epub 2025 Aug 25.PMID: 40865741

Molecular divergence and convergence of mammalian antibody responses to the influenza virus hemagglutinin stem.

Lv H, Teo QW, Pholcharee T, Liu W, Roy S, Shi L, Gopal AB, Ardagh MR, Chen C, Sun Y, Huan YW, Harrington WN, Mehta A, Szlembarski M, Choi D, Gao Q, Fung FSL, Xu F, Webby RJ, Mok CKP, Ma W, Wu

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

NC.Proc Natl Acad Sci U S A. 2025 Oct 7;122(40):e2510927122. doi: 10.1073/pnas.2510927122. Epub 2025 Sep 29.PMID: 41021799

Unveiling the responsible antigen in vaccine-induced immune thrombotic thrombocytopenia.

Uzoigwe CE.Br J Haematol. 2025 Oct;207(4):1726-1727. doi: 10.1111/bjh.70084. Epub 2025 Aug 5.PMID: 40762348

A consensus HA DNA vaccine targeting clade 2.3.4.4 H5Nx influenza viruses provides broad cross-clade protection in mice and ferrets.

Kim CU, Choi WS, Lee P, Jeong JH, Seo YB, Choi YW, Sohn MH, Choi SY, Jeong AY, Song MS, Kim DJ.Biomed Pharmacother. 2025 Oct;191:118485. doi: 10.1016/j.biopha.2025.118485. Epub 2025 Sep 2.PMID: 40902412

Safety, tolerability and immunogenicity of a quadrivalent recombinant norovirus vaccine (Pichia pastoris) in participants six weeks of age or older: Phase I/IIa trial.

Chen G, Shi L, Yu Q, Liu Q, Wang X, Liu Y, Ding F, Yuan L, Wang P, Zhou X, Zhang Y, Huang Z, Li J, Hu Z, Huang T.Emerg Microbes Infect. 2025 Dec;14(1):2565391. doi: 10.1080/22221751.2025.2565391. Epub 2025 Oct 2.PMID: 40977245

Determinants of vaccine hesitancy among pregnant women in South-West Nigeria: an explanatory sequential mixed method design.

Ogundele OA, Omoloja O, Zibiri AO, Dinehin AV, Adewusi AO, Nwabueze J.BMJ Open. 2025 Oct 2;15(10):e101767. doi: 10.1136/bmjopen-2025-101767.PMID: 41043834

Innovative nanotechnology for infectious and inflammatory disease control: From diagnostics to therapeutics.

Khosravi F, Rahmani P, Jahanban Esfahlan R.Biomed Pharmacother. 2025 Oct;191:118551. doi: 10.1016/j.biopha.2025.118551. Epub 2025 Sep 15.PMID: 40957245

Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3 months and 2 years.

Mayerlen LI, Wong TAS, To A, Smith O, Chuang E, Donini O, Lehrer AT.Vaccine. 2025 Oct 3;64:127684. doi: 10.1016/j.vaccine.2025.127684. Epub 2025 Sep 2.PMID: 40902221

Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.

Hodgson A, Haidara FC, Sow SO, Ansah PO, Ansah NA, Tapia MD, Bangre O, Enwere GC, Viviani S, Marchetti E, Montomoli E, Stanzani V, Tang Y, Plikaytis B, Parulekar V, Martellet L, Chaumont J, Makadi MF, Kulkarni PS, Carlone G, Borrow R, LaForce FM, Preziosi MP.Vaccine. 2025 Oct 3;64:127698. doi: 10.1016/j.vaccine.2025.127698. Epub 2025 Sep 17.PMID: 40966979

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Immunoinformatics-based multi-epitope vaccine design using transforming growth factor beta-2 proprotein (TGFB2) for glioblastoma multiforme (GBM): GVac.

Tülümen D, Aydemir E, Ayaz F.Methods. 2025 Oct;242:38-53. doi: 10.1016/j.ymeth.2025.07.001. Epub 2025 Jul 6.PMID: 40628361

Development of a novel nanobody-fused flagellin adjuvant to enhance immunogenicity in a PCV2 subunit vaccine.

Wang C, Xu T, Wang J, Li F, Guan Y, Dong L, Wang Y, Meng W, Tian F, Wei F.Microb Pathog. 2025 Oct;207:107912. doi: 10.1016/j.micpath.2025.107912. Epub 2025 Jul 15.PMID: 40675509

Comparative Cytokine and Histology Studies on HPV and Other Viral Vaccinations: No Pathogenicity of HPV Vaccine Adjuvants.

Shiro R, Sato F, Omura S, Park AM, Nguyen CT, Ahmad I, Rimal S, Kinoshita K, Matsumura N, Tsunoda I.Cancer Sci. 2025 Oct 6. doi: 10.1111/cas.70213. Online ahead of print.PMID: 41048017

Sustained efficacy of the RTS,S/AS01(E) malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial.

Osei-Tutu L, Kariuki SK, Lee CK, Fabre R, Bii DK, Adjei S, Oneko M, Attobrah Sarfo MA, Ockenhouse CF, Schuerman L, Buabeng PBY, Bakari A, Atieno C, Kotoh-Mortty MF, Otieno K, Ntiamoah Y, Sang T, Bollaerts A, Westercamp N, Ansong D, Agbenyega T, Samuels AM, Ofori-Anyinam O; RTS,S study group.Lancet Glob Health. 2025 Oct;13(10):e1723-e1736. doi: 10.1016/S2214-109X(25)00272-4.PMID: 40975080

Targeted vaccination is effective for mpox clade Ib in England despite increased household transmission: Predictions from a modelling study.

Brooks-Pollock E, Danon L.PLOS Glob Public Health. 2025 Oct 8;5(10):e0005188. doi: 10.1371/journal.pgph.0005188. eCollection 2025.PMID: 41060919

Relative effectiveness of the high-dose versus standard-dose influenza vaccines for the prevention of laboratory-confirmed influenza among Italian older adults during three recent seasons.

Domnich A, Orsi A, Signori A, Panatto D, Icardi G.Int J Infect Dis. 2025 Oct 1:108100. doi: 10.1016/j.ijid.2025.108100. Online ahead of print.PMID: 41043638

Overcoming Immune Evasion in Staphylococcus aureus: Strategies for Rational Vaccine Design.

Shinwari K, Vieira B, Ciaparin I, Hakansson AP, Darrieux M, Converso TR.ACS Infect Dis. 2025 Oct 10;11(10):2692-2705. doi: 10.1021/acsinfecdis.5c00569. Epub 2025 Sep 12.PMID: 40939045

Nosocomial outbreak of multidrug-resistant Streptococcus pneumoniae serotype 15A (non-vaccine serotype) in a community hospital.

Takahashi J, Yajima T, Kawaguchiya M, Hashimoto N, Furuya M, Kobayashi N, Sato N, Hata F.J Infect Chemother. 2025 Oct;31(10):102811. doi: 10.1016/j.jiac.2025.102811. Epub 2025 Sep 18.PMID: 40975130

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Family spillover effects in cost-effectiveness analyses of vaccines.

Qian Y, Phillips M, Eiden AL, Carias C, Lavelle TA.Vaccine. 2025 Oct 3;64:127755. doi: 10.1016/j.vaccine.2025.127755. Epub 2025 Sep 19.PMID: 40974734

Economic evaluation of prenatal GBS immunization in China: A modeling analysis.

Ji W, Du J, Procter SR, Cao Y, Zhao H, Zhao M, Fang Y.Hum Vaccin Immunother. 2025 Dec;21(1):2564937. doi: 10.1080/21645515.2025.2564937. Epub 2025 Oct 2.PMID: 41035373

Elucidating the risk factors and oncogene drivers of acute myeloid leukemia.

Sanya DRA, Onésime D.Hum Cell. 2025 Oct 4;38(6):171. doi: 10.1007/s13577-025-01294-9.PMID: 41046303

Is a second dose of yellow fever vaccine needed? A systematic review of humoral and cell-mediated immunity after revaccination.

Ferrara P, La Vecchia A, Losa L, Mantovani LG, Plana M, Agüero F.J Travel Med. 2025 Oct 10:taaf106. doi: 10.1093/jtm/taaf106. Online ahead of print.PMID: 41071104

Grouper interleukin 15-like acts as a cytokine adjuvant in grouper iridovirus subunit vaccine.

Zheng J, Chen H, Liu Q, Lin F, Guo X, Huang X, Qin Q, Huang Y.Fish Shellfish Immunol. 2025 Oct;165:110475. doi: 10.1016/j.fsi.2025.110475. Epub 2025 Jun 6.PMID: 40482865

Development of a novel live attenuated vaccine based on epitope-fused OmpU1-LptD(EP) antigen for vibriosis control in aquaculture.

Jin Q, Wu X, Cao F, Wang Y, Liu Y, Pan J.Fish Shellfish Immunol. 2025 Oct;165:110568. doi: 10.1016/j.fsi.2025.110568. Epub 2025 Jul 16.PMID: 40675272

Immunomodulatory Role of Milk on Gut Microbiota: Implications for Enhancing Oral Vaccine Efficacy.

Asri NAM, Bushra SMR, Asri AAM, Suppian R, Norazmi MN.Probiotics Antimicrob Proteins. 2025 Oct 8. doi: 10.1007/s12602-025-10785-y. Online ahead of print.PMID: 41060598

Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAXB/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand.

Akapirat S, Serti E, Pitisutthithum P, Nitayaphan S, Chariyalertsak S, Eamsila C, Panjapornsuk P, Kleebmontha A, Chantakulkij S, Tongchanakarn B, Savadsuk H, Dhitavat J, Gurunathan S, Sinangil F, Crowell TA, Michael NL, Robb ML, Vasan S, O'Connell RJ; RV306 Study Group.Open Forum Infect Dis. 2025 Sep 16;12(10):ofaf578. doi: 10.1093/ofid/ofaf578. eCollection 2025 Oct.PMID: 41031105

Resurgence of pertussis in Slovak Republic and surrounding Central European countries.

Neuschlova M, Kunc P, Pecova R.Acta Microbiol Immunol Hung. 2025 Jul 22;72(3):248-255. doi: 10.1556/030.2025.02654. Print 2025 Oct 9.PMID: 40694423

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Increased Risk of Subcutaneous Nodules and Lipomas Following Influenza Vaccination: A Multicenter TriNetX Cohort Study.

Gupta N, Collins A, Zafar K, Ray M, McGinnis S, Cohen M, Glick S, Jagdeo J.J Drugs Dermatol. 2025 Oct 1;24(10):974-978. doi: 10.36849/JDD.8989.PMID: 41037528

Comparative analysis of model antigen expression level driven by the microneme protein promoters in Eimeria tenella.

Wang L, Liao Y, Suo J, Liang L, Liang R, Ding J, Yu Y, Liu X, Suo X, Tang X.Poult Sci. 2025 Oct;104(10):105600. doi: 10.1016/j.psj.2025.105600. Epub 2025 Jul 26.PMID: 40774174

A reference-guided iterative approach to polish the nanopore sequencing basecalling for therapeutic RNA quality control.

Wang Z, Tu MJ, Liu Z, Wang KK, Fang Y, Hao N, Zhang HH, Que J, Sun X, Yu AM, Ding H.Commun Biol. 2025 Oct 1;8(1):1406. doi: 10.1038/s42003-025-08811-4.PMID: 41034556

IL-11 acts as a vaccine adjuvant in Nile tilapia (Oreochromis niloticus) against Streptococcus agalactiae, enhancing both cellular and humoral immune responses.

Sunthamala P, Wang T, Phadee P, Luang-In V, Srisapoome P, Zou J, Secombes CJ, Wangkahart E.Fish Shellfish Immunol. 2025 Oct 8;168:110917. doi: 10.1016/j.fsi.2025.110917. Online ahead of print.PMID: 41072832

Recombinant TgDDX3X DEAD-box protein confers partial protection in murine models of acute and chronic toxoplasmosis.

Wang S, Wang J, Fan Y, Zhang H, Wu J, Ying T, Ma H, Wang Q, Wang L, Wang Y, Tian X, Mei X, Zhang Z, Yang Z.Acta Trop. 2025 Oct;270:107780. doi: 10.1016/j.actatropica.2025.107780. Epub 2025 Aug 11.PMID: 40803623

Silent mutations in coding regions of Hepatitis C virus affect patterns of HCV RNA structures and attenuate viral replication and pathogenesis.

Dabour R, Bergman S, Zafrir Z, Davidovitch A, Werbner M, Gal-Tanamy M, Tuller T.Genome Biol. 2025 Oct 6;26(1):338. doi: 10.1186/s13059-025-03816-y.PMID: 41053842

Nationwide surveillance of bacterial pathogens isolated from children by the surveillance committee of the Japanese society of chemotherapy, Japanese association for infectious diseases, and Japanese society for clinical microbiology between April 2021 and March 2024: General overview of pathogenic antimicrobial susceptibility.

Ishiwada N, Nishi J, Fujimaki K, Takahashi S, Matsumoto T, Sato J, Watanabe M, Kakuya F, Oikawa J, Mori T, Takayanagi R, Yamaguchi Y, Hoshino T, Shinjoh M, Miyashita H, Tajima T, Funakoshi H, Narabayashi A, Oishi T, Okano R, Okada T, Furuno K, Tanaka Y, Ishii S, Yamatou T.J Infect Chemother. 2025 Oct;31(10):102812. doi: 10.1016/j.jiac.2025.102812. Epub 2025 Sep 22.PMID: 40992731

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Establishment of a Carrot Cell Plant Growth Regulators-free System to Produce a Low-Cost Vaccine Candidate.

Carreño-Campos C, Zarate SDE, Romero-Maldonado A, Villarreal ML, Rosales-Mendoza S, Ortiz-Caltempa A.Planta Med. 2025 Oct;91(12):656-663. doi: 10.1055/a-2626-4703. Epub 2025 Jun 3.PMID: 40461030

Immunogenicity and safety evaluation of a recombinant protective antigen anthrax vaccine (GC1109): A phase II, dose-confirmed, randomized, double-blind, placebo-controlled study.

Kang CK, Im YJ, Kim DY, Choe PG, Baek YJ, Lee E, Choi WS, Wie SH, Seo YB, Lee J, Kim NJ, Oh MD.Vaccine. 2025 Oct 8;65:127819. doi: 10.1016/j.vaccine.2025.127819. Online ahead of print.PMID: 41067086

Evaluating the effect of the end of the COVID-19 uninsured programme on COVID-19 vaccine administration in California: a quasi-experimental study.

Romano CJ, Nianogo RA, Hoover C, Quint JJ.J Epidemiol Community Health. 2025 Oct 9;79(11):821-827. doi: 10.1136/jech-2025-223751.PMID: 40670144

Breaking From CDC, ACOG Continues Recommending COVID-19 Vaccine During Pregnancy.

Anderer S.JAMA. 2025 Oct 7;334(13):1131-1132. doi: 10.1001/jama.2025.16943.PMID: 40911303

Understanding vaccine willingness in post-COVID America: Key determinants and demographic differences.

Yang Y, Jin SW, Lee S, Lartey S, Pichon L, Levy M.Vaccine. 2025 Oct 3;64:127740. doi: 10.1016/j.vaccine.2025.127740. Epub 2025 Sep 12.PMID: 40945178

Targeting the zinc metalloprotease gp63 of Leishmania for vaccine design and new drug discovery using immunoinformatics, molecular docking and molecular dynamics simulation studies.

Ali MT, Rahman T, Palit P, Uddin MI, Seidel V.Exp Parasitol. 2025 Oct;277:109009. doi: 10.1016/j.exppara.2025.109009. Epub 2025 Sep 2.PMID: 40907690

Germinal centre B cell disruption by non-typhoidal Salmonella.

Osorio-Barrios F, Hapfelmeier S.Trends Immunol. 2025 Oct 3:S1471-4906(25)00226-1. doi: 10.1016/j.it.2025.09.007. Online ahead of print.PMID: 41046209

Exploration of hypothetical proteins and reverse vaccinology approach for novel multi-epitope vaccine design against multidrug-resistant clinical isolate Pseudomonas aeruginosa JJPA01.

Narthanareeswaran B, Narthanareeswaran M, Ranganathan S, Pandian CJ, Jeyakanthan J.Comput Biol Med. 2025 Oct;197(Pt A):111045. doi: 10.1016/j.compbiomed.2025.111045. Epub 2025 Sep 5.PMID: 40912040

Tregitopes derived from canine proteins can enhance T regulatory lymphocytes frequency in dog PBMC culture in vitro.

Szydłowski P, Grabowski T, Chełmońska-Soyta A.J Leukoc Biol. 2025 Oct 10:qiaf143. doi: 10.1093/jleuko/qiaf143. Online ahead of print.PMID: 41067721

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Gene discovery and expression analysis of the B cell receptor repertoire in the domestic ferret model.

Hebert LS, Pickens W, Satterwhite E, Soto GB, Pflaum FM, Zhan M, Moody MA, Kain J, Kirchenbaum GA, Ferguson JA, Langel SN, Ross TM, Sautto GA, Uno N, Richardson RA, Georgiou G, Lavinder JJ, Ippolito GC, Seeger A.Vaccine. 2025 Oct 3;64:127725. doi: 10.1016/j.vaccine.2025.127725. Epub 2025 Sep 16.PMID: 40961800

Monitoring strategies after the incorporation of vaccines into national immunization programs: a systematic review.

de Melo Araújo AC, Frugoli AG, de Sena Gonçalves JE, Pércio J, Da Silva TP, da Fonseca Victer TN, Matozinhos FP, Fernandes ÉG.Vaccine. 2025 Oct 11;66:127850. doi: 10.1016/j.vaccine.2025.127850. Online ahead of print.PMID: 41076808

A follow-up study on the protective efficacy and anamnestic response of recombinant CHO hepatitis B vaccine 26 years after immunization.

Kang W, Wang F, Hao Z, Zhang Z, Su Q, Zhou H, Xu K.Vaccine. 2025 Oct 3;64:127743. doi: 10.1016/j.vaccine.2025.127743. Epub 2025 Sep 12.PMID: 40945180

Evaluation of various formulations of Contagious Bovine pleuropneumonia vaccine (T1/44) for thermotolerance and shelf life.

Killo AO, Oluwadare FA, Sanga RR, Ankeli PI, Chandipwisa C, Hashi Omar W, Suma F, Onidje E, Olabisi Ishola O, Gulak Ularamu H.Vet Ital. 2025 Oct 10;61(4). doi: 10.12834/VetIt.3773.35869.2.PMID: 41077875

Computational design of an mRNA vaccine targeting antifungal-resistant Lomentospora prolificans.

Rehmani MBI, Arshad F, Khan MU, Ejaz H, Nishan U, Alotaibi A, Ullah R, Chen K, Ojha SC, Shah M.Sci Rep. 2025 Oct 1;15(1):34157. doi: 10.1038/s41598-025-14907-y.PMID: 41034328

The association of oral polio vaccine doses and severity of paralysis: an analysis of wild poliovirus type 1 cases in Pakistan.

Soghaier M, Khan ZA, Taqi NM, Bhayo MH, Lodhi FR, Rahman AR.Infect Dis (Lond). 2025 Oct;57(10):948-955. doi: 10.1080/23744235.2025.2503467. Epub 2025 May 20.PMID: 40392750

US medical groups sue to reverse overhaul of vaccine recommendations.

Furlow B.Lancet Child Adolesc Health. 2025 Oct;9(10):694-695. doi: 10.1016/S2352-4642(25)00240-8. Epub 2025 Aug 5.PMID: 40774268

A Framework for Assessing the Opportunity for Advanced Research, Development, and Regulatory Approval of Medical Countermeasures: A Component of BARDA's Emerging Infectious Diseases Strategy.

White RC, Lewis RG, Little JD, Fredericksen BL, Sabourin CL, Lane MC, Loelius SG, Hofmeyer KA, Steele M, Tong X, Johnson RA.J Infect Dis. 2025 Oct 9:jiaf486. doi: 10.1093/infdis/jiaf486. Online ahead of print.PMID: 41063660

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Vaccine and Treatment Evaluation Units: A Historical Perspective.

Belshe RB, Bernstein DI, Edwards KM, Frey SE, Keitel WA, Levine MM, Treanor JJ, Wright PF.Clin Infect Dis. 2025 Oct 10;81(Supplement_2):S59-S77. doi: 10.1093/cid/ciaf454.PMID: 41071743

Hope and Hurdles: Unlocking the Potential of Modified Live Virus Vaccines for African Swine Fever.

Niu X, Shen D, Bu Z, Dixon LK, Zhao D.Emerg Microbes Infect. 2025 Oct 8:2572692. doi: 10.1080/22221751.2025.2572692. Online ahead of print.PMID: 41060257

FliC adjuvant augments protective efficacy of recombinant T2544 antigen against SalmonellaTyphiand Paratyphi A by increasing serum antibodies, intestinal secretory immunoglobulin A and T cell memory.

Chakraborty S, Dutta P, Pal A, Chakraborty S, Mitra S, Miyoshi SI, Das S.Vaccine. 2025 Oct 3;64:127767. doi: 10.1016/j.vaccine.2025.127767. Epub 2025 Sep 20.PMID: 40976078

Investigating endothelial cell transduction and hexon: platelet factor 4 binding of ChAdOx1 in the context of vaccine-induced thrombotic thrombocytopenia.

Lovatt C, Frängsmyr L, Swift EA, Mundy RM, Parker AL.J Thromb Haemost. 2025 Oct;23(10):3319-3326. doi: 10.1016/j.jtha.2025.06.006. Epub 2025 Jun 12.PMID: 40516826

Safety and immunogenicity of hepatitis E vaccine in compensated liver cirrhosis with chronic hepatitis B: author's response.

Liao X, Su Y, Zhang J, Zhang Z.Clin Microbiol Infect. 2025 Oct;31(10):1760-1761. doi: 10.1016/j.cmi.2025.06.019. Epub 2025 Jun 21.PMID: 40550360

Safety and immunogenicity of a reduced-dose inactivated poliovirus vaccine versus a full-dose inactivated poliovirus vaccine in infants in Bangladesh: a double-blind, non-inferiority, randomised, controlled, phase 3 trial.

Kulkarni PS, Zaman K, Desai SA, Bharati S, Goswami DR, Sharmeen AT, Rana S, Haque W, Khandelwal A, Manney S, Tyagi P, Gairola S, Zade JK, Pisal SS, Dhere RM, Poonawalla CS, Lamberigts C, Parulekar V, Potey AV.Lancet Infect Dis. 2025 Oct;25(10):1128-1137. doi: 10.1016/S1473-3099(25)00215-4. Epub 2025 Jun 9.PMID: 40505670

Molecular characteristics and genetic evolution of H9N2 avian influenza virus in eastern monsoon zone of China.

Zhang L, Shan X, Yin Y, Yuan W, Li L.Microb Pathog. 2025 Oct;207:107907. doi: 10.1016/j.micpath.2025.107907. Epub 2025 Jul 16.PMID: 40675505

High Levels of Endogenous Omega-3 Fatty Acids Promote Dendritic Cell Antigen Presentation and Improve Dendritic Cell-Based Cancer Vaccine Efficacy in Mice.

Tiwary S, Hsu KS, Goldfarbmuren KC, Xia Z, Berzofsky JA.Cancer Immunol Res. 2025 Oct 1;13(10):1609-1622. doi: 10.1158/2326-6066.CIR-24-0927.PMID: 40758122

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

A prophylactic study of curcumin nanoparticle-induced bacterial ghosts against Helicobacter pylori in a C57BL/6 mouse model.

Das S, Halder P, Banerjee S, Sultana S, Mukherjee A, Nandy P, Debnath A, Mukhopadhyay AK, Dutta S, Koley H.Microb Pathog. 2025 Oct 4;209:108084. doi: 10.1016/j.micpath.2025.108084. Online ahead of print.PMID: 41045975

Innovations in Career Development Through Mentoring in the VTEU/IDCRC Programs.

Danziger-Isakov L, Ofotokun I, Johnstone K, Edwards KM.Clin Infect Dis. 2025 Oct 10;81(Supplement_2):S103-S108. doi: 10.1093/cid/ciaf378.PMID: 41071736

Active surveillance for influenza A virus in swine reveals within-farm reassortment and cocirculation of distinct subtypes and genetic clades.

Thomas MN, Janzen GM, Markin A, Sharma A, Hewitt K, Li G, Baker AL, Gauger PC, Anderson TK.Vet Microbiol. 2025 Oct;309:110681. doi: 10.1016/j.vetmic.2025.110681. Epub 2025 Aug 11.PMID: 40818301

Comparison of 2 Doses vs 1 Dose in the First Season Children Are Vaccinated Against Influenza: A Systematic Review and Meta-Analysis.

Goldsmith JJ, Tavlian S, Vu C, Regan AK, Campbell PT, Sullivan SG.JAMA Netw Open. 2025 Oct 1;8(10):e2535250. doi: 10.1001/jamanetworkopen.2025.35250.PMID: 41042511

Cocktail vaccine induces immunoprotection and modulates the fecal microbiota in dogs against Echinococcus granulosus infection.

Shao G, Zhu X, Hua R, Lu Z, Chen Y, Yang A, Yang G.NPJ Vaccines. 2025 Oct 1;10(1):214. doi: 10.1038/s41541-025-01275-x.PMID: 41034249

Natural immune boosting biases pertussis infection estimates in seroprevalence studies.

Domenech de Cellès M, Wong A, Dalby T, Rohani P.Nat Commun. 2025 Oct 6;16(1):8883. doi: 10.1038/s41467-025-64716-0.PMID: 41053073

Multi-epitope vaccine construct against Staphylococcus aureus: insights from immunoinformatics and molecular dynamics simulations.

Nachammai K, Sangavi P, Abishek K, Langeswaran K.SAR QSAR Environ Res. 2025 Oct 1:1-31. doi: 10.1080/1062936X.2025.2558784. Online ahead of print.PMID: 41032074

Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine Is Reduced in Infants Immunized During the Respiratory Viral Season.

Dagan R, van der Beek BA.Clin Infect Dis. 2025 Oct 6;81(3):679-686. doi: 10.1093/cid/ciae619.PMID: 39686809

Coxiella burnetii: Emerging threats, molecular insights, and advances in diagnosis and control measures.

Mohammadi MR, Moradkasani S, Latifian M, Esmaeili S.J Microbiol Methods. 2025 Oct;237:107213. doi: 10.1016/j.mimet.2025.107213. Epub 2025 Aug 6.PMID: 40774611

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Pneumococcal vaccination knowledge, attitudes, and practices among surveyed U.S. adults aged 19-64 years at increased risk for pneumococcal disease.

Ramachandran V, Tangney S, Gedlinske A, Askelson NM, Parker AM, Gidengil CA, Albert AP, Lindley MC, Kobayashi M, Scherer AM.Vaccine. 2025 Oct 3;64:127739. doi: 10.1016/j.vaccine.2025.127739. Epub 2025 Sep 15.PMID: 40957308

GRP-based vaccines as a novel approach in cancer immunotherapy: mechanisms, challenges, and prospects.

Shahreza RM, Zare H, Rastegar-Pouyani N, Aria H, Hakim F, Arefnia M, Bakherad H.Cancer Cell Int. 2025 Oct 3;25(1):338. doi: 10.1186/s12935-025-03979-5.PMID: 41044622

A bivalent SARS-CoV-2 subunit vaccine for cats neutralizes both the original ancestral strain and BA.1 Pseudovirus carrying the 453F and 501 T mutation.

Zhao Y, Zhao Z, Cheng C, Tian M, Zhang Q, Jin M.Vaccine. 2025 Oct 3;64:127685. doi: 10.1016/j.vaccine.2025.127685. Epub 2025 Sep 8.PMID: 40925163

Safety of intradermal Danish- vs. transcutaneous Tokyo-strain BCG vaccination in Korean children: A nationwide cohort study.

Lee YH, Gwak E, Kang HM, Choe YJ, Choi YY, Kim KJ, Kang CR, Choi WS, Noh JY, Choi NK, Jeong NY, Lee JK.Vaccine. 2025 Oct 3;65:127828. doi: 10.1016/j.vaccine.2025.127828. Online ahead of print.PMID: 41045632

Genome-based screening and immunogenicity evaluation of outer membrane protein antigens for Vibrio harveyi subunit vaccine in pearl gentian grouper (Epinephelus lanceolatus Epinephelus fuscoguttatus).

Li F, Ge H, Lin P, Wang Y, Jiang Y, Zhang Z, Chen Y, Feng J.Fish Shellfish Immunol. 2025 Oct;165:110440. doi: 10.1016/j.fsi.2025.110440. Epub 2025 May 21.PMID: 40409699

Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.

Humphreys J, Blake A, Nicolay N, Braeye T, Van Evercooren I, Hansen CH, Moustsen-Helms IR, Sacco C, Mateo-Urdiales A, Castilla J, Martínez-Baz I, Machado A, Brito A, Ljung R, Pihlstrom N, Mansiaux Y, Monge S, Bacci S, Nunes B; VEBIS-EHR working group.Vaccine. 2025 Oct 3;64:127752. doi: 10.1016/j.vaccine.2025.127752. Epub 2025 Sep 19.PMID: 40974735

Feasibility and Acceptability of Respiratory Syncytial Virus Vaccination in Mothers for Infant Protection at Edward Francis Small Teaching Hospital, the Gambia.

Jasseh I, Manka M, Mendy S, Bajinka O, Makalo L.J Epidemiol Glob Health. 2025 Oct 10;15(1):118. doi: 10.1007/s44197-025-00467-x.PMID: 41071412

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

P-Pev: micelle-like complexes transformed from tumor extracellular vesicles by PEG-PE for personalized therapeutic tumor vaccine.

Tian H, Zeng W, Wang Z, Li S, Wei W, Li S, Yin X, Na W, Wang Y, Song K, Zhu P, Liang W.Biomaterials. 2025 Oct;321:123333. doi: 10.1016/j.biomaterials.2025.123333. Epub 2025 Apr 10.PMID: 40239595

Human papillomavirus vaccination willingness and influencing factors among women in China: A systematic review and meta-analysis.

Sun J, Dong S, Gong J, Xie J, Yan H.Prev Med Rep. 2025 Aug 18;58:103215. doi: 10.1016/j.pmedr.2025.103215. eCollection 2025 Oct.PMID: 40895341

Comparable effectiveness of MF59®-adjuvanted and high-dose quadrivalent inactivated influenza vaccines for prevention of test-confirmed influenza during the 2022-2023 influenza season.

Imran M, Chastek B, Bancroft T, Webb N, Pelton SI, Haag MDM, McGovern I.Int J Infect Dis. 2025 Oct;159:107983. doi: 10.1016/j.ijid.2025.107983. Epub 2025 Jul 12.PMID: 40659177

Vaccination protects animal and human health and reduces the economic burden of preventable cases: rabies in vaccinated dogs and cats (2002-2022).

Nathan M, Boutelle C, Ross Y, Wallace RM, Bonaparte S.J Am Vet Med Assoc. 2025 Aug 1;263(10):1213-1222. doi: 10.2460/javma.25.01.0036. Print 2025 Oct 1.PMID: 40752523

Genotyping of Rotavirus Gastroenteritis in Kerala, India, in the Postvaccination Period (2020-2023).

Namboodiripad A, Xavier R, Sreenivasan P, Ajithkumar VT, Fiji MD, Nasreen Abdul Jaleel S, George G, Thuruthiyath N, Chaudhary VS, Kharat N, Machathi A, Lingam R, Varghese T, Alappat MM.Indian J Pediatr. 2025 Oct 3. doi: 10.1007/s12098-025-05771-9. Online ahead of print.PMID: 41042471

A pilot investigation of the naturally acquired functional antibodies against pneumococcal vaccine serotypes in healthy adults from Bengaluru, India.

Sundaresan N, Dharmavaram S, Nagaraj G, Lingegowda RK.Microb Pathog. 2025 Oct;207:107898. doi: 10.1016/j.micpath.2025.107898. Epub 2025 Jul 12.PMID: 40659256

Lipid nanoparticle-encapsulated DNA vaccine induces balanced antibody and T-cell responses in pigs with maternally derived antibodies.

Lai DC, Nguyen TN, Trinh GP, Steffen D, Vu HLX.J Virol. 2025 Oct 9:e0112325. doi: 10.1128/jvi.01123-25. Online ahead of print.PMID: 41065389

Knowledge and attitude of parents towards the human papillomavirus vaccine for their daughters and associated factors in Debre Tabor town, northwest Ethiopia: a community-based cross-sectional study.

Aragaw GM, Aynalem GL, Abiy SA, Taye EB, Chernet SA, Haile TT, Tsega NT, Mesele TT, Seyoum AT, Tsega AG, Mengistie BA.BMJ Open. 2025 Oct 5;15(10):e088550. doi: 10.1136/bmjopen-2024-088550.PMID: 41047255

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

A BCG-boosting subunit vaccine RS2/DMI induces Th1-polarized immunity by targeting RD6 and secretory antigens of Mycobacterium tuberculosis.

Wang X, Zhong Q, Xu Y, Liu X.Arch Microbiol. 2025 Oct 6;207(11):290. doi: 10.1007/s00203-025-04481-2.PMID: 41051521

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study.

Pascual-Lucas M, Lacosta AM, Montañés M, Canudas J, Loscos J, Monleón I, Allué JA, Sarasa L, Fandos N, Romero J, Sarasa M, Torres M, Whyms D, Terencio J, Piñol-Ripoll G, Boada M.Alzheimers Dement. 2025 Oct;21(10):e70776. doi: 10.1002/alz.70776.PMID: 41058018

Immunogenicity and protection against infectious bursal disease via a transgenic Eimeria acervulina expressing IBDV VP2-2C3d fusion protein.

Sun Y, Liu Y, Wang H, Guo Q, Suo J, Zhang S, Tang X, Yin G, Suo X, Liu X.Vaccine. 2025 Oct 3;64:127715. doi: 10.1016/j.vaccine.2025.127715. Epub 2025 Sep 9.PMID: 40930043

Exceptional high number of IPD cases in winter season 2024-2025 in Belgium in concomitance with rise in vaccine serotypes.

Cuypers L, Dambre C, Desmet S.Vaccine. 2025 Oct 3;64:127763. doi: 10.1016/j.vaccine.2025.127763. Epub 2025 Sep 17.PMID: 40966978

Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial.

Morel J, Dernis E, Roux C, Richez C, Brocq O, Fautrel B, Salliot C, Vittecoq O, Mariette X, Lioté F, Lassoued S, Gaujoux-Viala C, Constantin A, Soubrier M, Devauchelle-Pensec V, Goeb V, Gottenberg JE, Marotte H, Moulard AR, Daien C, Mouterde G, Lukas C, Pissarra J, Huguet H, Launay O, Galtier F, Picot MC; I-REIVAC; CRI-IMIDIATE French Clinical Research Networks.Lancet Rheumatol. 2025 Oct;7(10):e675-e686. doi: 10.1016/S2665-9913(25)00071-2. Epub 2025 Jul 29.PMID: 40749694

U.S. Vietnamese Parents' Perceptions of Different Approaches for Confirming Adolescent HPV Vaccination Records in Research Studies.

Bui L, Espinoza V, Giang HA, Schiffer LP, Do P, Ngu P, Vu C, Tiro J, Adjei Boakye E, Phillips SM, Brandt H, Berry E, Tran S, Macdonald E, Khuc C, Nguyen J, Vuong T, Vu M.Health Expect. 2025 Oct;28(5):e70448. doi: 10.1111/hex.70448.PMID: 41020406

Latent class and time-to-event analyses of social determinants of health and COVID-19 vaccine uptake among Black women living with HIV.

Boga DJ, Robinson M, Tirupathi M, Juste RS, Lazarus K, Etienne K, Wright M, Reid R, Shahid N, Nelson CM, Koru-Sengul T, Safren SA, Ironson G, Rodriguez A, Wright I, Feaster D, Dale SK.Vaccine. 2025 Oct 3;64:127649. doi: 10.1016/j.vaccine.2025.127649. Epub 2025 Sep 6.PMID: 40913818

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Persistence of measles, mumps, and rubella immunity following childhood vaccination in Australian health science students: a cohort study.

Schoenfisch C, Kauter K, Walz N, Wang T, East L.Vaccine. 2025 Oct 6;65:127791. doi: 10.1016/j.vaccine.2025.127791. Online ahead of print.PMID: 41056756

Enhanced immunogenicity of COVID-19 RBD fused to mutant scorpion's phospholipase D for vaccine development.

Zareinejad MR, Behdani M, Goodarzi MT, Oghalaie A, Hosseininejad-Chafi M, Pooshang-Bagheri K, Shahbazzadeh D.New Microbes New Infect. 2025 Sep 2;67:101634. doi: 10.1016/j.nmni.2025.101634. eCollection 2025 Oct.PMID: 40980200

Purpura fulminans caused by Streptococcus pneumoniae serotype 23A in a young post-splenectomy man: A case report.

Hamasaki A, Yumoto T, Fukushima S, Hagiya H, Chang B, Akeda Y, Hongo T, Tsukahara K, Naito H, Nakao A.J Infect Chemother. 2025 Oct;31(10):102791. doi: 10.1016/j.jiac.2025.102791. Epub 2025 Aug 12.PMID: 40812724

Host-virus molecular arms race: RNAi-mediated antiviral defense and viral suppressor of RNAi.

Zhang B, Zhou X, Ren Y.Cell Insight. 2025 Aug 27;4(5):100276. doi: 10.1016/j.cellin.2025.100276. eCollection 2025 Oct.PMID: 40994739

Exploring the effectiveness of interventions to increase uptake of measles vaccination among healthcare workers: a systematic review.

Heinze N, Martin AF, Tirion ASC, Pae R, Islam J, Smith LE, Weston D, Rubin GJ.Vaccine. 2025 Oct 9;66:127808. doi: 10.1016/j.vaccine.2025.127808. Online ahead of print.PMID: 41072280

The 1904 Rio De Janeiro vaccine revolt: Resistance to compulsory smallpox vaccination.

Esparza J, Damaso CR.Vaccine. 2025 Oct 3;64:127774. doi: 10.1016/j.vaccine.2025.127774. Epub 2025 Sep 19.PMID: 40974738

Chimeric Glycoprotein Nanoparticles Elicit Robust Neutralizing Antibodies Against Epstein-Barr Virus.

Sun C, Xie C, Fang XY, Hong DC, Zhang H, Wu PH, Liu YN, Bu GL, Cao DH, Si-Tu MY, Peng YJ, Wang J, Feng GK, Zhong Q, Liu Z, Zeng MS.Adv Mater. 2025 Oct 4:e07012. doi: 10.1002/adma.202507012. Online ahead of print.PMID: 41045177

Cellular and humoral response after mRNA SARS-CoV-2 vaccination in kidney transplant recipients living with HIV: A cross-sectional study.

Cacho J, Nomah DK, Egri N, Cofán F, Marcos MÁ, Mosquera MM, Sanchez-Palomino S, Bruguera A, Esforzado N, Bodro M, Rovira C, Hurtado C, Vilella A, Diekmann F, Moreno A, Miro JM, Cucchiari D; COVIHVAC investigators.HIV Med. 2025 Oct;26(10):1562-1573. doi: 10.1111/hiv.70087. Epub 2025 Aug 25.PMID: 40853031

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Influenza vaccination hesitancy and decision between parental and grandparental caregivers of preschoolers: a comparative study.

Zhou Y, Wang H, Chu L, Chen K, Xu Y, Fu C.Vaccine. 2025 Oct 3;64:127696. doi: 10.1016/j.vaccine.2025.127696. Epub 2025 Sep 3.PMID: 40907066

Engaging Latinx Youth in PhotoVoice to Inform Message Development to Improve COVID-19 Vaccine Uptake.

Jimenez-Zambrano A, Reedy J, Scherer L, Dieujuste N, Saville A, Kempe A, Dorsey B.J Adolesc Health. 2025 Oct 9:S1054-139X(25)00407-0. doi: 10.1016/j.jadohealth.2025.08.025. Online ahead of print.PMID: 41065627

Re: 'Safety and immunogenicity of hepatitis E vaccine in compensated liver cirrhosis with chronic hepatitis B' by Liao et al.

Yang Y, Lai R.Clin Microbiol Infect. 2025 Oct;31(10):1758-1759. doi: 10.1016/j.cmi.2025.06.004. Epub 2025 Jun 7.PMID: 40490192

Harnessing Salmonella as a potent vaccine delivery platform: Targeted HA/NA epitope presentation via alphavirus RdRp-driven expression to boost immune efficacy.

Kwon J, Senevirathne A, Lee JH.Mater Today Bio. 2025 Aug 21;34:102224. doi: 10.1016/j.mtbio.2025.102224. eCollection 2025 Oct.PMID: 40977838

Seasonal influenza vaccination in childhood and adolescence. Consensus of the AEV, CAV-AEP and SEIP.

Alvarez Aldeán J, Alvarez García FJ, Cruz Cañete M, Fernández Prada M, Francisco González L, Grande Tejada AM, Iofrío de Arce A, Méndez Sánchez A, Moraga Llop F, Salamanca de la Cueva I; en representación del Comité Asesor de Vacunas de la Asociación Española, de Pediatría (CAV-AEP); Sociedad Española de Infectología Pediátrica (SEIP) y Asociación Española de Vacunología (AEV).An Pediatr (Engl Ed). 2025 Oct 10:503965. doi: 10.1016/j.anpede.2025.503965. Online ahead of print.PMID: 41076442

Enhanced protection through genotype-matched bivalent H9N2-Newcastle disease virus vaccination: Comparative efficacy against contemporary field strains in specific-pathogen-free chickens.

Abdelhalim A, Yahia N, Elharrak M, Rhazi H, Soliman AH, Turkistan A, Hussien HA, Khalil AA.Vet Microbiol. 2025 Oct 3;310:110744. doi: 10.1016/j.vetmic.2025.110744. Online ahead of print.PMID: 41045702

Healthcare worker perspectives on system-level barriers to hepatitis B birth dose vaccination: An analysis in five urban U.S. hospitals.

Shaw SC, Shaw J, Allis N, Stewart T, Yang YT.Hum Vaccin Immunother. 2025 Dec;21(1):2567043. doi: 10.1080/21645515.2025.2567043. Epub 2025 Oct 1.PMID: 41032379

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Whole genome characterisation of DS-1-like G8P[4] rotavirus A strains circulating in South Africa between 2009 and 2021 reveals endemic sub-lineages and evidence of radical epitope changes.

Shange ND, Mogotsi MT, Ogunbayo AE, Page N, Sondlane H, Esona MD, Kumwenda B, Mhango C, Kawonga F, Matambo E, Mingle SNK, Dennis FE, Khuzwayo JC, Makoah NA, Donato CM, Nyaga MM.Infect Genet Evol. 2025 Oct;134:105818. doi: 10.1016/j.meegid.2025.105818. Epub 2025 Sep 5.PMID: 40915595

Polymyxin B as a novel mucosal adjuvant for the intranasal whole inactivated influenza vaccine.

Odagiri T, Yoshino N, Sasaki Y, Ishikawa S, Muraki Y.Vaccine. 2025 Oct 3;64:127750. doi: 10.1016/j.vaccine.2025.127750. Epub 2025 Sep 15.PMID: 40957307

Decreased pathogenicity of triple-mutant of Aeromonas hydrophila flgK, flgL, flgE suggests its potential as a live attenuated vaccine for Carassius auratus.

Xiong C, Liu K, Wu Y, Ai Y, Yu Y, Mabrok M, Abu-Elala N, Li L, Xu H, Li Y, Ye H, Mei H, Wu R.Fish Shellfish Immunol. 2025 Oct;165:110486. doi: 10.1016/j.fsi.2025.110486. Epub 2025 Jun 16.PMID: 40516799

Evaluation of Leishmania homolog of activated C kinase (LACK) of Leishmania donovani in comparison to glycoprotein 63 as a vaccine candidate against visceral leishmaniasis.

Didwania N, Bhowmick S, Sabur A, Bhattacharya A, Ali N.Microbiol Spectr. 2025 Oct 7;13(10):e0339224. doi: 10.1128/spectrum.03392-24. Epub 2025 Aug 19.PMID: 40827885

Effectiveness of a Single Dose of Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Children: A Systematic Literature Review.

Dunne EM, Hong L, Althouse BM, Hayford K, Jodar L, Gessner BD, Theilacker C.Infect Dis Ther. 2025 Oct;14(10):2189-2203. doi: 10.1007/s40121-025-01211-5. Epub 2025 Aug 19.PMID: 40828221

An NLRP3-stimulatory adjuvant improves the immunogenicity of influenza virus vaccines in mice and non-human primates.

Finn K, Chow J, Zhivaki D, Sengupta D, Concepcion H, Komoroski V, MacFarlane C, Coblentz PD, Chokshi M, Matissek S, Gosselin E, Alkekhia D, Nikiforov A, Lamberti N, Iheanyichukwu V, Kelly C, Arinze C, Cornforth A, Elloul S, Kagan JC.mBio. 2025 Oct 8;16(10):e0234325. doi: 10.1128/mbio.02343-25. Epub 2025 Sep 8.PMID: 40919810

Novel Nanoadjuvant for Subunit Vaccines: Cyclic Seven-Membered Tertiary Amine-Based Polymer-Grafted Ethoxy-Acetalated Dextran Nanoparticles Encapsulating CpG Oligodeoxynucleotides.

Yang C, Wang Y, Han Y, Dong H, Tong W, Wu X.Mol Pharm. 2025 Oct 6;22(10):5831-5844. doi: 10.1021/acs.molpharmaceut.5c00122. Epub 2025 Aug 26.PMID: 40859606

Evaluation of vero and chicken embryo fibroblast cell-based newcastle disease vaccine efficacy in chickens.

Yami MM, Akalu M, Bayisa B, Tefera TA, Hurisa TT, Ayele G, Sherefa K, Legesse A, Adamu K, Dinka H.Poult Sci. 2025 Oct;104(10):105624. doi: 10.1016/j.psj.2025.105624. Epub 2025 Jul 29.PMID: 40782609

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Beta-Glucan in barley as a natural immunomodulator: mechanisms and therapeutic potential.

Ahmed HGMD, Yang L, Yang X, Yang J, Hussain S, Shafiq MD, Akram MI, Sajad M, Zeng Y.Mol Biol Rep. 2025 Oct 11;52(1):1012. doi: 10.1007/s11033-025-11136-4.PMID: 41075026

Interlaboratory study to assess precision and reproducibility of the meningococcal antigen surface expression (MEASURE) assay to quantify factor H binding protein expression at the surface of meningococcal serogroup B strains.

Loschko J, Liberator P, Findlow J, Yip J, Tan C, Garcia K, Murillo M, Gorantla Y, Moss KM, Maniatis P, Clark SA, Borrow R.Diagn Microbiol Infect Dis. 2025 Oct;113(2):116920. doi: 10.1016/j.diagmicrobio.2025.116920. Epub 2025 May 30.PMID: 40517645

Novel Mini-Hemagglutinin Subunit Vaccine Induces Robust Mucosal and Systemic Immunity and Protection Against a Lethal Challenge With the H1N1 and H5N1 Influenza Viruses in Mice.

Wang T, Han R, Li J, Cheng X, Qi Z, Bing J, Zhai C, Wang D, Deng Y, Tan W.J Med Virol. 2025 Oct;97(10):e70614. doi: 10.1002/jmv.70614.PMID: 40985326

Secret shopper survey indicates that veterinarians are split on how to respond to vaccine-hesitant dog owners.

Aggarwal A, Ramirez-Guillen Y, Haeder SF.Am J Vet Res. 2025 Jul 9;86(10):ajvr.25.05.0159. doi: 10.2460/ajvr.25.05.0159. Print 2025 Oct 1.PMID: 40639413

Vaccination versus antibody screening for measles immunity in health care workers.

Schieferdecker R, Menting T, Mankertz A, Santibanez S, Zimmermann C, Rockstroh JK, Eis-Hübinger AM, Schwarze-Zander C.Vaccine. 2025 Oct 9;66:127845. doi: 10.1016/j.vaccine.2025.127845. Online ahead of print.PMID: 41072277

Correction: Large Clostridial Toxins: A Brief Review and Insights into Antigen Design for Veterinary Vaccine Development.

Rodrigues Rodrigues R, Alves MLF, Bilhalva MA, Kremer FS, Junior CM, Ferreira MRA, Galvão CC, Quatrin PHDN, Conceição FR.Mol Biotechnol. 2025 Oct;67(10):4012. doi: 10.1007/s12033-024-01352-x.PMID: 39718703

Optimising pneumococcal vaccine efficacy in rheumatoid arthritis: a strategic delay in methotrexate initiation.

Bechman K, Galloway J.Lancet Rheumatol. 2025 Oct;7(10):e660-e661. doi: 10.1016/S2665-9913(25)00093-1. Epub 2025 Jul 29.PMID: 40749695

Epidemiology and Clinical Profile of Rotavirus Diarrhea in Children Aged Under 5 Years in Kerala, India After the Introduction of Rotavirus Vaccination: A Surveillance Study.

Ajithkumar VT, Fiji MD, Abdul Jaleel SN, Namboodiripad A, Sreenivasan P, Xavier R, Chaudhary VS, Varghese T, Kharat N, Machathi A, Lingam R.Indian J Pediatr. 2025 Oct 2. doi: 10.1007/s12098-025-05775-5. Online ahead of print.PMID: 41034607

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The relationship between state vaccination exemption policies and MMR vaccination trends in the U.S.

Saiyed S, Dong E, Gardner LM.Vaccine. 2025 Oct 3;64:127773. doi: 10.1016/j.vaccine.2025.127773. Epub 2025 Sep 20.PMID: 40976077

Lyophilized Listeria monocytogenes vaccines for storage at non-ultra-low temperatures and cancer therapy.

Paulishak W, Isenhower L, Modaresahmadi S, Hajimirzaei S, Shoultz J, Wood LM.Int J Pharm. 2025 Oct 9:126239. doi: 10.1016/j.ijpharm.2025.126239. Online ahead of print.PMID: 41076206

Oral live attenuated polio vaccines induce enhanced T-cell responses with broad antigen recognition compared to inactivated polio vaccines.

Snyder J, Slavik M, Harvey P, Del Rio-Guerra R, Mainou BA, Sette A, Kirkpatrick BD, Grifoni A, Crothers JW.Clin Immunol. 2025 Oct 10:110607. doi: 10.1016/j.clim.2025.110607. Online ahead of print.PMID: 41077293

Harnessing the composition of lipid nanoparticles to selectively deliver mRNA to splenic immune cells for anticancer vaccination.

Younis MA, Sato Y, Elewa YHA, Harashima H.Drug Deliv Transl Res. 2025 Oct;15(10):3626-3641. doi: 10.1007/s13346-025-01824-w. Epub 2025 Mar 7.PMID: 40055249

Investigating genetic, antigenic, and structural diversity in the Neisseria gonorrhoeae outer membrane protein, PorB: implications for vaccine design.

Harrison OB, Bash M, Ramirez-Bencomo F, Thistlethwaite A, Jones R, Stejskal L, Sanders E, Feavers IM, Jerse A, Derrick JP, Tang CM, Maiden MCJ.mBio. 2025 Oct 8;16(10):e0130925. doi: 10.1128/mbio.01309-25. Epub 2025 Aug 25.PMID: 40853111

The COVID-19 vaccination health literacy questionnaire (CVHL-Q): Design and validation according to classic psychometric and Rasch analyses.

Rodríguez-Blázquez C, Ayala A, Bas-Sarmiento P, Fernandez-Gutiérrez M, Falcon M, Romay-Barja M, Forjaz MJ.Public Health. 2025 Oct;247:105842. doi: 10.1016/j.puhe.2025.105842. Epub 2025 Jul 2.PMID: 40609232

A case of metastatic breast carcinoma to the skin expressing SARS-CoV-2 spike protein possibly derived from mRNA vaccine.

Sano S.J Dermatol Sci. 2025 Oct 3:S0923-1811(25)00180-X. doi: 10.1016/j.jdermsci.2025.09.007. Online ahead of print.PMID: 41076388

A modified-live Mannheimia haemolytica expressing Mycoplasma bovis EFTu and Hsp70 induced systemic and mucosal antibody responses in American bison but failed to fully protect against Mycoplasma bovis challenge.

Kaplan BS, Dassanayake RP, Chriswell BO, Boatwright WD Jr, Olsen SC, Palmer MV, Boggiatto PM, Kanipe CR, Casas E, Briggs RE, Tatum FM.Vet Microbiol. 2025 Oct;309:110680. doi: 10.1016/j.vetmic.2025.110680. Epub 2025 Aug 11.PMID: 40829208

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.

Wang Y, Sun D, Laney V, Wang H, Wang LL, Lu ZR.Adv Drug Deliv Rev. 2025 Oct;225:115675. doi: 10.1016/j.addr.2025.115675. Epub 2025 Aug 14.PMID: 40818568

Feasibility and Acceptability of Respiratory Syncytial Virus Vaccination in Mothers for Infant Protection at Edward Francis Small Teaching Hospital, the Gambia.

Jasseh I, Manka M, Mendy S, Bajinka O, Makalo L.J Epidemiol Glob Health. 2025 Oct 10;15(1):118. doi: 10.1007/s44197-025-00467-x.PMID: 41071412

Assembly of the Mycobacterium tuberculosis type VII ESX-1 secretion system in Mycobacterium smegmatis identifies a new transcriptional activator of esx-1 genes and a novel TB vaccine.

Zriba S, Lim ZL, Snider M, Niroula N, Hardouin M, Chen JM.Microbiol Spectr. 2025 Oct 7;13(10):e0113125. doi: 10.1128/spectrum.01131-25. Epub 2025 Sep 12.PMID: 40938095

Potential immunoprophylactic use of a multi-epitope protein of $CD4^+$ and $CD8^+$ T cells against visceral leishmaniasis in Balb/c mice.

Costa SS, Ribeiro NR, Dos Reis Cruz L, Moreira GJL, Martins VT, Lage DP, Vale DL, Costa CVS, Galvani NC, Luiz GP, de Oliveira ME, Machado-de-Ávila RA, Carvalho AMRS, Eleutério NM, Fernandes APSM, Coelho EAF, Roatt BM, Menezes-Souza D, Duarte MC.Res Vet Sci. 2025 Oct;194:105820. doi: 10.1016/j.rvsc.2025.105820. Epub 2025 Jul 26.PMID: 40753819

Ebola vaccine safe for mothers and infants.

Kampmann B, Hucko A.Nat Med. 2025 Oct 9. doi: 10.1038/s41591-025-04000-2. Online ahead of print.PMID: 41068467

Dermatologic reactions comprise a minority of adverse events following Jynneos monkeypox vaccination: A retrospective pharmacovigilance study.

Pathak GN, Pathak A, Desai AD, Elman SA.J Am Acad Dermatol. 2025 Oct;93(4):1097-1099. doi: 10.1016/j.jaad.2025.05.1444. Epub 2025 Jun 6.PMID: 40484134

Prevention of varicella-zoster virus infection in early childhood children: effect of 1 versus 2 doses of varicella vaccine on antibody levels.

Wu D, Han C, Xiong S, Zhang P, Gao H, Jiang J, Wang F, Lv X, Yao F, Xu Q.Infection. 2025 Oct;53(5):1993-2003. doi: 10.1007/s15010-025-02532-w. Epub 2025 Apr 7.PMID: 40192960

Developing Community-Informed Communication Resources to Improve Human Papillomavirus Vaccine Uptake in Tonga.

Mohamed Y, Luey E, Kata ', Overmars I, Tukia O, Frawley J, Tei A, Lotulelei S, Toluta'u ', Lomu M, Vodonaivalu L, Leask J, Seale H, Jenkins K, 'Ofanoa R, Joshi K, Datt H, Sagan S, Dynes M, Danchin M, Kaufman J.Health Expect. 2025 Oct;28(5):e70422. doi: 10.1111/hex.70422.PMID: 40914932

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Immunoinformatics design of multi-epitope vaccine candidates against "ESKAPE" pathogens as nosocomial infection.

Khalaj A, Moghri SAHMH.Comput Biol Med. 2025 Oct;197(Pt B):111100. doi: 10.1016/j.compbiomed.2025.111100. Epub 2025 Sep 15.PMID: 40957351

Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review.

Yao K, Feng H, Chen Y, Bao Y, Yan M, Li W, Wu B.Clin Drug Investig. 2025 Oct;45(10):681-700. doi: 10.1007/s40261-025-01477-0. Epub 2025 Sep 17.PMID: 40960675

Plasmodium vivax circumsporozoite surface protein (PvCSP) as a vaccine candidate: a brief review.

Alves KCS, Mourão EMV, Melo JM, Almeida MEM, Oliveira JGS, Mariúba LAM.Rev Inst Med Trop Sao Paulo. 2025 Oct 3;67:e66. doi: 10.1590/S1678-9946202567066. eCollection 2025.PMID: 41059857

QS-21: Structural insights, immunological mechanisms, and prospects for rational design of safer vaccine adjuvants.

Hu Y, Wu Y, Liu H, Cheng S, Wen F, Wan L.Eur J Med Chem. 2025 Oct 2;301:118223. doi: 10.1016/j.ejmech.2025.118223. Online ahead of print.PMID: 41046625

Feline leukaemia virus (FeLV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management.

Westman ME, Coggins SJ, van Dorsselaer M, Norris JM, Squires RA, Thompson M, Malik R.Aust Vet J. 2025 Oct;103(10):617-635. doi: 10.1111/avj.13470. Epub 2025 Jul 26.PMID: 40716042

A new study provides details on COVID-19 vaccine booster efficacy among children receiving immunosuppressive medications.

Hooven TA.Pediatr Res. 2025 Oct 3. doi: 10.1038/s41390-025-04470-7. Online ahead of print.PMID: 41044222

Assessment of critical bioprocess parameters for broadly cross-reactive chimeric hemagglutinin influenza virus vaccines.

Scherm MJ, Hölzl R, González-Domínguez I, Hjorth R, Chiou SS, Maughan MF, Martik D, Krammer F, Puente-Massaguer E.Vaccine. 2025 Oct 3;64:127671. doi: 10.1016/j.vaccine.2025.127671. Epub 2025 Sep 18.PMID: 40972238

Predicting influenza vaccine-elicited antibody responses with practical point systems.

Shen Y, Sung MH, Ge Y, Chen Y, Carlock MA, Hanley HB, Jiang S, Handel A, Ross TM.Vaccine. 2025 Oct 3;64:127737. doi: 10.1016/j.vaccine.2025.127737. Epub 2025 Sep 16.PMID: 40961797

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Exploring the effectiveness of interventions to increase uptake of measles vaccination among healthcare workers: a systematic review.

Heinze N, Martin AF, Tirion ASC, Pae R, Islam J, Smith LE, Weston D, Rubin GJ.Vaccine. 2025 Oct 9;66:127808. doi: 10.1016/j.vaccine.2025.127808. Online ahead of print.PMID: 41072280

Corrigendum to "Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC" [Vaccine 62 (2025) 127537].

Kahusu CM, Peckeu-Abboud L, Goovaerts O, Matungulu E, Heyndrickx L, Ariën KK, Oostvogels S, Mubiala A, Milua S, Mbilizi IM, Shamamba S, Bayoka N, Ishara-Nshombo E, Tshimanga C, Nkuba A, Peeters M, Bazola B, Sabue J, Ngimba M, Mukanya N, Tshita P, Kinzungu C, Kasumba DM, Tshiani O, Mbala-Kingebeni P, Liesenborghs L, Mukadi-Bamuleka D, Mulangu S, Kavunga-Membo H, Adriaensen W.Vaccine. 2025 Oct 3;64:127719. doi: 10.1016/j.vaccine.2025.127719. Epub 2025 Sep 17.PMID: 40966976

Pro-Vax, Anti-Vax, or Shades of Gray? Segmenting Consumers Based on Attitudes to Vaccination.

Rigoni D, Desmet T, Brengman M.Health Educ Behav. 2025 Oct;52(5):584-596. doi: 10.1177/10901981251334105. Epub 2025 May 14.PMID: 40366342

Advances in recombinant protein vaccines against Leishmania infantum: a systematic review of vaccinal constructs and delivery strategies.

Martins AZ, Grossi de Oliveira AL, Bueno LL, Oliveira FMS, Fujiwara RT.Acta Trop. 2025 Oct;270:107796. doi: 10.1016/j.actatropica.2025.107796. Epub 2025 Aug 19.PMID: 40840696

Safety and Efficacy of MV140 Sublingual Vaccine (Uromune) in Preventing Recurrent Urine Infections Post Renal Transplant: A Case Series.

Palladino B, O'Shea-Farren D, Boan P, Ho S, Irish A, Pereira L, Robinson JO, Swaminathan R.Transpl Infect Dis. 2025 Oct 10:e70114. doi: 10.1111/tid.70114. Online ahead of print.PMID: 41071264

Analysis of the potential for immunosuppression of infants with in-utero and breast milk exposure to antitumor necrosis factor alpha agents: are all agents equally safe?

Yaghi M, Dulai AS, Haddad NR, Murase EM, Murase JE.Int J Womens Dermatol. 2025 Sep 8;11(3):e220. doi: 10.1097/JW9.0000000000000220. eCollection 2025 Oct.PMID: 40927444

In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation.

Shi Y, Hou Y, Mabrouk MT, Yu C, Yang Y.Adv Sci (Weinh). 2025 Oct;12(37):e09836. doi: 10.1002/advs.202509836. Epub 2025 Aug 19.PMID: 40827547

Application prospects of tumor vaccines for pancreatic cancer: From TAAs to TSAs and combination strategies.

Lu Z, Zhu W, Liu X.Semin Oncol. 2025 Oct;52(5):152399. doi: 10.1016/j.seminoncol.2025.152399. Epub 2025 Aug 20.PMID: 40839910

Bifunctional Behavior of Conformationally Constrained Methamphetamine Analogs: Unexpected Heteroclitic Immune Response and Antagonist Effects Altering Methamphetamine and Fentanyl Pharmacology.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Lee S, Eubanks LM, Zhou B, Janda KD.J Med Chem. 2025 Oct 9. doi: 10.1021/acs.jmedchem.5c02002. Online ahead of print.PMID: 41066151

Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016-2020.

Nair NP, Reddy SN, Giri S, Thiyagarajan V, Muliyil J, Hemavathy P, Khakha SA, Arora R, Gupte MD, Tate JE, Parashar UD, Mohan VR, Kang G; Collaborators of the rotavirus vaccine effectiveness and impact assessment network.Nat Med. 2025 Oct 7. doi: 10.1038/s41591-025-03998-9. Online ahead of print.PMID: 41057654

Beta-Glucan in barley as a natural immunomodulator: mechanisms and therapeutic potential.

Ahmed HGMD, Yang L, Yang X, Yang J, Hussain S, Shafiq MD, Akram MI, Sajad M, Zeng Y.Mol Biol Rep. 2025 Oct 11;52(1):1012. doi: 10.1007/s11033-025-11136-4.PMID: 41075026

Intussusception risk after rotavirus vaccination in Korean infants.

Cho H, Jeong NY, Kim HJ, Lee HE, Bae H, Lee H, Choi NK.Vaccine. 2025 Oct 3;64:127782. doi: 10.1016/j.vaccine.2025.127782. Epub 2025 Sep 23.PMID: 40992076

Dendritic cell-based vaccine prepared with recombinant Lactococcus lactis eukaryotic-prokaryotic dual expressing OVA enhances antitumor efficacy by both direct and cross-presentation.

Zhang T, Huang S, Liu P, Su X, Zou J, Wu Y, Li Y, Xu Y, Li J.Int Immunopharmacol. 2025 Oct 10;163:115263. doi: 10.1016/j.intimp.2025.115263. Epub 2025 Jul 23.PMID: 40706205

A scoping review of multicomponent interventions to improve uptake of routine childhood vaccines in low- and middle-income countries.

Mohamed Y, Danchin M, Boyd L, Nightingale C, Belizario VY, Kaufman J.Vaccine. 2025 Oct 3;64:127727. doi: 10.1016/j.vaccine.2025.127727. Epub 2025 Sep 10.PMID: 40934734

A review of methodologic & data considerations for vaccine safety surveillance in the wake of the COVID-19 pandemic.

Mues KE, Zhou CK, Gerber JE, van Hunsel F, Klein NP, Izurieta HS, Chen RT.Vaccine. 2025 Oct 3;64:127691. doi: 10.1016/j.vaccine.2025.127691. Epub 2025 Sep 5.PMID: 40913819

Evaluation of the efficacy of microencapsulatedscaffold against Edwardsiellatardain oral vaccinated Nile tilapia (Oreochromis niloticus).

Elumalai P, Nandhakumar K, Lakshmi S, Wangkahart E.Fish Shellfish Immunol. 2025 Oct;165:110513. doi: 10.1016/j.fsi.2025.110513. Epub 2025 Jun 23.PMID: 40562259

[Factors associated with adherence to COVID-19 vaccination in young adults: a systematic review].

Escandell Rico FM, Pérez Fernández L.Rev Esp Salud Publica. 2025 Oct 2;99:e202510057.PMID: 41065536

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Evaluating the Impact of the "We Can Do This" Campaign's Heavy-Up Advertising on Initial COVID-19 Vaccine Uptake.

Kim JC, Dahlen H, Dupervil D, Ihongbe TO, Moffett KW, Hoffman B, Denison B, Kranzler EC, Yu K, Margolis KA, Hoffman L.Health Commun. 2025 Oct;40(11):2300-2309. doi: 10.1080/10410236.2025.2449713. Epub 2025 Jan 19.PMID: 39828658

The incremental net monetary benefit of higher-valent pneumococcal conjugate vaccines for adults: a systematic review and meta-analysis of economic evaluations.

Lee H, Cho JY, Vietri J, Dawson E, Chaiyakunapruk N.J Med Econ. 2025 Dec;28(1):1761-1778. doi: 10.1080/13696998.2025.2565902. Epub 2025 Oct 10.PMID: 40994424

Corrigendum to "Cost-effectiveness of different HPV vaccination strategies for cervical cancer prevention in South Africa" [Vaccine 64 (2025) 127770].

van Schalkwyk C, Meyer-Rath G, Masuku S, Jamieson L, Bloem P, Rangaraj A, Chidarikire T, Dlamini-Nqeteko S, Doherty M, Johnson LF, Dalal S.Vaccine. 2025 Oct 3;65:127797. doi: 10.1016/j.vaccine.2025.127797. Online ahead of print.PMID: 41045635

Mumps Seroprevalence in Vellore, South India: A Community-Based Cross-Sectional Study.

Madhavan R, Varghese T, Eswaran A, Gandhi V, Saravanan P, Raj L, Raju R, Xavier JVL, Joseph JS, Premkumar PS, Rose W, John J.Am J Trop Med Hyg. 2025 Aug 12;113(4):883-887. doi: 10.4269/ajtmh.25-0069. Print 2025 Oct 1.PMID: 40795852

COVID-19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey.

Li Y, Muppidi S, Unnithan S, Al-Khalidi HR, Masterson S, Huff W, Juel VC, Guptill JT, Raja SM.Muscle Nerve. 2025 Oct;72(4):597-605. doi: 10.1002/mus.28466. Epub 2025 Jul 10.PMID: 40635622

Re: 'Association between pertactin-producing Bordetella pertussis and fulminant pertussis in infants: a multicentre study in France, 2008-2019' by Leroux et al.

Guiso N, Heininger U, Macina D, Soubeyrand B, Vargas-Zambrano JC, Wirsing von König CH.Clin Microbiol Infect. 2025 Oct;31(10):1746-1747. doi: 10.1016/j.cmi.2025.04.040. Epub 2025 May 6.PMID: 40339801

A novel MF59 and CpG1018 adjuvant combination enhances the humoral and cellular immune responses against a truncated varicella-zoster viral glycoprotein E.

Yang J, Hu X, Chen X, Li W, Yin Q, Xiong Y, An Y, Li H, Liu Z.Immunol Lett. 2025 Oct;275:107025. doi: 10.1016/j.imlet.2025.107025. Epub 2025 Apr 14.PMID: 40239819

Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization.

Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Caserta S, Mendicino F, Morabito F, Gentile M.Eur J Haematol. 2025 Oct 7. doi: 10.1111/ejh.70049. Online ahead of print.PMID: 41058125

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Design and in vivo evaluation of a multi-epitope vaccine that suppresses tumor growth in a murine colorectal cancer model.

Khodadadi A, Afshar S, Najafi R, Zamani A, Dalirfardouei R, Soleimani M.J Drug Target. 2025 Oct 9:1-22. doi: 10.1080/1061186X.2025.2573054. Online ahead of print.PMID: 41063694

Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network.

Atmar RL, Abate G, Deming ME, George SL, Fleming A, Frey SE, Lyke KE, Stephens DS, Del Rio C, El Sahly HM.Clin Infect Dis. 2025 Oct 10;81(Supplement_2):S89-S102. doi: 10.1093/cid/ciaf380.PMID: 41071737

Comment on "Indirect effect of the COVID-19 pandemic on cardiovascular diseases incidence, mortality, and healthcare use among patients with hypertension but without SARS-CoV-2 infection in Hong Kong".

Daungsupawong H, Wiwanitkit V.Hypertens Res. 2025 Oct 8. doi: 10.1038/s41440-025-02279-9. Online ahead of print.PMID: 41062616

Immunoinformatics investigation on pathogenic Escherichia coli proteome to develop an epitope-based peptide vaccine candidate.

Chowdhury S, Sadhukhan P, Mahata N.Mol Divers. 2025 Oct;29(5):4293-4321. doi: 10.1007/s11030-024-11034-0. Epub 2024 Nov 8.PMID: 39516450

Reasons for over-reporting of routine immunization administrative data in the Democratic Republic of Congo: a mixed cross-sectional study to determine explanatory factors for poor data quality.

Ngo-Bebe D, Kwilu FN, Konde JN, Ishoso DK, Langwana F, Mwanga C, Kinuani LM, Luhata CL, Mukendi JC, Cikomola AM, Nimpa MM.BMC Public Health. 2025 Oct 1;25(1):3272. doi: 10.1186/s12889-025-24639-3.PMID: 41034861

Glyceraldehyde-3-phosphate dehydrogenase facilitates Mycoplasma synoviae colonisation in the lower respiratory system.

Zare S, Marenda MS, Arachchige SNK, Shil P, Shahid MA, Kordafshari S, Rodrigo CH, Kawarizadeh A, O'Rourke D, Noormohammadi AH.Vet Microbiol. 2025 Oct;309:110675. doi: 10.1016/j.vetmic.2025.110675. Epub 2025 Aug 11.PMID: 40803170

Bacterial outer membrane vesicles: a novel target in mediating bacterial infection and host immune responses.

Miao B, Han J, Jiang Y, Yu L, Liu Y, Du F, Zhu X, Gong X, Li Z, Chen Z, Liu S.World J Microbiol Biotechnol. 2025 Oct 8;41(10):363. doi: 10.1007/s11274-025-04597-z.PMID: 41060345

Long-term protection of turkeys with a live clonal monoxenic Histomonas meleagridis vaccine.

Hatfaludi T, Rezaee MS, Vlerick L, Sulejmanovic T, De Gussem M, Vereecken M, De Gussem K, Liebhart D, Hess M.Avian Pathol. 2025 Oct;54(5):633-644. doi: 10.1080/03079457.2025.2497814. Epub 2025 May 23.PMID: 40406918

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

An inactivated trivalent virion-based vaccine protects against aerosol challenge with encephalitic alphaviruses in mice and macaques.

Lam LKM, Gilliland T Jr, Dunn M, Alcorn-Burckhardt MD, Terada Y, Sun C, Vasilatos S, Midgett M, Williams C, Laughlin A, Lundy J, Gardner CL, Thomas A, Raué HP, Gertje HP, O'Connell AK, Crossland NA, Reed DS, Diamond MS, Slifka MK, Klimstra WB.Sci Transl Med. 2025 Oct;17(818):eadv7079. doi: 10.1126/scitranslmed.adv7079. Epub 2025 Oct 1.PMID: 41032627

Epidemiological Investigation of Infectious Coryza in Central China and the Effect of Enterococcus faecium on Improving Vaccine Immunity.

Cui W, Wang C, Wu Y, Wang T, Wang Z, Zhang W, Hu T, Zhang W, Hu S, Zhou H, Li Z, Zhou Z.Poult Sci. 2025 Oct;104(10):105622. doi: 10.1016/j.psj.2025.105622. Epub 2025 Jul 29.PMID: 40769017

RNA vaccines for cancer: revolutionizing immunization strategies.

Huang D, Zhang J, Zeng X, Zhang Y, Song E.Trends Cancer. 2025 Oct 10:S2405-8033(25)00231-6. doi: 10.1016/j.trecan.2025.09.003. Online ahead of print.PMID: 41073150

Safety, immunogenicity and efficacy of the Shingrix vaccine in immunocompromised varicella zoster virus naive pediatric patients.

Hamad Saied M, El Bied N, Khoury L, Vastert SJ, Swart J, van Royen A, van Nieuwenhove E, Wolters VM, van Montfrans J, Lunel FV, de Roock S, Jansen M.Vaccine. 2025 Oct 3;64:127708. doi: 10.1016/j.vaccine.2025.127708. Epub 2025 Sep 6.PMID: 40916263

Evaluation of a strategy to enhance the efficacy and ease of application of porcine reproductive and respiratory syndrome virus vaccines.

Schiavone A, Edwards JC, Vigneswaran E, De Brito RCF, Hothi H, Frossard JP, Beechener ES, Calvert JG, Burkard CT, Balasch M, Seaton AV, Stevens M, Howard MK, Graham SP, Opriessnig T.Vaccine. 2025 Oct 3;64:127757. doi: 10.1016/j.vaccine.2025.127757. Epub 2025 Sep 19.PMID: 40974733

Fusion membrane proteins derived subunit vaccine candidates effectively protect against Mycoplasma bovis challenge in mice.

Wang YX, Cheng HS, Yue J, Hu Q, Han SB, Li YF, Chen YJ, Zhu EP, Cheng ZT.BMC Vet Res. 2025 Oct 2;21(1):559. doi: 10.1186/s12917-025-04980-w.PMID: 41039518

Penny wise, pound foolish: The cost of reduced support for measles prevention.

Mattingly TJ 2nd.Vaccine. 2025 Oct 3;65:127830. doi: 10.1016/j.vaccine.2025.127830. Online ahead of print.PMID: 41045634

Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and children.

Pial RH, Capeding MR, Tadesse BT, Excler JL, Song KR, Park EL, Park IY, Yang JS, Kim S, Lee EY, Eluru JR, Kwon SY, Jo SK, Ryu JH, Park HK, Shin JH, Yang SY, Kim DR, Song M, Wartel TA, Kim HS, Saluja T,

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Sahastrabuddhe S.Vaccine. 2025 Oct 3;64:127751. doi: 10.1016/j.vaccine.2025.127751. Epub 2025 Sep 16.PMID: 40961798

Application of a multi-epitope DNA vaccine against viral hemorrhagic septicemia virus type a.

Ryu NG, Yang YJ, Kim KI.Arch Virol. 2025 Oct 10;170(11):222. doi: 10.1007/s00705-025-06430-2.PMID: 41071347

An optimized intranasal LNP formulation for potent immune responses of mRNA-based RSV vaccines.

Li Y, Long H, Wang C, Weng J, Kuang Z, Peng Y.Nanoscale. 2025 Oct 10. doi: 10.1039/d5nr01452b. Online ahead of print.PMID: 41071038

Recombinant vaccinia virus expressing MIC8, AMA1, or RON4 induce protection against Toxoplasma gondii ME49 strain infection.

Kang HJ, Quan FS.Acta Trop. 2025 Oct;270:107812. doi: 10.1016/j.actatropica.2025.107812. Epub 2025 Aug 29.PMID: 40886931

Determinants of measles second-dose vaccine coverage in the Gambia - a secondary analysis of 2019 demographic and health survey data.

Bruce AA, Gallagher K.Vaccine. 2025 Oct 4;65:127789. doi: 10.1016/j.vaccine.2025.127789. Online ahead of print.PMID: 41046835

Safety and immunogenicity of COVAC-2, a Sepivac SWE adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Hamonic G, Pastural E, Arora S, Lew J, Cai Y, Scruten E, Buchanan R, ElSherif M, Ye L, Courant T, Ventura RA, Collin N, Daugan M, Gagnon L, Hodgson P, van Drunen Little-van den Hurk S, Falzarano D, Sanche S, Halperin SA, Langley JM, Gerdts V, Racine T.Vaccine. 2025 Oct 3;64:127748. doi: 10.1016/j.vaccine.2025.127748. Epub 2025 Sep 16.PMID: 40957309

Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications.

Yan Y, Liu S, Wen J, He Y, Duan C, Nabavi N, Ashrafizadeh M, Sethi G, Liu L, Ma R.Mol Cancer. 2025 Oct 9;24(1):251. doi: 10.1186/s12943-025-02463-y.PMID: 41068915

Modest Protective Immune Responses Induced by a DNA Vaccine Expressing IMP1 of Toxoplasma gondii in BALB/c Mice.

Alizadeh F, Hataminejad M, Yaghoobi H, Azizi H.Parasite Immunol. 2025 Oct;47(10):e70025. doi: 10.1111/pim.70025.PMID: 41069133

Development of African horse sickness disabled infectious single animal (DISA)-DIVA vaccine platform applied for all nine serotypes.

van Rijn PA, Wernery U, Feddema AJ, Maris-Veldhuis MA, Joseph S, van Gennip RGP.Vaccine. 2025 Oct 3;64:127772. doi: 10.1016/j.vaccine.2025.127772. Epub 2025 Sep 23.PMID: 40992078

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Efficacy of novel SARS-CoV2 vaccines in preventing SARS- CoV- 2 infection: a systematic review and meta-analysis.

Teffera ZH, Belay WY, Tegegne BA, Belew H, Adugna A, Laykun Y, Tefera S, Muche Y, Melkamu A, Amare GA, Abebaw D, Akelew Y, Jemal M, Getinet M, Fenta Mengist E, Baylie T, Haimanot AB, Hibistu T, Enchalew K.BMC Infect Dis. 2025 Oct 10;25(1):1267. doi: 10.1186/s12879-025-11717-5.PMID: 41073977

Safety and immunogenicity of investigational herpes simplex virus-2 vaccines in adults with recurrent genital infection.

Laing KJ, Sholukh AM, MacPhee KJ, McClurkan CL, Pagnon A, Ruiz J, Bchir S, Oualim A, Hyrien O, Corey L, Wald A, Gurunathan S, Noriega F, Coronel D, Koelle DM.Vaccine. 2025 Oct 6;65:127821. doi: 10.1016/j.vaccine.2025.127821. Online ahead of print.PMID: 41056754

Corrigendum to "Sendai virus-based immunoadjuvant in hydrogel vaccine intensity-modulated dendritic cells activation for suppressing tumorigenesis" [Bioact. Mater. 6 (2021) 3879-3891].

Zheng B, Peng W, Gan L, Guo M, Wang S, Zhang XD, Ming D.Bioact Mater. 2025 Jul 3;52:877. doi: 10.1016/j.bioactmat.2025.06.011. eCollection 2025 Oct.PMID: 40688066

Inclusion of Women, Children, the Elderly, and Individuals With Underlying Medical Conditions: Prioritizing Vulnerable Populations in Clinical Research.

Bruxvoort KJ, Bahakel H, Martin JM, Nayak JL, Rolsma SL, Healy CM, Creech CB.Clin Infect Dis. 2025 Oct 10;81(Supplement_2):S78-S88. doi: 10.1093/cid/ciaf408.PMID: 41071738

Correction: Outcomes After Decompressive Surgery for Severe Cerebral Venous Sinus Thrombosis Associated or Not Associated with Vaccine-Induced Immune Thrombosis with Thrombocytopenia: A Multicenter Cohort Study.

Pelz JO, Kenda M, Alonso A, Etminan N, Wittstock M, Niesen WD, Lambeck J, Güresir E, Wach J, Lampmann T, Dziewas R, Wiedmann M, Schneider H, Bayas A, Christ M, Mengel A, Poli S, Brämer D, Lindner D, Pfrepper C, Roth C, Salih F, Günther A, Michalski D; IGNITE Study Group.Neurocrit Care. 2025 Oct;43(2):711-712. doi: 10.1007/s12028-025-02354-6.PMID: 40825920

Missed Opportunities for Adolescent HPV Vaccination in the United States: Parents' Perceptions of a Range of Healthcare Providers and Settings.

Owens H, Daley EM, Cayama MR, Villa A, Beckstead J, Pezzo M, Sauls R, Vamos CA.J Cancer Educ. 2025 Oct;40(5):767-773. doi: 10.1007/s13187-025-02572-8. Epub 2025 Jan 31.PMID: 39890751

Development and characterization of an innovative Flavobacterium oreochromis antigen-encapsulated hydrogel bead for enhancing oral vaccine delivery in hybrid red tilapia (Oreochromis spp.).

Thangsunan P, Thangsunan P, Mahatnirunkul T, Buncharoen W, Saenphet K, Saenphet S, Phaksopa J, Thompson KD, Srisapoome P, Kumwan B, Meachasompop P, Suree N, Uchuwittayakul A.Fish Shellfish Immunol. 2025 Oct;165:110483. doi: 10.1016/j.fsi.2025.110483. Epub 2025 Jun 10.PMID: 40505878

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Effects of an educational health promotion intervention to improve human papillomavirus vaccination acceptance and uptake among adolescent girls: a cluster randomized controlled trial.

Lo SHS, Chau JPC, Choi KC, Butt L, Lui GCY, Lee VWY, Lau AYL.BMC Public Health. 2025 Oct 9;25(1):3419. doi: 10.1186/s12889-025-24511-4.PMID: 41068722

Identification of potential antigenic proteins and epitopes for the development of a monkeypox virus vaccine: an in silico approach.

Aktaş E, Sezerman OU, Özer M, Kırboğa KK, Köseoğlu AE, Özgentürk NÖ.Mol Divers. 2025 Oct;29(5):4273-4291. doi: 10.1007/s11030-024-11033-1. Epub 2024 Nov 15.PMID: 39546220

Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial.

Pathirana J, Ramgopal M, Martin C, Lombaard JJ, Chahin C, Launay O, Ratanasuwan W, Greenberg D, Grijalva CG, Orenstein WA, Shenkerman A, Hall L, Fernsler D, Kim Y, Li J, Platt HL; STRIDE-7 Study Group.Lancet HIV. 2025 Oct;12(10):e679-e690. doi: 10.1016/S2352-3018(25)00165-1. Epub 2025 Sep 12.PMID: 40953572

An update on SARS-CoV-2 prevention strategy in solid organ transplant recipients: an expert opinion.

Grossi PA, Burra P, Cozzi E, Gesualdo L, Grandaliano G, Potena L, Vitulo P.Transplant Rev (Orlando). 2025 Oct 2;39(4):100966. doi: 10.1016/j.trre.2025.100966. Online ahead of print.PMID: 41067176

Niosomes as a vehicle for excretory/secretory antigens enhance immunization efficacy of Toxoplasma gondii vaccine.

Younis SS, Gamea GA, El Maghraby GM, Arafa MF, Khalifa RA, Shoeib SM, El-Gohary RM, Elmansory BM.Exp Parasitol. 2025 Oct;277:109024. doi: 10.1016/j.exppara.2025.109024. Epub 2025 Sep 9.PMID: 40935060

Routine immunisation coverage in the context of seasonal influenza vaccine introduction for children in Nakuru and Mombasa counties in Kenya, 2019-21: an observational study.

Igboh LS, Ayugi JO, Nyawanda BO, Otieno NA, Ondeng'e K, Dawa J, Osoro EM, Ebama MS, Lafond KE, Onyango C, Wallace AS, Jalang'o R, Mangtani P, Nguipdop-Djomo P, Emukule GO.Lancet Glob Health. 2025 Oct;13(10):e1737-e1749. doi: 10.1016/S2214-109X(25)00265-7.PMID: 40975081

Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection.

Raccagni AR, Morsica G, Reali P, Lolatto R, Bertoni C, Hasson H, Siribelli A, Bruzzesi E, Passini F, Canetti D, Castagna A, Nozza S.Vaccine. 2025 Oct 10;66:127825. doi: 10.1016/j.vaccine.2025.127825. Online ahead of print.PMID: 41075401

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Promoting public health with blunt instruments: Evidence from vaccine mandates.

Abouk R, Earle JS, Maclean JC, Park S.Labour Econ. 2025 Oct;96:102715. doi: 10.1016/j.labeco.2025.102715. Epub 2025 Apr 2.PMID: 40657478

Human papillomavirus awareness in a digital world: The intersection of faith and online media.

Laily A, Jo S, Duncan RJ, Hubach RD, LaRoche KJ, Rodriguez NM, Kasting ML.Prev Med Rep. 2025 Sep 12;58:103241. doi: 10.1016/j.pmedr.2025.103241. eCollection 2025 Oct.PMID: 41020203

COVID-19 vaccination lowers SARS-CoV-2 infection risk independent of diabetes, cancer and smoking in SHIP-COVID cohort, Northern Germany.

Khattak MNK, Haß JP, Ittermann T, Dörr M, Sidahmed O, Kristiansen NO, Ulm L, Lehmann K, Becker K, Görig T, Hübner NO, Völzke H.Sci Rep. 2025 Oct 7;15(1):35032. doi: 10.1038/s41598-025-22334-2.PMID: 41057499

Complete genome sequence of Baby Chick Ranikhet Disease Vaccine (BCRDV) strain in Bangladesh.

Parveen N, Karim MR, Happy SS, Begum T, Hossen A, Uddin AA, Ahmed T, Jahan S, Kamal MM, Samad MA.Microbiol Resour Announc. 2025 Oct 9;14(10):e0068125. doi: 10.1128/mra.00681-25. Epub 2025 Sep 17.PMID: 40960370

Association of prepartum clostridial vaccine administration with mitigation of respiratory and gastrointestinal disorders in calves.

Nakayama S, Aomori D, Mune F, Sato H, Nishino O, Tose S.Vet J. 2025 Oct;313:106368. doi: 10.1016/j.tvjl.2025.106368. Epub 2025 May 9.PMID: 40349751

Evaluation of humoral immunity and maternal antibody transfer in Nile tilapia (Oreochromis niloticus) broodstock following immunization with a bivalent vaccine.

Pardo AN, Dong HT, Salin KR, Senapin S.Fish Shellfish Immunol. 2025 Oct;165:110545. doi: 10.1016/j.fsi.2025.110545. Epub 2025 Jul 5.PMID: 40617412

Association between maternal influenza vaccination and childhood vaccination among participants of the 2015 Pelotas (Brazil) birth cohort.

Sartori AL, Buffarini R, Bertoldi AD, da Silveira MF.Vaccine. 2025 Oct 3;64:127761. doi: 10.1016/j.vaccine.2025.127761. Epub 2025 Sep 22.PMID: 40987000

Implementation of the ICH E9 (R1) addendum in vaccine efficacy studies: the hypothetical and principal stratum strategies.

Noirjean S, Bottigliengo D, Cinconze E, Charkhi A, Zahaf T, Li F, Callegaro A.J Biopharm Stat. 2025 Oct 2:1-18. doi: 10.1080/10543406.2025.2547588. Online ahead of print.PMID: 41037669

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Antibody Level against Hepatitis B Virus in Term and Preterm Infants Following Three Doses of Pentavalent Vaccine as per EPI Schedule.

Kar N, Hossain MA, Islam MN, Adhikary PD, Saha BK, Chowdhury B, Mazumder M, Fahmin F, Banik BK, Akhter H, Adhikary DD, Tazmin T.Mymensingh Med J. 2025 Oct;34(4):1030-1035.PMID: 41024538

Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo.

Garcia-Fogeda I, Abrams S, Vanhee S, Salloum M, Ogunjimi B, Hens N.Vaccine. 2025 Oct 3;64:127707. doi: 10.1016/j.vaccine.2025.127707. Epub 2025 Sep 10.PMID: 40934735

Acting CDC director calls for MMR break-up in overhaul of US vaccine schedule.

Tanne JH.BMJ. 2025 Oct 9;391:r2130. doi: 10.1136/bmj.r2130.PMID: 41067782

Enhanced protective efficacy of a dendritic cell-targeting truncated F protein delivery via minicircle DNA vaccine against genotype VII newcastle disease virus in chickens.

Bao M, Wang W, Sun Y, Zhang Y, Gao Y, Zhang Y, Yang T, Guo Q, Zhang G, Wang M, Gong J, Tian Y, He Y, Wang J, Huang H, Wang Z, Wang C, Jiang Y.Vet Microbiol. 2025 Oct;309:110685. doi: 10.1016/j.vetmic.2025.110685. Epub 2025 Aug 18.PMID: 40834623

Correction: Reverse vaccinology-based identification and in silico characterization of immunogenic membrane proteins of Salmonella Typhimurium as novel vaccine targets against multidrug-resistant infections.

Habiba TU, Hussain Z, Asghar F, Nawaz W.BMC Microbiol. 2025 Oct 8;25(1):639. doi: 10.1186/s12866-025-04381-x.PMID: 41057782

Determinants of Changes in HPV Vaccination Willingness Among Men Who Have Sex With Men: An Observational Cohort Study.

He J, Tian T, Tuo X, Yu W, Asilibieke S, Zhang Z, Liu L, Xi M, Yang H, Zhang G, Dai J.J Med Virol. 2025 Oct;97(10):e70611. doi: 10.1002/jmv.70611.PMID: 40988579

Differences in influenza vaccination coverage by race and ethnicity across age groups in the Vaccine Safety Datalink, 2017-18 through 2022-23 influenza seasons.

Irving SA, Groom HC, Belongia EA, Crane B, Daley MF, Jackson LA, Kenigsberg TA, Kuckler L, Tseng HF, Williams JTB, Zerbo O, Naleway AL.Vaccine. 2025 Oct 3;64:127667. doi: 10.1016/j.vaccine.2025.127667. Epub 2025 Sep 4.PMID: 40912094

Complete genome sequencing, molecular and antigenic characterization of duck hepatitis A virus type 1 isolated in Benha, Egypt.

Moharam I, Abaza MA, Khalil NW, El-Nahas EM, El-Habbaa AS, Najar FZ, Radi M, El Nagar EMS, Omar L, Gamal MAN, El-Mayet FS.BMC Vet Res. 2025 Oct 3;21(1):571. doi: 10.1186/s12917-025-05010-5.PMID: 41044682

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking case.

Maia A, Schuhmacher J, Nadalin S, Königsrainer A, Thiel K, Nelde A, Zinser RS, Schroeder C, Mattern S, Singer S, Bösmüller H, Rammensee HG, Löffler MW, Gouttefangeas C.J Immunother Cancer. 2025 Oct 9;13(10):e012107. doi: 10.1136/jitc-2025-012107.PMID: 41067882

Toxicity study of SARS-CoV-2 Spike protein expressed on Bacillus subtilis spores.

Hazan A, Saperi AA, Zulkifli N, Rahim NM, Tiong V, Lee HY, AbuBakar S.BMC Microbiol. 2025 Oct 6;25(1):633. doi: 10.1186/s12866-025-04186-y.PMID: 41053546

HIV-1 gp160 in nanodiscs: Unravelling structures and guiding vaccine design.

Elbaz NM, Nasr ML.Curr Opin Struct Biol. 2025 Oct;94:103122. doi: 10.1016/j.sbi.2025.103122. Epub 2025 Aug 5.PMID: 40763538

Contextualizing HPV vaccination intention among Haitian immigrant and migrant women through exploring cultural worldviews and affective risk perception: a qualitative study.

Guillaume D, Alcaide ML, Sternberg CA, Hay J, Augustin A, Wenzel J, Doriscan LJ, Limaye R, Brown J, Pierre-Joseph N, Rolland C, Alexander KA.Ethn Health. 2025 Oct;30(7):806-823. doi: 10.1080/13557858.2025.2544114. Epub 2025 Aug 19.PMID: 40827459

Efficacy of a non-recombinant NADC34-like PRRSV-2 vaccine candidate against a recombinant NADC34-like PRRSV-2 isolate.

Qiu M, Li S, Cui M, Yang S, Zhu X, Meng Y, Lin Y, Lin H, Sun Z, Wang Y, Sen Jiang, Zheng W, Zhu J, Chen N.Vet Microbiol. 2025 Oct;309:110676. doi: 10.1016/j.vetmic.2025.110676. Epub 2025 Aug 11.PMID: 40812026

Humoral response dynamics following inactivated SARS-CoV-2 vaccination and their association with subsequent infection and symptoms in individuals with and without prior SARS-CoV-2 infection: evidence from Sichuan Province, China.

Yu Y, Jia M, Zhong J, Feng L, Jiang X, Li Y, Huang Q, Chen Y, Wang X, Yue Y, Guo L, Liang X, Ren L, Yang W.Microbiol Spectr. 2025 Oct 7;13(10):e0219124. doi: 10.1128/spectrum.02191-24. Epub 2025 Aug 11.PMID: 40788170

Vaccination Rates Among Long-Term Care Staff During the SARS-COVID-19 Pandemic.

Leng LN, Hua CL, Dosa DM, Dobbs D, Peterson LJ.J Am Med Dir Assoc. 2025 Oct 8:105913. doi: 10.1016/j.jamda.2025.105913. Online ahead of print.PMID: 41075822

Trace amounts of cobalt serve as an adjuvant for unglycosylated JEV-ED3 expressed in E. coli, inducing a potent virus-neutralizing immune response.

Islam MD, Kurosu T, Okawa M, Morikoshi N, Islam MM, Tsurui H, Kuroda Y.Vaccine. 2025 Oct 3;64:127742. doi: 10.1016/j.vaccine.2025.127742. Epub 2025 Sep 13.PMID: 40945179

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The Long-term Effects of Acute Total-Body Irradiation on Pre-irradiation Measles-vaccine-induced Immunological Memory.

Stover EL, Rock ML, Olson JD, Schaaf GW, Oguin TH 3rd, Cline JM, Macintyre AN.Radiat Res. 2025 Oct 1;204(4):329-342. doi: 10.1667/RADE-23-00203.1.PMID: 40048630

Impact of vaccination on pertussis-related hospital admissions in children in Scotland from January 2013 to July 2024: a cohort study.

Hasan T, Wilkinson E, Decraene V, Kouzeli A, Gibbons C, Chua V, Vivancos R, Ghebrehewet S.Euro Surveill. 2025 Oct;30(39):2500270. doi: 10.2807/1560-7917.ES.2025.30.39.2500270.PMID: 41040065

A Review of Respiratory Syncytial Virus Vaccines in the Older Adult.

Torres B, King JM, Richardson RM.Sr Care Pharm. 2025 Oct 1;40(10):402-411. doi: 10.4140/TCP.n.2025.402.PMID: 41039710

Out-of-pocket vaccination of 0-6 aged children: choice or face of women's status.

Sütlü S, Çatak B.Ir J Med Sci. 2025 Oct 11. doi: 10.1007/s11845-025-04112-1. Online ahead of print.PMID: 41073838

Impact of 10-year measles, mumps and rubella booster vaccination program among healthcare personnel: a cross-sectional study.

Hwang LE, Lin KY, Tseng PH, Ho SY, Lu CY, Cheng SY, Hsieh MJ, Huang YT, Chien SF, Su CH, Pan SC, Chiu HM, Chen YC, Chang SC.Vaccine. 2025 Oct 3;64:127758. doi: 10.1016/j.vaccine.2025.127758. Epub 2025 Sep 23.PMID: 40992077

Mpox among people reporting being unhoused or engaging in transactional sex within a multijurisdictional case-control study of sexually and gender minoritized individuals- United States, August 2022-March 2024.

Sherman JP, Morris AL, Niccolai LM, Ruff A, Schneider D, Sutton M, Hawkins S, Pathela P, Betancourt GS, Rothrock G, Nadle J, Rowlands JV, Felsen CB, Britton A, Farley MM, Duval LM, Kamis KF, Still WL, Morrow AS, Waddell CJ.Soc Sci Med. 2025 Oct;383:118497. doi: 10.1016/j.socscimed.2025.118497. Epub 2025 Aug 15.PMID: 40857851

Variation in anti-SARS-CoV-2 spike antibody responses by variants in patients with severe mental illness after COVID-19 vaccination.

Lin CY, Song YC, Yang CC, Yeh PS, Yu YY, Huang CC.Brain Behav Immun. 2025 Oct;129:434-441. doi: 10.1016/j.bbi.2025.06.015. Epub 2025 Jun 9.PMID: 40499845

Anti-tumor vaccine efficacy depends on adjuvant type and associates with induced IgG subclass and glycosylation profiles.

Lehrian S, Wasynczuk A, Petry J, Guderian M, Nouta J, Buhre JS, Lunding HB, Köcher P, Schumacher HF, Dühring L, Kurwahn K, Manzhula K, Manz R, Bartsch YC, Wuhrer M, Ehlers M.Exp Hematol Oncol. 2025 Oct 6;14(1):122. doi: 10.1186/s40164-025-00708-6.PMID: 41053886

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Polyclonal Vβ21.3 expansion in multisystem inflammatory syndrome in children despite SARS-CoV-2 vaccination.

Netea S, Khoryati L, Nagelkerke S, Benezech S, Keijser J, Gruppen M, Biesbroek G, Lubbers R, Ketharanathan N, Buddingh E, Schoenmaker N, Brandsma A, Rispens T, Kuipers I, Belot A, Kuijpers T.RMD Open. 2025 Oct 5;11(4):e005231. doi: 10.1136/rmdopen-2024-005231.PMID: 41052890

Modelling the determinants of uptake of complete immunization of children in Ghana.

Yeboah D, Engmann GM, Jakperik D.BMC Pediatr. 2025 Oct 11;25(1):808. doi: 10.1186/s12887-025-06224-0.PMID: 41073918

Ionizable Lipid Nanoparticles for mRNA Delivery: Internal Self-Assembled Inverse Mesophase Structure and Endosomal Escape.

Yu H, Dyett BP, Drummond CJ, Zhai J.Acc Chem Res. 2025 Oct 8. doi: 10.1021/acs.accounts.5c00522. Online ahead of print.PMID: 41060394

Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study.

Folegatti PM, Pepin S, Tabar C, Fries K, Talanova O, See S, Essink B, Bertoch T, Drazan D, Natalini Martínez S, Konieczny M, Kaas-Leach K, De Bruijn I.Lancet Infect Dis. 2025 Oct;25(10):1097-1105. doi: 10.1016/S1473-3099(25)00153-7. Epub 2025 May 21.PMID: 40412421

CD8+ lymphocytes in immunity against tuberculosis.

Li J, Simonson AW, Flynn JL.J Immunol. 2025 Oct 10:vkaf268. doi: 10.1093/jimmun/vkaf268. Online ahead of print.PMID: 41072549

Plant-derived extracellular vesicles: composition, function and clinical potential.

Huang D, Chen J, Zhao M, Shen H, Jin Q, Xiao D, Peng Z, Chen T, Zhang Y, Rao D, Liu M.J Transl Med. 2025 Oct 8;23(1):1065. doi: 10.1186/s12967-025-07101-1.PMID: 41063262

Non-neutralizing antibodies against SARS-CoV-2 nucleocapsid protein mediate variant transcendent antibody-dependent cellular cytotoxicity.

Osuagwu AE, Payne M, Bosch J, Mbonye U, Nguyen K, Karn J, Bruchez A, King CL.J Immunol. 2025 Oct 8:vkaf123. doi: 10.1093/jimmun/vkaf123. Online ahead of print.PMID: 41060789

Comparative evaluation of PRRSV MLV vaccine efficacy administered via intranasal and intramuscular routes in early age of piglets.

Prapattanakullawong A, Sirisereewan C, Boonprakob R, Kamenkit O, Kesdangsakonwut S, Thanawongnuwech R, Woonwong Y, Nedumpun T.Vaccine. 2025 Oct 3;65:127822. doi: 10.1016/j.vaccine.2025.127822. Online ahead of print.PMID: 41046831

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Statistical Methods for Multi-jurisdictional Australian Vaccine Safety Investigations of Rare Adverse Events.

Morgan HJ, Bloomfield L, Clothier HJ, Ngeh S, Cadby G, Carcione D, Boyd JH, Kattan GS, Buttery JP, Effler P.Drug Saf. 2025 Oct 1. doi: 10.1007/s40264-025-01615-9. Online ahead of print.PMID: 41032228

Maternal Immunization With RSVpreF Vaccine: Effectiveness in Preventing Respiratory Syncytial Virus-associated Hospitalizations in Infants Under 6 Months in Argentina: Multicenter Case-control Study.

Gentile A, Juárez MDV, Lucion MF, Gregorio G, López O, Fernández T, Gioiosa A, Lobertti S, Pejito N, López L, Ensinck G.Pediatr Infect Dis J. 2025 Oct 1;44(10):988-994. doi: 10.1097/INF.0000000000004878. Epub 2025 May 28.PMID: 40440704

Paternal factors affecting under-five immunization status in Sub-Saharan Africa: A systematic review and meta-analysis.

Musuka G, Moyo E, Mano O, Madziva R, Pierre G, Iradukunda PG, Sayem ASM, Dhliwayo T, Herrera H, Mutata C, Dzinamarira T.Vaccine. 2025 Oct 3;64:127695. doi: 10.1016/j.vaccine.2025.127695. Epub 2025 Sep 9.PMID: 40930045

Reduced vaccine-induced germinal center outputs in patients with inflammatory bowel disease treated with anti-TNF biologics.

Cheung MW, Xu S, Shapiro JR, Qi F, Delgado-Brand M, Colwill K, Dayam RM, Liu Y, Lee JD, Stempak JM, Rini JM, Chandran V, Silverberg MS, Gingras AC, Watts TH.J Clin Invest. 2025 Jul 29;135(19):e192589. doi: 10.1172/JCI192589. eCollection 2025 Oct 1.PMID: 40728886

Genomic and pathological insights into the first identified genotype IIIb chicken anemia virus strain in Bangladesh.

Akter M, Mia R, Hasan SN, Mozumder A, Jeba N, Farazi R, Akter F, Akter S, Rahman MZ, Saha S, Islam T, Hossain MG.Microbiol Spectr. 2025 Oct 10:e0079625. doi: 10.1128/spectrum.00796-25. Online ahead of print.PMID: 41071091

ASXL1 deficiency causes epigenetic dysfunction, combined immunodeficiency, and EBV-associated lymphoma.

Fu MP, Sharma M, Yousefi P, Merrill SM, Tan R, Samra S, Setiadi A, Golding L, Modi BP, Del Bel KL, Deyell RJ, Rozmus J, Rehmus W, Hildebrand KJ, James E, Blanchard-Rohner G, Lin S, Shopsowitz KE, Terry J, Lee AF, Drögemöller BI, Matthews A, Tarailo-Graovac M, Sauvé L, Mitchell H, Prendiville JS, MacIsaac JL, Dever K, Lin DTS, Meijer M, Ross CJD, Dobson SRM, Vercauteren SM, Wasserman WW, van Karnebeek CDM, McKinnon ML, Kobor MS, Turvey SE, Biggs CM.J Exp Med. 2025 Oct 6;222(10):e20240945. doi: 10.1084/jem.20240945. Epub 2025 Jul 31.PMID: 40742536

Replacing cholesterol and PEGylated lipids with zwitterionic ionizable lipids in LNPs for spleen-specific mRNA translation.

Zhao Y, Tian Z, Wang J, Cui M, Cao Z, Liu P, Li R, Cai S, Hu Y, Ma Y, Wagner E, Laflin A, Gu W, Cui Y, Tang C, Fountain H, Wang R, Jiang S.Sci Adv. 2025 Oct 10;11(41):eady6460. doi: 10.1126/sciadv.ady6460. Epub 2025 Oct 8.PMID: 41061074

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Medical importance and pharmacokinetics of gold nanoparticles in the human body.

Singh P, Joshi AS, Singh H, Mijakovic I.Mol Cancer. 2025 Oct 10;24(1):252. doi: 10.1186/s12943-025-02418-3.PMID: 41068777

[Oral fluid PCR monitoring for Aujeszky's disease virus detection in a swine farm].

Fossaroli MG, Biscia M, Spadaro MV, Anthony LM, Tugores PS, Sarradell JE.Rev Argent Microbiol. 2025 Oct 6:S0325-7541(25)00091-4. doi: 10.1016/j.ram.2025.08.001. Online ahead of print.PMID: 41058419

[[Translated article]]Erythema Papulatum Centrifugum: A Clinically Distinct Dermatosis. CLINI-AEDV Case Series.

Allegue F, Zulaica A, Pastor-Nieto MA, Ballester-Nortes I, Fernández-Tapia V, Parera-Amer ME, García-Doval I.Actas Dermosifiliogr. 2025 Oct 7:S0001-7310(25)00653-2. doi: 10.1016/j.ad.2025.10.006. Online ahead of print.PMID: 41067618

Rv2647-Mediated NLRP3 Ubiquitination Inhibits Macrophage Pyroptosis and Promotes *Mycobacterium tuberculosis* Survival.

Jin X, Yan H, Chen X, Feng J, Li G, Yao J, Du X, Feng G.ACS Infect Dis. 2025 Oct 10;11(10):2739-2753. doi: 10.1021/acsinfecdis.5c00192. Epub 2025 Oct 1.PMID: 41032685

The Effects of Chirality and Salt Addition on Phase Separation and Complexation Morphology in Mixtures of Polypeptides and Polypeptoids.

Mirlohi K, Thapa A, Zhang D, Blocher McTigue WC.Biomacromolecules. 2025 Oct 8. doi: 10.1021/acs.biomac.5c01165. Online ahead of print.PMID: 41061706

Seasonal Influenza Viruses Show Distinct Adaptive Dynamics During Growth in Chicken Eggs.

Kistler K, Bedford T.Mol Biol Evol. 2025 Oct 1;42(10):msaf227. doi: 10.1093/molbev/msaf227.PMID: 40974095

Preprints in COVID-19 news coverage: Comparing student and general population perceptions of preliminary science about booster vaccination.

Wicke R, Ratcliff CL, Fleerackers A, Wang Y, King AJ, Jensen JD.Risk Anal. 2025 Oct;45(10):3018-3029. doi: 10.1111/risa.70071. Epub 2025 Jun 29.PMID: 40583032

Attenuated Clostridium perfringens Epsilon Toxin Mutants and Insights Into the Mechanism of Attenuation.

Huang Z, Wang H, Huang J, Liu W.J Basic Microbiol. 2025 Oct 3:e70107. doi: 10.1002/jobm.70107. Online ahead of print.PMID: 41039925

Impact of naturally occurring hemagglutinin substitutions on antigenicity and fitness of influenza A(H5N1) virus.

Wang L, Hatta M, Feng C, Carney P, Almanzar-Jordan MR, Wang J, Hossain J, Atteberry G, Assad-Garcia N, Sheffield S, DaSilva J, De La Cruz JA, Hatta Y, Johnson MC, Frederick J, Hart R, Lacek KA, Wilson M,

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Keong LM, Lin X, Huang Y, Currier M, Tan G, Vashee S, Dugan VG, Rambo-Martin B, Di H, Kirby MK, Davis CT, Stevens J, Zhou B.Npj Viruses. 2025 Oct 2;3(1):72. doi: 10.1038/s44298-025-00154-5.PMID: 41034380

Current Epidemiological Trends and Public Health Challenges of Hepatitis A Virus Infection in Thailand.

Poovorawan Y, Kanokudom S, Inma P, Nilyanimit P, Wanlapakorn N.Am J Trop Med Hyg. 2025 Aug 5;113(4):724-727. doi: 10.4269/ajtmh.25-0083. Print 2025 Oct 1.PMID: 40763728

Characterisation of chikungunya virus neutralising monoclonal antibodies expressed in tobacco plants.

Moore CM, Paul MJ, Pinneh E, Shanmugaraj B, Ashall J, Ramalingam S, Hewson R, Diamond MS, Fox JM, Ma JK.J Biotechnol. 2025 Oct;406:53-59. doi: 10.1016/j.jbiotec.2025.06.014. Epub 2025 Jul 2.PMID: 40615050

From Silkroad to Bioroad-Silkworm Biotechnology.

Park EY.Protein Expr Purif. 2025 Oct;234:106762. doi: 10.1016/j.pep.2025.106762. Epub 2025 Jun 16.PMID: 40532866

Uncovering novel OMPs of Vibrio cholerae: Biophysical insights and epitope prediction of AcfA, Opa, VxrD, LamB, and VpsM for immunotherapy and vaccine design.

Singh B, Kodgire P.Microb Pathog. 2025 Oct 3;209:108089. doi: 10.1016/j.micpath.2025.108089. Online ahead of print.PMID: 41046953

Advances of mRNA vaccines in genitourinary cancers.

Shen YM, Wan FN, Xu H, Yu L, Huang SL, Ye DW, Dai B.Biochim Biophys Acta Rev Cancer. 2025 Oct;1880(5):189427. doi: 10.1016/j.bbcan.2025.189427. Epub 2025 Aug 20.PMID: 40846251

Affinity-purified sHBsAg-based virus-like particles as a platform for foreign mRNA binding.

Gackowska K, Krejmer-Rabalska M, Drazkowska K, Jemielity J, Krol E, Szewczyk B.Virology. 2025 Oct;611:110651. doi: 10.1016/j.virol.2025.110651. Epub 2025 Aug 11.PMID: 40815903

Autologous Cancer Vaccines: A Precision Immunotherapy Strategy for Veterinary Cancer Patients.

Greenberg CB, Suckow MA, Clauson RM, Kalinauskas AE, Lucroy MD.Anticancer Res. 2025 Oct;45(10):4115-4130. doi: 10.21873/anticanres.17766.PMID: 41006003

Immunization acceptance after broad recommendation for RSV prophylaxis: Results from a cross-sectional study in Germany.

Wetzke M, Lange M, Beinhauer K, Röpe E, Borgmann J, Ritter S, Brodowski L, Müller F, Happle C.Vaccine. 2025 Oct 3;64:127716. doi: 10.1016/j.vaccine.2025.127716. Epub 2025 Sep 11.PMID: 40939533

Large Clostridial Toxins: A Brief Review and Insights into Antigen Design for Veterinary Vaccine Development.

Rodrigues Rodrigues R, Alves MLF, Bilhalva MA, Kremer FS, Junior CM, Ferreira MRA, Galvão CC, Quatrin PHDN, Conceição FR.Mol Biotechnol. 2025 Oct;67(10):3823-3839. doi: 10.1007/s12033-024-01303-6. Epub 2024 Oct 29.PMID: 39472390

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Purification of the HBV middle protein by two simple steps, application of ion exchange chromatography to improve protein homogeneity.

Hadiji-Abbes N, Ammous-Boukhris N, Borchani-Chabchoub I, Gargouri A, Mokdad-Gargouri R.Protein Expr Purif. 2025 Oct;234:106765. doi: 10.1016/j.pep.2025.106765. Epub 2025 Jun 28.PMID: 40588194

PLM-IL4: Enhancing IL-4-inducing peptide prediction with protein language model.

Liu R, Yan S, Zhang Z, Xu J, Meng Y, Zhang Q, Wei L, Zou Q, Cui F.Comput Biol Chem. 2025 Oct;118:108448. doi: 10.1016/j.compbiolchem.2025.108448. Epub 2025 Apr 4.PMID: 40203796

Effect of Brazil's national human papillomavirus vaccination programme on the incidence of cervical cancer and cervical intraepithelial neoplasia grade 3 in women aged 20-24 years: a population-based study.

Cerqueira-Silva T, Barral-Netto M, Boaventura VS.Lancet Glob Health. 2025 Oct;13(10):e1715-e1722. doi: 10.1016/S2214-109X(25)00279-7.PMID: 40975079

Prevalence and Factors Associated With Hepatitis B Virus Infection in Tigray Region, Northern Ethiopia.

Bugssa G, Teklehaymanot T, Medhin G, Nayagam S, Johannessen A, Berhe N.J Viral Hepat. 2025 Oct;32(10):e70077. doi: 10.1111/jvh.70077.PMID: 40952341

Socio-demographic factors associated with incomplete vaccination or non-vaccination among children aged 12-23 months in Sierra Leone.

Djossaya D, Igbu T, Kangbai D, Nuwagira I, Kemoh A, Jones M, Sesay T, Lansana S, Williams SA, Saffa G, Kamara IF, Amani A, Fouda AAB, Anya BPM.BMC Public Health. 2025 Oct 9;25(1):3423. doi: 10.1186/s12889-025-24588-x.PMID: 41068721

Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination among Adults in the USA Aged 50-59 Years at Increased Risk of Severe RSV Disease.

Singer D, La EM, Graham J, Molnar D, Grace M, Poston S, Verelst F.Infect Dis Ther. 2025 Oct 11. doi: 10.1007/s40121-025-01238-8. Online ahead of print.PMID: 41075052

Development and preclinical evaluation of next-generation ΔsigH-based live candidate vaccines.

Arora G, Munson CW, Ahmed M, Shivanna V, Devi A, Devireddy VS, Antony B, Hall-Ursone S, Gonzalez OD, Dick EJ Jr, Jagannath C, Alvarez X, Mehra S, Khader SA, Singh DK, Kaushal D.JCI Insight. 2025 Aug 28;10(19):e195947. doi: 10.1172/jci.insight.195947. eCollection 2025 Oct 8.PMID: 40875531

Reverse genetics study disclaims the role of African swine fever virus gene I196L in the pathogenesis in pigs.

Yoshimoto A, Kitamura T, Ikezawa M, Kokuho T, Masujin K.J Vet Med Sci. 2025 Oct 1. doi: 10.1292/jvms.25-0245. Online ahead of print.PMID: 41034131

Effect of paratuberculosis vaccination before and after oral experimental infection with *Mycobacterium avium* subspecies *paratuberculosis* in goats.

Royo M, Elguezábal N, Arrazuria R, Benavides J, Fernández M.Vet Q. 2025 Dec;45(1):2566363. doi: 10.1080/01652176.2025.2566363. Epub 2025 Oct 1.PMID: 41031840

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Regulatory limits of aluminium content of vaccines have not been set based on toxicological studies.

Angrand L, Gherardi RK, Crépeaux G.Environ Toxicol Pharmacol. 2025 Oct;119:104812. doi: 10.1016/j.etap.2025.104812. Epub 2025 Aug 26.PMID: 40876523

Exploring the effects of excipients on complex coacervation.

Zeng X, Joshi PU, Lawton A, Manchester L, Heldt CL, Perry SL.J Colloid Interface Sci. 2025 Oct;695:137808. doi: 10.1016/j.jcis.2025.137808. Epub 2025 May 5.PMID: 40359635

Within-host genetic diversity of pneumococcal serotype 3 during one-year prolonged carriage in a healthy adult.

Sibale LL, Lo SW, Kalata N, Nyazika TK, Mitole N, Dyster V, Kusakala A, Khwiya M, Sagawa G, Phiri JA, Kalizang'oma A, Swarthout TD, Malisita K, Kamng'ona AW, Heyderman RS, Bentley SD, Kwambana-Adams BA, Chaguza C, Jambo KC.Nat Commun. 2025 Oct 7;16(1):8920. doi: 10.1038/s41467-025-63974-2.PMID: 41057336

Fragile methods, fractured trust: rethinking scientific responsibility.

Bustin SA, Wittwer CT.Methods. 2025 Oct;242:54-61. doi: 10.1016/j.ymeth.2025.07.003. Epub 2025 Jul 7.PMID: 40633818

20 years of Flash NanoPrecipitation - from controlled precipitation to global medicine.

Ristroph KD, Pinkerton NM, Markwalter CE, D'Addio SM, Gindy ME, Pagels RF.Adv Drug Deliv Rev. 2025 Oct 2;227:115700. doi: 10.1016/j.addr.2025.115700. Online ahead of print.PMID: 41046104

Advances in RSV Immunoprophylaxis: Evolution, Efficacy, and Implementation Challenges.

Al Gharaibeh F, Deshmukh V, Deshmukh H.Neoreviews. 2025 Oct 1;26(10):e704-e711. doi: 10.1542/neo.26-10-062.PMID: 41027626

Structure and function of a pair of non-competing monoclonal antibodies against Langya henipavirus attachment glycoprotein.

Li W, Wu S, Gui Q, Liu C, Zhou B, Yan H, Sun Y, Fan Q, Zhou Y, Guo H, Tang S, Ge X, Ju B, Yan R, Zhang Z.Cell Rep. 2025 Oct 9;44(10):116407. doi: 10.1016/j.celrep.2025.116407. Online ahead of print.PMID: 41071677

Cutaneous Rosai-Dorfman Disease After COVID-19 Vaccination: Rare Occurrence with Challenging Presentation.

Harb Z, Toorani Z, Ali M, Redha A, Husain R.Semin Musculoskelet Radiol. 2025 Oct;29(5):816-821. doi: 10.1055/s-0045-1810629. Epub 2025 Oct 7.PMID: 41056943

Structure and function of a cross-neutralizing influenza neuraminidase antibody that accommodates recent N2 NA Asn245 glycosylation.

Zhu X, Khalil AM, Piepenbrink MS, Yu W, Ma Y, Martinez-Sobrido L, Wilson IA, Kobie JJ.Commun Biol. 2025 Oct 6;8(1):1427. doi: 10.1038/s42003-025-08830-1.PMID: 41053391

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

A descriptive investigation of the impact of statewide distribution policies and consumer vulnerabilities on COVID-19 vaccination in the united States.

Iacocca K, Vallen B, Strandberg A, Meinzen-Dick L.Health Care Manag Sci. 2025 Oct 4. doi: 10.1007/s10729-025-09727-5. Online ahead of print.PMID: 41045428

Challenge Specific Modulation of Responses to Adjuvant-Induced Innate Immune Memory.

Pasco ST, Martín-Ruiz I, Araujo-Aris S, Barriales D, Castelo J, Egia-Mendikute L, Gonzalez M, Martin JE, Molina E, Mugica M, Palacios A, Seoane I, Gutiez N, Atondo E, Fernández ES, Oyanguren M, Jimenez-Lasheras B, Peña-Cearra A, Aransay AM, Palazon A, Pellón A, Abecia L, Rodriguez H, Elguezabal N, Anguita J.Immunology. 2025 Oct 1. doi: 10.1111/imm.70047. Online ahead of print.PMID: 41034176

Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies.

Roark RS, Habib R, Gorman J, Li H, Connell AJ, Bonsignori M, Guo Y, Hogarty MP, Olia AS, Sowers KJ, Zhang B, Bibollet-Ruche F, Bylund T, Callaghan S, Carey JW, Cerutti G, Harris DR, He W, Lewis E, Liu T, Mason RD, Qiao Y, Park Y, Rando JM, Singh A, Wolff JJ, Lei QP, Louder MK, Andrabi R, Doria-Rose NA, Saunders KO, Seaman MS, Haynes BF, Kulp DW, Mascola JR, Roederer M, Pierson TC, Sheng Z, Hahn BH, Shaw GM, Kwong PD, Shapiro L.J Exp Med. 2025 Oct 6;222(10):e20250638. doi: 10.1084/jem.20250638. Epub 2025 Aug 18.PMID: 40824240

Exploring γδ T-Cell Responses in Malaria and Tuberculosis: Implications for Immunity, Coinfection, and Disease Management.

Mohamud YN, Chaijaroenkul W, Na-Bangchang K.Am J Trop Med Hyg. 2025 Oct 7:tpmd250316. doi: 10.4269/ajtmh.25-0316. Online ahead of print.PMID: 41056925

HPV42 - a human papillomavirus classified as a low-risk type with oncogenic potential.

Burmann SN, Wieland U, Silling S, Oellig F, Chromy D, Hyun J, Gambichler T, Kreuter A.J Dtsch Dermatol Ges. 2025 Oct 6. doi: 10.1111/ddg.15981. Online ahead of print.PMID: 41047841

VLRB antibodies: advances in screening, molecular engineering, and application.

Zhang D, Li P, Li B, Chi Y.Life Sci. 2025 Oct 8:124016. doi: 10.1016/j.lfs.2025.124016. Online ahead of print.PMID: 41072891

Evolutionary dynamics of Influenza A(H3N2) virus in India from 2009 to 2023.

Potdar V, Dhawlarker A, Vipat V, Gaikwad S, Kelkar P, Jadhav S, Choudhary ML, Bhardwaj S, Vijay N, Gupta N; VRDL Laboratory network.Gene. 2025 Oct 9;971:149798. doi: 10.1016/j.gene.2025.149798. Online ahead of print.PMID: 41067552

Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2.

Changrob S, Yasuhara A, Park S, Bangaru S, Li L, Troxell CA, Halfmann PJ, Erickson SA, Catanzaro NJ, Yuan M, Zhou P, Huang M, Wilbanks GD, McGrath JJC, Singh G, Nelson SA, Fu Y, Zheng NY, Carayannopoulos SM, Dugan HL, Shaw DG, Stamper CT, Madariaga MLL, Krammer F, Andrabi R, Burton

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

DR, Ward AB, Wilson IA, Kawaoka Y, Wilson PC.J Exp Med. 2025 Dec 1;222(12):e20251146. doi: 10.1084/jem.20251146. Epub 2025 Oct 9.PMID: 41066082

An insight into the synthesis, structure-activity relationships, and bioactivity of synthetic small molecule ligands targeting toll-like receptor 4.

Normizan SN', Wang H, Wang X, Lam KW, Islam R, Khor PY.Eur J Med Chem. 2025 Oct 8;301:118225. doi: 10.1016/j.ejmech.2025.118225. Online ahead of print.PMID: 41075606

Manipulating Zika virus RNA tertiary structure for developing tissue-specific attenuated vaccines.

Chen X, Cheng ML, Huang XY, Sun MX, Li RT, Wu M, Li YY, Xu Q, Guan MY, Zhao H, Qin CF.EMBO Mol Med. 2025 Oct;17(10):2787-2808. doi: 10.1038/s44321-025-00304-5. Epub 2025 Sep 8.PMID: 40926050

Anti-inflammatory agent 35 reduces ASFV replication by suppressing the nuclear translocation of p65.

Dai G, Zhou Y, Song D, Cai Y, Yan L, Li D, Zheng H.Virology. 2025 Oct;611:110664. doi: 10.1016/j.virol.2025.110664. Epub 2025 Aug 20.PMID: 40848492

BCG-Derived Outer Membrane Vesicles Induce TLR2-Dependent Trained Immunity to Protect Against Polymicrobial Sepsis.

Gong Y, Hao W, Xu L, Yang Y, Dong Z, Pan P, Bai Z, Huang J, Yang K, Jin Z, Kang R, Shan Q, Wang JH, Zhou Z, Tang D, Wang J, Zhou H.Adv Sci (Weinh). 2025 Oct;12(37):e04101. doi: 10.1002/advs.202504101. Epub 2025 Jun 24.PMID: 40552375

Microorganism delivery of cancer vaccines.

Han F, Yin L, Qu L, Han S, Sun M, Xi Y.J Control Release. 2025 Oct 2:114288. doi: 10.1016/j.jconrel.2025.114288. Online ahead of print.PMID: 41045964

Cryo-EM structure of endogenous Pfs230:Pfs48/45 complex with six antibodies reveals mechanisms of malaria transmission-blocking activity.

Bekkering ET, Yoo R, Hailemariam S, Heide F, Ivanochko D, Jackman M, Proellochs NI, Stoter R, van Gemert GJ, Maeda A, Yuguchi T, Wanders OT, van Daalen RC, Inklaar MR, Andrade CM, Jansen PWTC, Vermeulen M, Bousema T, Takashima E, Rubinstein JL, Kooij TWA, Jore MM, Julien JP.Immunity. 2025 Oct 9:S1074-7613(25)00425-X. doi: 10.1016/j.immuni.2025.09.014. Online ahead of print.PMID: 41072404

How does the credibility of vaccine information compare across traditional search engines and AI-based conversational agents?

Dyda A, Stanceski K, Dakiniewich A, Pan A, Dunn AG.Public Health. 2025 Oct;247:105876. doi: 10.1016/j.puhe.2025.105876. Epub 2025 Aug 1.PMID: 40752474

Augmented humoral responses to HIV Env trimers delivered as transmembrane immunogens by self-replicating RNA.

Yousefpour P, Ghosh AR, Chawla H, Yeung R, Gregory J, Si K, Remba TK, Rodrigues KA, Melo MB, Dye J, Steichen JM, Zhang Y, Dong Y, Crispin M, Schief WR, Batista FD, Irvine DJ.Mol Ther. 2025 Oct 1;33(10):4858-4873. doi: 10.1016/j.ymthe.2025.07.036. Epub 2025 Jul 29.PMID: 40739754

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Inhibition of monkeypox polymerase holoenzyme and methyltransferase using bioactive compounds of black tea: a computational approach.

Mumtaz M, Khan K, Khan A, Rashid HU, Jan AU, Shah T, Ahmad N.Sci Rep. 2025 Oct 3;15(1):34639. doi: 10.1038/s41598-025-14583-y.PMID: 41044091

1'-Cyanocytidine-5'-isobutyryl is a potent SARS-CoV-2 inhibitor in culture and infected Syrian hamsters.

Amblard F, Kasthuri M, LeCher JC, Tao S, De R, Abdelnabi R, Marko I, Zhou L, Li C, Shi J, Goh SL, Downs-Bowen J, Bassit L, Hurwitz S, Zandi K, McBrayer T, Weynand B, Johnson KA, Neyts J, Schinazi RF.Sci Adv. 2025 Oct 3;11(40):eadz5913. doi: 10.1126/sciadv.adz5913. Epub 2025 Oct 3.PMID: 41042868

Screen first, vaccinate later: Enhancing tuberculosis vaccination safety through newborn immunodeficiency screening.

Nosan G, Cerkvenik Škafar A.Vaccine. 2025 Oct 3;64:127679. doi: 10.1016/j.vaccine.2025.127679. Epub 2025 Sep 3.PMID: 40907067

Dynamic Size-Change Nanovaccine for Enhancing Lymph Node Deep Penetration and Eliciting Robust Antitumor Immune Responses.

Liu L, Huang Z, Zhu Z, Sun A, Zhao J, Xu Y, Song W, Tang Z, Chen X.Adv Mater. 2025 Oct;37(39):e2504909. doi: 10.1002/adma.202504909. Epub 2025 Jul 14.PMID: 40653912

Comparing neutralizing antibody activity over time between naïve and convalesced COVID-19 vaccinated individuals.

Pillis L, Caffrey R, Chen G, Dela M, Eldevik L, Liu H, McConnell JP, Shabahang S, Varvel SA.Sci Rep. 2025 Oct 6;15(1):34800. doi: 10.1038/s41598-025-18673-9.PMID: 41053351

Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1/2 randomised controlled trial.

Jongihlati B, Segall N, Block SL, Absalon J, Perez J, Munson S, Sanchez-Pearson Y, Simon R, Silmon de Monerri NC, Radley D, McLaughlin LC, Gaylord M, Gruber WC, Jansen KU, Scott DA, Anderson AS.Lancet Infect Dis. 2025 Oct;25(10):1138-1148. doi: 10.1016/S1473-3099(25)00216-6. Epub 2025 Jun 13.PMID: 40523378

SARS-CoV-2 and chronic kidney disease: challenges and future directions.

Olivier G, Luigia E.Curr Opin Immunol. 2025 Oct;96:102642. doi: 10.1016/j.coi.2025.102642. Epub 2025 Aug 18.PMID: 40829499

Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database.

Wang B, Bao EH, Jiang BL, Yang L, Liu Y, Xia L, Wang JH, Wang L, Zhu PY.Expert Opin Drug Saf. 2025 Oct;24(10):1241-1248. doi: 10.1080/14740338.2024.2388212. Epub 2024 Aug 8.PMID: 39096111

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Subjective norms and perceived behavior control are more critical than attitudes in HPV vaccination: An investigation in China.

Shi N, Xiu S, Wang J, Shen Y, Jin H.Vaccine. 2025 Oct 3;65:127800. doi: 10.1016/j.vaccine.2025.127800. Online ahead of print.PMID: 41046836

Do we know about respiratory syncytial virus in Türkiye?

Başkol Elik D, Vatansever G, Taşbakan SE, Ateş S, Pullukçu H, Taşbakan M, Köksal İ.Expert Rev Respir Med. 2025 Oct 4:1-8. doi: 10.1080/17476348.2025.2569125. Online ahead of print.PMID: 41038803

Identification of claudin-3 as an entry factor for rat hepacivirus.

Tanaka T, Akaike Y, Kasai H, Yamashita A, Matsuura Y, Moriishi K.Proc Natl Acad Sci U S A. 2025 Oct 7;122(40):e2508736122. doi: 10.1073/pnas.2508736122. Epub 2025 Oct 2.PMID: 41037638

The curious case of anti-PEG antibodies.

Denman DS, Dalhaimer P.Nanoscale. 2025 Oct 9;17(39):22594-22605. doi: 10.1039/d5nr02301g.PMID: 40984753

Transmission dynamics and risk factors for pertussis during the 2023-2024 outbreak in Korea.

Kim SH, Lee H, Wi YM, Cho UJ, Lee SE, Ma SH.Vaccine. 2025 Oct 3;64:127726. doi: 10.1016/j.vaccine.2025.127726. Epub 2025 Sep 12.PMID: 40945177

A novel glutathione peroxidase (EnGPX) from Eimeria necatrix contributes to oocyst wall biogenesis and confers protective immunity in chickens.

Wang F, Peng Y, Ye Z, Feng Y, Zhang Y, Xu J, Tao J, Liu D.Vet Parasitol. 2025 Oct;339:110588. doi: 10.1016/j.vetpar.2025.110588. Epub 2025 Aug 28.PMID: 40885022

A novel ionizable lipid with comprehensive improvements in transfection potency, immune profile and safety of lipid nanoparticle.

Guo K, Bu L, Du J, Zhang W, Xia J, Tao M, Shao X, Liu L, Zhao W, Cai Y, Yang Y, Hou X, Lin A.J Control Release. 2025 Oct 10;386:114126. doi: 10.1016/j.jconrel.2025.114126. Epub 2025 Aug 14.PMID: 40818720

Repurposing the bacterial surface display technology for drug delivery.

Yang S, Yang M, Jennings M, Timek H, Haley AE, Romee R, Li J.Adv Drug Deliv Rev. 2025 Oct 3;227:115701. doi: 10.1016/j.addr.2025.115701. Online ahead of print.PMID: 41046872

Ribosomal protein L35 negatively regulates FMDV replication by recruiting AMFR to promote the ubiquitination and degradation of VP2.

Shao W, Zhang W, Yang Y, Zhao X, Cao W, Chen C, Wang W, Huang M, Zhou T, Zhu Z, Yang F, Zheng H.J Virol. 2025 Oct 9:e0145325. doi: 10.1128/jvi.01453-25. Online ahead of print.PMID: 41065387

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Timing is everything - Choosing the right time to screen the herd for neosporosis.

Tirosh-Levy S, Blinder E, Doekes JJ, Mazuz ML.Vet Parasitol. 2025 Oct 2;340:110622. doi: 10.1016/j.vetpar.2025.110622. Online ahead of print.PMID: 41061371

An Approach to Design Adaptive Clinical Trials With Time-to-Event Outcomes Based on a General Bayesian Posterior Distribution.

McGree JM, Overstall AM, Jones M, Mahar RK.Stat Med. 2025 Oct;44(23-24):e70207. doi: 10.1002/sim.70207.PMID: 41066086

Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in Qatar.

Sukik L, Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, Al Thani AA, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Abu-Raddad LJ.Sci Rep. 2025 Oct 8;15(1):35179. doi: 10.1038/s41598-025-19168-3.PMID: 41062635

Social media insights on the introduction of RSV immunoprophylaxis in Italy.

Gesualdo F, Casigliani V, Arzilli G, De Vita E, Porretta AD, Croci I, Carrozzo A, Bartolucci V, Buquicchio C, Rizzo C.Hum Vaccin Immunother. 2025 Dec;21(1):2569734. doi: 10.1080/21645515.2025.2569734. Epub 2025 Oct 8.PMID: 41063506

Classic versus innovative strategies for immuno-therapy in pancreatic cancer.

Formelli MG, Palloni A, Tavolari S, Deiana C, Andrini E, Di Marco M, Campana D, Lamberti G, Brandi G.Adv Drug Deliv Rev. 2025 Oct;225:115671. doi: 10.1016/j.addr.2025.115671. Epub 2025 Aug 7.PMID: 40783052

Changing landscape of advanced esophageal squamous cell carcinoma: Breakthroughs in systemic therapies (Review).

Li Y, Li J, Mo W, Xu X.Oncol Rep. 2025 Oct;54(4):120. doi: 10.3892/or.2025.8953. Epub 2025 Jul 19.PMID: 40682837

Cryogel-Based Dendritic Cell Immunotherapy for Post-Surgical Breast Cancer Treatment.

Nguyen LD, Cheng SL, Yen YT, Lee HM, Wu TH, Wang J, Lin SY, Chen Y.Adv Sci (Weinh). 2025 Oct;12(37):e03238. doi: 10.1002/advs.202503238. Epub 2025 Jul 11.PMID: 40642931

Attenuated Salmonella Gallinarum strain shows increased survival in primary chicken macrophage infection.

Campos IC, Saraiva MMS, Lima TS, Benevides VP, Almeida AM, Horn F, Berchieri Junior A.Microb Pathog. 2025 Oct;207:107858. doi: 10.1016/j.micpath.2025.107858. Epub 2025 Jun 30.PMID: 40602449

Genetic diversity and natural selection of circumsporozoite surface protein in Vietnam Plasmodium falciparum isolates.

Võ TC, Lê HG, Kang JM, Trinh NTM, Van Khanh C, Cho M, Quang HH, Na BK.Malar J. 2025 Oct 8;24(1):320. doi: 10.1186/s12936-025-05585-2.PMID: 41063188

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Epidemiology, clinical characteristics, and genetic diversity of Nipah virus strains from Bangladesh: 2016-2023.

Satter SM, Rahman DI, Sultana S, Rahman MM, Aquib WR, Nazneen A, Farzin A, Chowdhury KIA, Sarkar T, Ema FA, Choudhury SS, Siddika A, Alam MR, Abdulla F, Ghosh PK, Qayum MO, Sarker MFR, Nasif MAO, Sen B, Chowdhury M, Hossain MS, Rahman M, Alam AN, Hossain ME, Shoemaker T, Spiropoulou C, Gurley ES, Luby SP, Klena JD, Banu S, Rahman MZ, Montgomery JM, Shirin T.Int J Infect Dis. 2025 Oct;159:108010. doi: 10.1016/j.ijid.2025.108010. Epub 2025 Aug 7.PMID: 40783163

Post-pandemic outbreak of measles seen in Japan, 2024.

Amemiya Y, Kobayashi T, Nishiura H.J Infect Public Health. 2025 Oct;18(10):102887. doi: 10.1016/j.jiph.2025.102887. Epub 2025 Jul 3.PMID: 40633194

Coordinated responses to maintain tuberculosis care amid climate emergencies: challenges and perspectives based on the events of Brazil.

Lima LV, Pelissari DM, Pavinati G, Dockhorn Costa Johansen F, Barreira Filho EB, Magnabosco GT, Maciel ELN.BMJ Glob Health. 2025 Oct 7;10(10):e019123. doi: 10.1136/bmjgh-2025-019123.PMID: 41062129

Expanding the clinical spectrum of pediatric ataxia-telangiectasia: a case series of novel genetic variants, lupus vulgaris, and hyper-IgM phenotypes.

Bakır DB, Atay Ö, Yağmur H, Kabadayı G, Kocabey M, Asilsoy S, Uzuner N.Orphanet J Rare Dis. 2025 Oct 3;20(1):500. doi: 10.1186/s13023-025-03942-7.PMID: 41044616

Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM.

Withers HG, Figel SA, Qiu J, Ahluwalia MS, Reardon D, Abad AP, Curry WT, Wong ET, Peereboom DM, Dhawan A, Liu S, Ciesielski MJ, Fenstermaker RA.Cancer Immunol Immunother. 2025 Oct 9;74(11):332. doi: 10.1007/s00262-025-04193-y.PMID: 41066027

Synthetic genomics-based generation of the tick-borne encephalitis virus Siberian subtype prototype strain and E51K-attenuated variant for vaccine development and antiviral screening.

Kulatay T, Sedova E, Shevtsov A, Zauatbayeva G, Ingirbay B, Keyer V, Shakhmanova Z, Zhumabekova M, Abduraimov Y, Rsaliyev A, Sikhayeva N, Kozlova I, Zaripov M, Shustov AV.Virol Sin. 2025 Oct 2:S1995-820X(25)00136-1. doi: 10.1016/j.virs.2025.09.010. Online ahead of print.PMID: 41046071

Navigating the Colorectal Cancer Maze: Unveiling Pathways To Diagnosis, Management, Pathophysiology and Prevention.

Al Kamzari KAM, Constantinou C.Curr Oncol Rep. 2025 Oct;27(10):1115-1130. doi: 10.1007/s11912-025-01707-w. Epub 2025 Aug 9.PMID: 40781184

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Structural insights into Leishmania donovani mevalonate kinase and its interaction with toll-like receptors during early infection.

Dikhit MR, Roy C, Kayet P, Basak S, Ganguly S, Das P.Acta Trop. 2025 Oct;270:107774. doi: 10.1016/j.actatropica.2025.107774. Epub 2025 Aug 7.PMID: 40783067

Perspectives on prevention of type 1 diabetes and heterogeneities.

Stene LC.Diabetologia. 2025 Oct;68(10):2104-2115. doi: 10.1007/s00125-025-06512-5. Epub 2025 Aug 6.PMID: 40768045

Nanoparticle-supported, rapid, digital quantification of neutralizing antibodies against SARS-CoV-2 variants.

Mirjalili S, Ikbal MA, Hou CW, Mohammadi MK, Choi Y, Kelbauskas L, VanBlargan LA, Hogue BG, Murugan V, Diamond MS, Wang C.Biosens Bioelectron. 2025 Oct 1;285:117549. doi: 10.1016/j.bios.2025.117549. Epub 2025 May 7.PMID: 40383030

A review of childhood rotavirus vaccination policies and a presentation of vaccine coverage trends at national and regional level, Italy, 2016 to 2023.

Farina S, Maio A, Zaino A, Russo L, Ricciardi W, Ieraci R, Villani L.Euro Surveill. 2025 Oct;30(39):2500026. doi: 10.2807/1560-7917.ES.2025.30.39.2500026.PMID: 41040063

Extracellular vesicles in malaria pathogenesis and Therapy: Emerging insights and future perspectives.

Abida, Kamal M, Alqurashi AA, Alhuthli SM, Alharbi MA, Alghamdi BJ, Alsharari SH, Khobrani MA, Almakrami JA, Albishri JO, Alshammari AK, Imran M.Microb Pathog. 2025 Oct;207:107902. doi: 10.1016/j.micpath.2025.107902. Epub 2025 Jul 14.PMID: 40669759

Antibody-mediated multicellular pathophysiology of HIT and VITT: the dynamic roles of platelets, neutrophils, endothelial cells, and monocytes.

Meier RT, Kapur R.J Thromb Haemost. 2025 Oct 9:S1538-7836(25)00605-1. doi: 10.1016/j.jtha.2025.09.014. Online ahead of print.PMID: 41076270

Analysing the effect of multidisciplinary teams to address preventive healthcare gaps in a rural teaching clinic: a quality improvement project.

Hill V, Woody B, Abid FI, Barros M, Pohani P.BMJ Open Qual. 2025 Oct 6;14(4):e003319. doi: 10.1136/bmjoq-2025-003319.PMID: 41057206

NIR-Triggered Metal-Polyphenol Nanoparticles Enhance HPV-Driven Cancer Immunotherapy via Immunogenic Cell Death and STING Sequential Activation.

Liu M, Zhang J, Chen S, Zheng J, Xiao L, Liu X, Cao Y, Zhu S, Chang S.Adv Healthc Mater. 2025 Oct 2:e02884. doi: 10.1002/adhm.202502884. Online ahead of print.PMID: 41039768

HI-CeFSpot: high-throughput immune cell FluoroSpot assay.

Jethmalani Y, Sutton MS, Carroll R, Kazmierski R, Low K, Mughal M, Bullock J, Lindestam Arlehamn CS, Lewinsohn DM, Lewinsohn DA, Lehman CC, Green C, Moshi J, Mueller A, Darrah PA, Seder RA, Lin BC,

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Koup RA, Serebryannyy LA, Roederer M.Methods. 2025 Oct 7:S1046-2023(25)00210-5. doi: 10.1016/j.ymeth.2025.10.002. Online ahead of print.PMID: 41067553

Efficient expression of UreB by *Helicobacter pylori* in rapeseed (*Brassica napus*) using a plant viral vector.

Nasab MA, Gharibi N, Mirzaee S.3 Biotech. 2025 Oct;15(10):364. doi: 10.1007/s13205-025-04481-5. Epub 2025 Oct 1.PMID: 41049529

Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies.

McMyn NF, Varriale J, Wu HWS, Hariharan V, Moskovljevic M, Tan TS, Lai J, Singhal A, Lynn K, Mounzer K, Tebas P, Montaner LJ, Hoh R, Yu XG, Lichterfeld M, Simonetti FR, Kovacs C, Deeks SG, Siliciano JM, Siliciano RF.J Clin Invest. 2025 Jul 29;135(19):e194081. doi: 10.1172/JCI194081. eCollection 2025 Oct 1.PMID: 40728901

PHLA-SiNet: A novel peptide-HLA binding prediction model using heterogeneous Siamese neural networks.

Nazarloo M, Saadat M, Zare-Mirakabad F.Comput Biol Med. 2025 Oct;197(Pt A):111017. doi: 10.1016/j.compbiomed.2025.111017. Epub 2025 Sep 1.PMID: 40896909

MDCK cell line expressing H9N2 avian influenza virus NS1 protein promotes replication of the NS1 gene truncation virus.

Liu Y, Yang Y, Quan K, Yin Y, Su X, Mao X, Yang H, Qin T, Peng D, Chen S.Vet Microbiol. 2025 Oct;309:110694. doi: 10.1016/j.vetmic.2025.110694. Epub 2025 Aug 25.PMID: 40884961

Protection and safety of aluminum hydroxide adjuvant and chimeric antigen containing predicted epitopes from bacteria murC gene in Aeromonas hydrophila fish infection.

Rodrigues J, Roméria da Silva M, Martins CA, Zuanon LA, Boechat Martins KV, Tótola PS, Pereira Rocha JG, Parma MG, Lima Castro IS, Nascimento TF, Pires AR, Azevedo FS, Gonçalves RV, Carmali S, Sampaio Zuanon JA, Antônio de Oliveira Mendes T.Fish Shellfish Immunol. 2025 Oct;165:110543. doi: 10.1016/j.fsi.2025.110543. Epub 2025 Jul 3.PMID: 40617414

Rabies in livestock in the United States (2012-2021).

Payette-Stroman A, Ross Y, Ma X, Boutelle C, Holschbach C, Blanton JD, Wallace R.Am J Vet Res. 2025 Jun 30;86(10):ajvr.25.01.0019. doi: 10.2460/ajvr.25.01.0019. Print 2025 Oct 1.PMID: 40588167

Hantavirus Gn^H Nanoparticle Immunogen Elicits a Cross-Neutralizing Antibody Response in Mice.

Ramos KE, Mariano MC, Mittler E, Pardo R, Zylberman V, Guardado-Calvo P, Chandran K, Lai JR.ACS Infect Dis. 2025 Oct 12. doi: 10.1021/acsinfecdis.5c00415. Online ahead of print.PMID: 41077721

Barriers to rabies control through mass dog vaccination in rural Uganda: Insights from community perspectives and key informant interviews.

Akankwatsa D, Bagonza A, Kiguli J, Kambugu A, Lamorde M, Okech SG, Kankya C, Agado D, Apio F, Odoch T, Kahunde AM, Hartnack S, Léchenne M, Lohr F, Herrera A, Dürr S.PLoS Negl Trop Dis. 2025 Oct 9;19(10):e0013578. doi: 10.1371/journal.pntd.0013578. Online ahead of print.PMID: 41066505

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Serotyping and Identification of Antimicrobial Resistance Genes in Avian Pathogenic *Escherichia coli* Isolated from Poultry Flocks in Jiangxi Province, China.

Tan J, Zhang FF, Li HQ, Huang JN, Kang ZF, Wei QP, Zeng YB, Tan MF.Foodborne Pathog Dis. 2025 Oct;22(10):709-714. doi: 10.1089/fpd.2023.0159. Epub 2024 Dec 4.PMID: 39630541

Lessons learned from upstream wastewater sampling in response to poliovirus in New York State.

Godinez A, Alazawi M, Neyra M, Hanson B, Neigel D, St George K, Lang D, Larsen DA.Sci Total Environ. 2025 Oct 1;997:180216. doi: 10.1016/j.scitotenv.2025.180216. Epub 2025 Aug 8.PMID: 40782399

Phylodynamics of human metapneumovirus and evidence for a duplication-deletion model in G gene variant evolution.

Goya S, Nunley EB, Longley PC, Mathis JR, Varela CG, Kim DY, Nurik M, Naccache SN, Greninger AL.J Clin Virol. 2025 Oct;180:105848. doi: 10.1016/j.jcv.2025.105848. Epub 2025 Aug 5.PMID: 40769077

A case of autosomal dominant polycystic kidney disease with systemic lupus erythematosus developing after SARS-CoV-2 vaccination.

Miyauchi K, Usui J, Shimizu T, Hattori A, Nomura S, Higashi T, Usui T, Saito C, Kai H, Yamagata K.CEN Case Rep. 2025 Oct;14(5):679-685. doi: 10.1007/s13730-025-00999-y. Epub 2025 May 20.PMID: 40392435

Meta-analysis of genetic diversity of VP1 gene of foot and mouth disease virus serotypes prevalent in Bangladesh from 2010 to 2024.

Rahman MA, Zereen F, Al-Amin M, Hossain MG, Alam J, Shimada M, Rahman MT, Saha S.Infect Genet Evol. 2025 Oct 1;135:105835. doi: 10.1016/j.meegid.2025.105835. Online ahead of print.PMID: 41043698

A SpyCatcher-assembled mannosylated nanovaccine elicits potent and cross-protective immunity against monkeypox virus.

Yan W, Shen L, Qi J, Yu W, Hu T.Eur J Pharm Biopharm. 2025 Oct 8:114878. doi: 10.1016/j.ejpb.2025.114878. Online ahead of print.PMID: 41072867

Characterization of a novel invasive virulence of chymotrypsin-like elastase family member 2A from Trichinella spiralis.

Guo X, Zhang XZ, Zhang Y, Zhang R, Long SR, Dan Liu R, Cui J, Wang ZQ.Acta Trop. 2025 Oct;270:107803. doi: 10.1016/j.actatropica.2025.107803. Epub 2025 Aug 23.PMID: 40854405

Vaccinating children against SARS-CoV-2 - parents' attitude.

Rakoczy K, Kaczor J, Sołtyk A, Mastalska I, Saczko M, Kulbacka J.Arch Pediatr. 2025 Oct 8:S0929-693X(25)00139-3. doi: 10.1016/j.arcped.2025.05.012. Online ahead of print.PMID: 41067959

CD4$^+$ T-cell help delivery to monocyte-derived dendritic cells promotes effector differentiation of helper and cytotoxic T cells.

Bosma DMT, Busselaar J, Staal MD, Frijlink E, Mack M, Salerno F, Borst J.Immunol Lett. 2025 Oct;275:107022. doi: 10.1016/j.imlet.2025.107022. Epub 2025 Apr 14.PMID: 40239818

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Effective mRNA-based therapy using E7 antigen and IL-12 cytokine in head and neck cancer mice models.

Lee S, Lee J, Lee YS, Lee S, Yoon S, Roh G, Cho Y, Lee SY, Ha D, Oh A, Choi EJ, Lee Y, Bae SH, Cho S, Choi H, Jo S, Kim J, Kim A, Park HJ, Nam JH.Vaccine. 2025 Oct 3;64:127766. doi: 10.1016/j.vaccine.2025.127766. Epub 2025 Sep 21.PMID: 40987001

The decrease in childhood vaccination coverage and its sociodemographic determinants, the Netherlands, birth cohorts 2008 to 2020.

Pijpers J, van Roon A, Schipper M, Stok M, van den Hof S, van Gaalen R, Hahné S, de Melker H.Euro Surveill. 2025 Oct;30(39):2500251. doi: 10.2807/1560-7917.ES.2025.30.39.2500251.PMID: 41040066

Impact of vaccination on the development of acute kidney injury in Japanese COVID-19 patients: a retrospective observational analysis.

Taito K, Oka M, Sugimoto H, Fukagawa H, Izawa A, Tsuchiya T, Matsuno S, Yamanaka N, Yumura W, Suzuki N, Itabashi M, Takei T.Clin Exp Nephrol. 2025 Oct;29(10):1425-1434. doi: 10.1007/s10157-025-02740-6. Epub 2025 Jul 30.PMID: 40736658

STING-activating layered double hydroxide nano-adjuvants for enhanced cancer immunotherapy.

Jia L, Qin Y, Li X, Liu H, He Z, Wang Y.Biomaterials. 2025 Oct;321:123294. doi: 10.1016/j.biomaterials.2025.123294. Epub 2025 Mar 26.PMID: 40164041

Analysis of the Main Checkpoints of the JNK-MAPK Pathway in HTLV-1-Associated Leukemia/Lymphoma via Boolean Network Simulation.

Mardi S, Letafati A, Hosseini A, Faraji R, Hosseini P, Mozhgani SH.Biochem Genet. 2025 Oct;63(5):4231-4246. doi: 10.1007/s10528-024-10916-0. Epub 2024 Sep 25.PMID: 39320417

Community-acquired bacterial meningitis in Southern Sweden 2013-2023: a population-based study of incidence, aetiology and diagnostic yield.

West T, Carlander R, Sunnerhagen T, Torisson G, Ljungquist O.Eur J Clin Microbiol Infect Dis. 2025 Oct 1. doi: 10.1007/s10096-025-05247-w. Online ahead of print.PMID: 41032173

Avian HEV triggered egg decline: Viral-host, immune-neuroendocrine mechanisms in layers.

Zhang B, Kuang S, He Z, Zhang J, Li S, Duan H, Ma Z, Ding J.Vet Microbiol. 2025 Oct;309:110687. doi: 10.1016/j.vetmic.2025.110687. Epub 2025 Aug 21.PMID: 40848355

Next-generation sequencing of Omicron SARS-CoV-2 variants in Hormozgan Province, Iran, and evaluation of the effects of mutations on RBD and ORF9b protein function.

Ahmadi K, Kavousipour S, Shahbazi B, Farzin F, Gharibi Z, Pishva MS, Pishahang A, Gouklani H.Infect Genet Evol. 2025 Oct;134:105812. doi: 10.1016/j.meegid.2025.105812. Epub 2025 Aug 12.PMID: 40812543

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Racial and gender disparities in HPV vaccination: Implications for reducing head and neck cancer.

Ogbutor K, McMillan E, Ramkissoon N, Elkomi R, Monroe D, Zinabu S, Ali A, Gasmelseed H, Michael M.J Natl Med Assoc. 2025 Oct;117(5):311-314. doi: 10.1016/j.jnma.2025.07.001. Epub 2025 Jul 24.PMID: 40713314

Behavioral and Sociodemographic Determinants of Influenza Vaccination Among Caregivers During the COVID-19 Pandemic.

Williams DM, Weber AM, Cook DM, Lu M, Yang W.Am J Health Promot. 2025 Oct 3:8901171251383862. doi: 10.1177/08901171251383862. Online ahead of print.PMID: 41044898

Intestinal inflammation induced by heat-labile toxin-producing enterotoxigenic E: Coli infection and impact on immune responses in an experimental human challenge model.

Zhang X, Brubaker J, Talaat KR, Porter CK, Feijoo BL, Adjoodani BM, DeNearing B, Prouty MG, Bourgeois AL, Sack DA, Eder-Lingelbach S, Taucher C, Chakraborty S.PLoS Negl Trop Dis. 2025 Oct 3;19(10):e0013025. doi: 10.1371/journal.pntd.0013025. eCollection 2025 Oct.PMID: 41042820

Incorporation of monophosphoryl lipid A and CpG-oligodeoxynucleotides into lipid nanoparticles activates toll-like receptor signaling pathways while maintaining antigen expression for mRNA-based vaccinations.

Vaquero AP, Calderon-Ruiz P, Gambaro R, Rivero-Berti I, Limeres MJ, Ghazi SF, Huck-Iriart C, Meyer CU, Cacicedo ML, Hankeln T, Si S, Lieberwirth I, Landfester K, Soto CA, Tekiel V, Bros M, Gehring S, Islan GA.Int J Biol Macromol. 2025 Oct 1;330(Pt 1):148058. doi: 10.1016/j.ijbiomac.2025.148058. Online ahead of print.PMID: 41043736

COVID-19 pandemic disruptions drive decreases in HPV prevalence and shift genotype distribution in Western China.

Liu Y, Xiang Y, Liu Y, Deng H, Zhang F, Liu Y, Huang X.BMC Infect Dis. 2025 Oct 8;25(1):1254. doi: 10.1186/s12879-025-11706-8.PMID: 41063026

Monkeypox in South Asia: A systematic Review.

Wangdi K, Adhikary R, Liu Z, Vardoulakis S, McFarlane RA, Kotepui M, Hu W, Suwannatrai AT, Tsheten T.Emerg Microbes Infect. 2025 Oct 8:2572677. doi: 10.1080/22221751.2025.2572677. Online ahead of print.PMID: 41060816

Associations of altruistic factors and perceptions with intention to receive Respiratory Syncytial Virus (RSV) vaccination among older adults in China.

Liu L, Cao H, Ou Z, Peng W, Chen H, Fang Y, Chen S, Xu S, Wang Z.Hum Vaccin Immunother. 2025 Dec;21(1):2567705. doi: 10.1080/21645515.2025.2567705. Epub 2025 Oct 1.PMID: 41031491

Antibody preparation and immunological analysis of RBD from the SARS-CoV-2 Omicron BF.7 variant.

Wang Q, Wang C, Zhang Z, Fan S, Lei P, Liu S, Li M, Wang K, Zhang Y, Kang L, Weng S, Kong L, Wang T.Mol Immunol. 2025 Oct 7;187:188-197. doi: 10.1016/j.molimm.2025.09.008. Online ahead of print.PMID: 41061453

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Long-term results of a multidisciplinary medication optimization program for older adults including primary care and hospital team.

Guerin C, Leguillon R, Cherel A, Valembois L, Brochard G, Pierre M, Bourderont A, Gaillot B, Bernardeau C, Vaesken C, Tebourski I, Descatoire P, Saint-Lorant G, Villain C, Meurant A.Eur J Clin Pharmacol. 2025 Oct;81(10):1461-1471. doi: 10.1007/s00228-025-03889-5. Epub 2025 Jul 28.PMID: 40721888

HBV-encoded circRNA-5 promotes hepatocellular carcinoma progression by regulating the miR-9-3p/Hippo signaling axis.

Yang Y, Shen Y, Dang Y, Huang J, Su Y, Zhang J, Jiang X, Luo X, Wang J, Liu J.Microbiol Spectr. 2025 Oct 7;13(10):e0143925. doi: 10.1128/spectrum.01439-25. Epub 2025 Sep 5.PMID: 40910771

Mpox: transmission dynamics, treatment, and innovations.

Satapathy P, Yoosuf BT, Gaidhane AM, Vadia N, Menon SV, Chennakesavulu K, Panigrahi R, Kaur M, Bushi G, K T MF, Shabil M, Goyal M, Kumar H, Rani A, Ansar S, Sah S, Jena D, Khatib MN, Neyazi A, Goh KW.Ther Adv Infect Dis. 2025 Oct 5;12:20499361251357521. doi: 10.1177/20499361251357521. eCollection 2025 Jan-Dec.PMID: 41059470

HPV vaccination willingness and behavior among nursing female students in China based on the protection motivation theory: A cross-sectional study.

Nie R, Ma Z, Rui X, Li T.Hum Vaccin Immunother. 2025 Dec;21(1):2569738. doi: 10.1080/21645515.2025.2569738. Epub 2025 Oct 7.PMID: 41056529

Estimation of the risk of cohabitation with Johne's disease-infected cattle in Japanese dairy cows.

Murato Y, Hayama Y, Kondo S, Yamaguchi E, Yamamoto T.Prev Vet Med. 2025 Oct;243:106611. doi: 10.1016/j.prevetmed.2025.106611. Epub 2025 Jul 1.PMID: 40609493

Trend Analysis of HPV Prevalence in Weifang City Using a Bayesian Structural Time Series Model: A Longitudinal Study From 2012 to 2023.

Yang H, Xu J, Wang H, Kou H, Yang X, Li J.J Med Virol. 2025 Oct;97(10):e70624. doi: 10.1002/jmv.70624.PMID: 41031571

The effectiveness of repeated vaccination for COVID-19 symptom resolution during the KP.3-dominant epidemic period in Japan: A retrospective multicenter study.

Bando T, Ikematsu H, Kawai N, Shibao K, Mizuguchi M, Amemiya T, Tsuchiya S, Oribe Y, Lee WJ, Maeda T, Kawashima T, Matsuura S, Doniwa KI, Asamoto H, Sugawara M.J Infect Chemother. 2025 Oct;31(10):102798. doi: 10.1016/j.jiac.2025.102798. Epub 2025 Aug 18.PMID: 40835168

Human Papillomavirus in the Neovagina of Transgender Women in Thailand: Prevalence, Diversity, and Associated Risk Factors.

Rerkasem A, Oo MZ, Mattawanon N, Sakkhachornphop S, Siriaunkgul S, Jakkaew T, Rerkasem K, Smith MK.Sex Transm Dis. 2025 Oct 1;52(10):641-648. doi: 10.1097/OLQ.0000000000002196. Epub 2025 Jun 2.PMID: 40456170

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Investigation of a Salmonella Typhi cluster among a Pacific Islander labour community in a fruit industry: perspective from a regional public health unit.

Schulz C, Rashidul Hashan M, Doshi K, Williams O, Graham R, Walker J, Khandaker G.Commun Dis Intell (2018). 2025 Oct 1;49. doi: 10.33321/cdi.2025.49.032.PMID: 41027415

Cost-effectiveness of different HPV vaccination strategies for cervical cancer prevention in South Africa.

van Schalkwyk C, Meyer-Rath G, Masuku S, Jamieson L, Bloem P, Rangaraj A, Chidarikire T, Dlamini-Nqeteko S, Doherty M, Johnson LF, Dalal S.Vaccine. 2025 Oct 3;64:127770. doi: 10.1016/j.vaccine.2025.127770. Epub 2025 Sep 22.PMID: 40992075

Aspiration in intramuscular injection: a meta-analysis of pain, duration, and clinical outcomes.

Yıldız Karaahmet A, Senturan L.Contemp Nurse. 2025 Oct 6:1-18. doi: 10.1080/10376178.2025.2568580. Online ahead of print.PMID: 41051060

Clinical Characteristics and Management of Infective Native Arterial Aneurysms Associated with BCG Therapy for Bladder Cancer.

Colonna G, Liesker D, M WB, Taurino M, Zeebregts CJ, Saleem BR.Ann Vasc Surg. 2025 Oct 8:S0890-5096(25)00659-4. doi: 10.1016/j.avsg.2025.09.053. Online ahead of print.PMID: 41072608

Caregivers' attitudes toward school-based vaccination programs: A comparison of COVID-19, HPV, influenza, and dengue vaccines in Brazil.

Barberia LG, Seelaender ICR, Carvalho RJ, de Moraes JC, de Paula Moreira N, de Toledo Vieira M, Pinto DAV, Moraes de Sousa TC.Vaccine. 2025 Oct 3;64:127709. doi: 10.1016/j.vaccine.2025.127709. Epub 2025 Sep 9.PMID: 40930042

Systematic review of pro-equity strategies to improve vaccination among priority populations.

Tinessia A, Sabahelzain MM, King C, Khalatbari-Soltani S, Gunaratnam P, Dadari I, Lorenzo JC, Bhaumik S, Sheel M.Vaccine. 2025 Oct 3;64:127694. doi: 10.1016/j.vaccine.2025.127694. Epub 2025 Sep 8.PMID: 40925162

An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity.

Gonzalez-Bocco IH, Frierson R, Cho A, Reyes Curcio FA, Franceschi AE, Lahoud C, Moshovitis DG, Beluch K, Balusu M, Keleher CE, Sullivan KM, Dougan M, Wang Q, Han JH, Nader A, Aylott A, Wang W, Chan BT, Hammond SP, Manne-Goehler J, Koo S.New Microbes New Infect. 2025 Aug 8;67:101620. doi: 10.1016/j.nmni.2025.101620. eCollection 2025 Oct.PMID: 40893477

A Narrative Review on the Recent Insights Into the Pathogenicity and Potential Role of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in the Emergence of "Disease X".

Ahmed Z, Prattay KMR, Sharmin S, Fatema-Tuz-Zohora, Raj A, Faruk FB, Ahmed B, Omer HBM, Omi AA, Rabbi F, Bahar NB, Mou SS, Islam M, Karim E, Al-Mamun ME.Health Sci Rep. 2025 Oct 6;8(10):e71327. doi: 10.1002/hsr2.71327. eCollection 2025 Oct.PMID: 41064195

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

HCMV infection of terminally differentiated neurons disrupts microtubule organization, resulting in neurite retraction.

Adelman JW, Sukowaty AT, Partridge KJ, Gawrys JE, Akins A, Terhune SS, Ebert AD.Microbiol Spectr. 2025 Oct 8:e0119825. doi: 10.1128/spectrum.01198-25. Online ahead of print.PMID: 41059695

Global, regional and national burden of chikungunya: force of infection mapping and spatial modelling study.

Kang H, Lim A, Auzenbergs M, Clark A, Colón-González FJ, Salje H, Clapham H, Carrera JP, Kim JH, Malarski M, López-Vergès S, Cucunubá ZM, Cerqueira-Silva T, Edmunds WJ, Sahastrabuddhe S, Brady OJ, Abbas K.BMJ Glob Health. 2025 Oct 1;10(10):e018598. doi: 10.1136/bmjgh-2024-018598.PMID: 41033690

Virus-Like Particle-Based Personalized Neoantigen Nano-Vaccine for Tumor Immunotherapy and Recurrence Prevention.

Zhou S, Wang C, Ning Y, Wang Y, Xin F, Ren L, Wang Y.ACS Nano. 2025 Oct 1. doi: 10.1021/acsnano.5c06278. Online ahead of print.PMID: 41032465

[Utilization of the influenza vaccination among individuals over 60 years: spatial variations and regional risk factors].

Akmatov MK, Kohring C, Holstiege J, Müller D.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 Oct;68(10):1138-1146. doi: 10.1007/s00103-025-04103-8. Epub 2025 Aug 18.PMID: 40825876

Identification of the T-box transcription factor t-bet in chickens and its role in immune response.

Guo Y, Zhou Z, Gao H, Zhang S, Chen Z, Chang H, Cao H, Gao L, Wang Y, Zheng SJ.Poult Sci. 2025 Oct;104(10):105589. doi: 10.1016/j.psj.2025.105589. Epub 2025 Jul 19.PMID: 40737904

Characteristics and case fatality factors of atypical canine infectious respiratory disease: an observational survey using dog owners' data in the United States.

Hasan M, Romano TA, Miller LC.Am J Vet Res. 2025 Jul 8;86(10):ajvr.25.04.0133. doi: 10.2460/ajvr.25.04.0133. Print 2025 Oct 1.PMID: 40628286

Disparities in Preventive Health Services Between Transgender and Cisgender Adults by State-Level Policy Environments.

Degtiar I, Kim J, Michaels EK, Huff IR, Rudacille ME, Clusen NA, Ferguson A, Smith-Howell ER, Gonzales G.Am J Prev Med. 2025 Oct;69(4):107954. doi: 10.1016/j.amepre.2025.107954. Epub 2025 Jun 25.PMID: 40578577

A systematic comparison of in-house prepared transfection reagents in the delivery of mRNA or DNA to a wide range of cultured cells.

Ojha R, Timin E, Szirovicza L, Xu W, Hepojoki J.J Biol Chem. 2025 Oct 3:110742. doi: 10.1016/j.jbc.2025.110742. Online ahead of print.PMID: 41047124

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Comparative transcriptomic and machine learning analysis identifies key genes and immune dysregulation in goats exposed to peste des petits ruminants virus.

Ramesh V, Suresh KP, Mambully S, Rani S, Patil AV, Anand J, Yamini Sri S, Balamurugan V.Virus Genes. 2025 Oct 2. doi: 10.1007/s11262-025-02188-6. Online ahead of print.PMID: 41037245

Factors associated with respiratory syncytial virus-neutralizing antibody titers in adults.

Shoji K, Yamada M, Hisano M, Okubo Y, Obikane E, Yamaguchi K.J Infect Chemother. 2025 Oct;31(10):102801. doi: 10.1016/j.jiac.2025.102801. Epub 2025 Aug 26.PMID: 40876754

CagA-dependent Hobit⁺ gastric tissue-resident memory T cells confer full protection from *Helicobacter pylori* reinfection.

Gong R, Huang B, Ralser A, Friedrich V, Mibus C, Engelsberger V, Koch MRA, Skerhut M, Giese T, Andrä I, Vieth M, van Gisbergen KPJM, Semper RP, Gerhard M, Mejías-Luque R.Gut. 2025 Oct 8;74(11):1792-1803. doi: 10.1136/gutjnl-2025-334781.PMID: 40473399

Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study.

Antoon JW, Amarin JZ, Hamdan O, Stopczynski T, Stewart LS, Michaels MG, Williams JV, Klein EJ, Englund JA, Weinberg GA, Szilagyi PG, Schuster JE, Selvarangan R, Harrison CJ, Boom JA, Sahni LC, Muñoz FM, Staat MA, Schlaudecker EP, Chappell JD, Clopper BR, Moline HL, Campbell AP, Spieker AJ, Olson SM, Halasa NB.Clin Infect Dis. 2025 Oct 6;81(3):623-633. doi: 10.1093/cid/ciae573.PMID: 39688383

Racial and Ethnic Disparities in COVID-19 Vaccination Intention and Uptake by July 2022 in Wisconsin.

Alishahi ML, Modji K, Seibert G, Pray I, Westergaard R.Public Health Rep. 2025 Oct 9:333549251368671. doi: 10.1177/00333549251368671. Online ahead of print.PMID: 41068049

Rubella Seropositivity and Associated Factors Among Young Female Adults in Bangladesh: A Cross-Sectional Study.

Nuruzzaman M, Wichaidit W, Islam QM, Nessa A, Liabsuetrakul T.Int J Gen Med. 2025 Oct 3;18:6043-6054. doi: 10.2147/IJGM.S536793. eCollection 2025.PMID: 41064497

Innovative Applications and Synergistic Strategies for Covalent Organic Frameworks in Multimodal Phototherapy.

Chen H, Mei J, Chen J, Wu T, Ma T, Su Y, Zhou N, Sun B.Acta Biomater. 2025 Oct 10:S1742-7061(25)00756-1. doi: 10.1016/j.actbio.2025.10.013. Online ahead of print.PMID: 41077296

Impact of rotating night shift work on immune homeostasis among hospital employees during the COVID-19 pandemic.

Lin SC, Lin CF, Wu SY, Yang CC, Chen WM, Tseng PC, Shih FC, Nanda JD, Chen CL.Cytokine. 2025 Oct;194:157003. doi: 10.1016/j.cyto.2025.157003. Epub 2025 Jul 30.PMID: 40743640

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Qualification of a reporter virus microneutralization assay for evaluation of influenza specific antibodies in human clinical trials.

Harit D, Sawant S, Spreng RL, Gurley S, Schechter A, Sharak A, Bae A, Creanga A, Kanekiyo M, Li Z, Sarzotti-Kelsoe M, Walter EB, Moody MA, Tomaras GD.Vaccine. 2025 Oct 3;64:127699. doi: 10.1016/j.vaccine.2025.127699. Epub 2025 Sep 19.PMID: 40974739

Did the Medicaid expansion improve immunization among U.S. pregnant women?

Zhao J, Jaggad R, El Fatmaoui A, Ghosh PK.Prev Med Rep. 2025 Aug 20;58:103214. doi: 10.1016/j.pmedr.2025.103214. eCollection 2025 Oct.PMID: 41050852

Investigation of synergistic effects of beta-defensin, vesatolimod and resiquimod in increasing the potency of a therapeutic HIV-1 vaccine candidate.

Alarzi SSH, Bolhassani A, Agi E, Nekouian R.J Pharm Sci. 2025 Oct 7:104019. doi: 10.1016/j.xphs.2025.104019. Online ahead of print.PMID: 41067501

Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma.

Lutz J, Feist RK, Sonntag T, Peguero-Sánchez E, Wolter K, Bick R, Bauer J, Walz JS, Heidenreich R.Cancer Immunol Immunother. 2025 Oct 6;74(11):329. doi: 10.1007/s00262-025-04178-x.PMID: 41051649

Genomic insights into a diarrheal outbreak in Bangladesh reveal novel ETEC lineages and expansion of CS23 colonization factor.

Rahman SIA, Jubair M, Akhtar M, Akter A, Tauheed I, Begum YA, Bhattacharjee P, Afrad MH, Khanam F, Islam MT, Khan AI, Rahman M, Ryan ET, Fleckenstein JM, Bhuiyan TR, Thomson NR, Qadri F, von Mentzer A, Chowdhury F.Microbiol Spectr. 2025 Oct 7;13(10):e0331524. doi: 10.1128/spectrum.03315-24. Epub 2025 Sep 10.PMID: 40928300

Murine antibody 4B1D3 exhibits broad cross-reactivity and neutralizing activity against SARS-CoV-2 variants.

Silva MO, Daher IP, Oda Ibrahim CH, de Souza EE, Postol E, de Alencar RE, de Souza Silva GA, Marques RF, Adami FL, Schuch V, Yamamoto MM, da Silva Almeida B, Koike G, Azevedo IR, Castro-Amarante MF, Rosa DS, Durigon EL, Wrenger C, Cunha-Neto E, Kalil J, Boscardin SB.Virology. 2025 Oct;611:110629. doi: 10.1016/j.virol.2025.110629. Epub 2025 Jul 21.PMID: 40712305

Quality indicators for pharmacist follow-up of diabetes mellitus: A RAND-modified Delphi method.

Christiaens L, Meel L, Buyl M, De Wulf I, Van den Bulck S, Vaes B, Raat W, Van de Putte M.Int J Clin Pharm. 2025 Oct;47(5):1406-1415. doi: 10.1007/s11096-025-01942-y. Epub 2025 Jun 23.PMID: 40549248

Increased GII.3[P12] norovirus outbreaks and viral whole genome analysis in Beijing, China during 2021 and 2023.

Fu J, Shen L, Li W, Tian Y, Liu B, Wang Y, Jia L, Feng Z, Zhang D, Yang P, Gao Z, Wang Q.Gut Pathog. 2025 Oct 2;17(1):76. doi: 10.1186/s13099-025-00756-7.PMID: 41039622

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Comparing respiratory illness surveillance case definitions to detect Bordetella pertussis in children aged <5 years with respiratory illness in South Africa, 2017-2023.

Bishop K, Moosa F, Makhasi M, Kleynhans J, Naby F, du Plessis M, Reubenson G, Dawood H, Zar HJ, Meiring S, Quan V, Wolter N, von Gottberg A, Cohen C, de Voux A, Walaza S.J Infect Dis. 2025 Oct 6:jiaf501. doi: 10.1093/infdis/jiaf501. Online ahead of print.PMID: 41052289

Knowledge, Attitude and Practice about Hepatitis C Virus Infection among the Health Care Workers in a Tertiary Care Hospital of Bangladesh.

Hossain MA, Alam MK, Rahman MM, Ashrafozzaman SM, Ahamed F, Bhuiyan S, Islam MA, Das PR, Bhat D, Karim MR, Shahidullah M, Junaid M, Moshwan MM, Hoque MA, Haidar MR, Rouf MA, Mural MA.Mymensingh Med J. 2025 Oct;34(4):974-980.PMID: 41024531

Vaccination coverage by age 24 months among children born in 2020 and 2021 in China, during the COVID-19 pandemic: A study based on the national immunization information system.

Huang W, Xu M, Diao Z, Chen J, Lv H, Li J, Guang M, Liang H, Wang D, Zeng F, Liu D, Jing F, Liang X.Vaccine. 2025 Oct 3;64:127717. doi: 10.1016/j.vaccine.2025.127717. Epub 2025 Sep 12.PMID: 40945181

H1N1pdm09 returns: a comparative study in Anhui, China.

Yang S-T, Hu M-H, Fang W-X, Diao H-M, Musonye HA, Huang J-X, Xia Y-D, Yu J-L, Gong L, Hou S, Li D-X, Luo W-R, Zhou X, Luo X-W, Wu J-B, Pan H-F, He J.Microbiol Spectr. 2025 Oct 7;13(10):e0221824. doi: 10.1128/spectrum.02218-24. Epub 2025 Sep 8.PMID: 40919781

Whole genome sequencing and phylogenetic classification accelerate the implementation of respiratory syncytial virus genomic surveillance in Canada: a pilot study.

Gao R, Buchanan C, Dust K, Van Caeseele P, Wong H, Sjaarda C, Sheth PM, Jassem AN, Minion J, Bastien N.Microbiol Spectr. 2025 Oct 7;13(10):e0314224. doi: 10.1128/spectrum.03142-24. Epub 2025 Sep 3.PMID: 40899818

Cross-species characterization of feline parvovirus and Feline-Origin canine parvovirus Southern China (2023-2024): insights into epidemiology, genetic evolution and recombination.

Fang N, Li M, Zhang A, Wen L, Li H, Ye X, Zhang F, Chen R.BMC Vet Res. 2025 Oct 6;21(1):583. doi: 10.1186/s12917-025-05019-w.PMID: 41053788

Determinants of severe COVID-19 in vaccinated adults: a study from southern Brazil (2021-2023).

Sorio GGL, da Silva Gregory V, Sganzerla D, Rodrigues Gonçalves M, Fernandes Dantas Filho F, da Silva Pitombeira Rigatto MH.Pathog Glob Health. 2025 Oct;119(7):235-242. doi: 10.1080/20477724.2025.2554138. Epub 2025 Sep 14.PMID: 40946344

Acquisition and clearance of enteric pathogens in children under 5 years of age in Kigali and Musanze, Rwanda, 2022: a longitudinal cohort study.

Munyemana JB, Kabayiza JC, Seruyange E, Nilsson S, Andersson ME, Lindh M.Clin Microbiol Infect. 2025 Oct;31(10):1684-1690. doi: 10.1016/j.cmi.2025.06.018. Epub 2025 Jun 21.PMID: 40550361

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Impact of systemic SARS-CoV-2 vaccination on mucosal IgA responses to subsequent breakthrough infection.

Marking U, Bladh O, Aguilera K, Pongracz T, Havervall S, Greilert-Norin N, Blom K, Klingström J, Wang Y, Åberg M, Thålin C.EBioMedicine. 2025 Oct;120:105912. doi: 10.1016/j.ebiom.2025.105912. Epub 2025 Sep 16.PMID: 40961508

Optimizing surveillance post-pandemic: an evaluation of COVID-19 and other respiratory virus surveillance systems in the Philippines, April 2023.

Lofgren H, Donadel M, Lacson RS, Pacial DR, de Guzman AR, Almendares O; Philippines COVID-19 Surveillance System Evaluation Team.BMC Public Health. 2025 Oct 8;25(1):3378. doi: 10.1186/s12889-025-24208-8.PMID: 41063013

Real-world use of maintenance bacillus Calmette-Guérin therapy in patients with non-muscle-invasive bladder cancer in Japan: ASUKA study.

Miyake M, Tokumaru J, Oi H, Kitagawa H, Fujimoto K, Nishiyama N, Kitamura H.BJUI Compass. 2025 Oct 1;6(10):e70091. doi: 10.1002/bco2.70091. eCollection 2025 Oct.PMID: 41040503

Predicting the trend of SARS-CoV-2 mutation frequencies using historical data.

Zhou X, Yan Y, Hu K, Tang H, Wang Y, Wang L, Zhang C, Cao S.Bioinformatics. 2025 Oct 2;41(10):btaf508. doi: 10.1093/bioinformatics/btaf508.PMID: 40973044

Influenza vaccination coverages in Italy from 1999/00 to 2023/24: A joinpoint regression analysis.

Zaino A, Bonacquisti M, Russo L, Sabetta T, Solipaca A, Ricciardi W, Boccia S, Villani L.J Infect Public Health. 2025 Oct;18(10):102875. doi: 10.1016/j.jiph.2025.102875. Epub 2025 Jun 18.PMID: 40616909

Comparing methods collecting mucosal secretions and detecting SARS-CoV-2 spike IgA in three laboratories across three countries.

Bladh O, Aguilera K, Sheikh-Mohamed S, Nardulli J, Bhavsar D, Fitzgerald D, Singh G, Ward LA, Kleiner G, Chao GYC, Norin NG, Pongrácz T, Gleason C, Berkell M, Åberg M, Krammer F, Gommerman JL, Thålin C, Simon V.Vaccine. 2025 Oct 4;65:127792. doi: 10.1016/j.vaccine.2025.127792. Online ahead of print.PMID: 41046839

Invited review: Lung ultrasonography-Improving our understanding and management of respiratory disease in young calves.

Buczinski S, Ollivett TL, Pardon B.J Dairy Sci. 2025 Oct 9:S0022-0302(25)00808-2. doi: 10.3168/jds.2025-26764. Online ahead of print.PMID: 41076264

Prognostic Impact of PD-1 Polymorphisms in Non-small Cell Lung Cancer Receiving Dendritic Cell Vaccination.

Ogasawara M, Miyashita M, Yamagishi Y, Ota S.Anticancer Res. 2025 Oct;45(10):4295-4304. doi: 10.21873/anticanres.17780.PMID: 41006036

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The prevalence and role of human metapneumovirus in respiratory tract infections: a systematic review and meta-analysis of global data.

Khales P, Razizadeh MH, Ghorbani S, Tameshkel FS, Saadati H, Vazirzadeh M, Moattari A, Tavakoli A.EClinicalMedicine. 2025 Aug 30;88:103480. doi: 10.1016/j.eclinm.2025.103480. eCollection 2025 Oct.PMID: 40932845

Evolution and transmission dynamics of infectious bronchitis virus in southern China during 2018-2023: Emergence of a novel GI-19 subtype and re-emergence of GI-28.

Xie Y, Fan W, Lin Z, Li J, Zhang T, Zhang Y, Liu L, Chen S, Dong X, Chen Q, Li H, Zhao W, Chen J, Lv D, Wang W, Mo M.Poult Sci. 2025 Oct;104(10):105564. doi: 10.1016/j.psj.2025.105564. Epub 2025 Jul 11.PMID: 40774171

Incidence of and Risk Factors for SARS-CoV-2 Infection Among Vaccinated Healthcare Workers During Emergence of SARS-CoV-2 Gamma Variant in the Amazon Region, Brazil, 2021.

Parra G, Lessa FC, Campelo E, Amorim Ramos TC, Vieira AR, Lalwani P, Nichiata LYI, Silva-Flannery L, Siza C, Lima KJV, Tapajos AC, Vieira A, Plucinski M, Marston BJ, Morgan J, Esteves RJF, Fernandes da Costa C, Naveca FG, Araujo G, Padoveze MC; Brazil Healthcare Personnel COVID-19 Team.Clin Infect Dis. 2025 Oct 6;81(3):451-458. doi: 10.1093/cid/ciaf339.PMID: 40736251

Screening and eradication of *Helicobacter pylori* for gastric cancer prevention: Taipei Global Consensus II.

Liou JM, Malfertheiner P, Hong TC, Cheng HC, Sugano K, Shah S, Sheu BS, Chen MJ, Chiang TH, Chen YC, Yamaoka Y, Wong SH, Chen CC, Lee YY, Quach DT, Wu DC, Hsu PI, Wu CY, Wu JY, Luo JC, Chang WL, Lu H, Suzuki H, Jung HY, Mahachai V, Vilaichone RK, Mégraud F, Lin JT, Yeoh KG, Leung WK, El-Omar EM, Lee YC, Wu MS; Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM).Gut. 2025 Oct 8;74(11):1767-1791. doi: 10.1136/gutjnl-2025-336027.PMID: 40912906

Wzy 3D structural models correlate with inter-repeat unit glycosidic bond configuration in pneumococcal capsule polysaccharides.

Ganaie FA, Oliver MB, Saad JS, Glanville DG, Ulijasz AT, Nahm MH.Microbiol Spectr. 2025 Oct 7;13(10):e0032825. doi: 10.1128/spectrum.00328-25. Epub 2025 Sep 3.PMID: 40899850

COVID-19 Exposure, Protective Measures, Symptom Assessment, and Risk Perception Among Healthcare Workers in Peru: A Longitudinal Cohort Study (2020-2021).

Ponce D, Westercamp M, Soto G, Lessa FC, Marcenac P, Romero C, Silva M, Smith R, Mahon G, Llanos-Cuentas A, Matos E, Prouty M, Espinosa-Bode A, Neyra J.Clin Infect Dis. 2025 Oct 6;81(3):467-477. doi: 10.1093/cid/ciaf343.PMID: 40728296

Exploring the critical risk factors in COVID-19 vaccination clinics aimed uncertainty: Insight from Pakistan.

Abbas HW, Khalid N, Anjum R, Nawaz R, Zhou Z, Gong S.Eval Program Plann. 2025 Oct;112:102651. doi: 10.1016/j.evalprogplan.2025.102651. Epub 2025 Jul 11.PMID: 40674873

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Knowledge, attitudes, and practices regarding tetanus: a case of healthcare workers in the emergency and intensive care departments of a regional hospital in the northern region of Morocco.

Mourabit N, Elwardi K, Mahrach Y, Kaissi O, Elboussaadni Y, Oulmaati A.BMC Health Serv Res. 2025 Oct 8;25(1):1325. doi: 10.1186/s12913-025-13522-x.PMID: 41063173

Long-term effects of COVID-19 on cardiopulmonary health, muscle strength, and quality of life: A comparative study.

Tavakoli M, Abbasi L, Rojhani-Shirazi Z, Ahmadi E.Respir Med. 2025 Oct;247:108302. doi: 10.1016/j.rmed.2025.108302. Epub 2025 Aug 14.PMID: 40818761

Epidemiology of Thrombotic Thrombocytopenia Syndrome 2011 to 2022: English Sentinel Network Cohort Studies.

Ordóñez-Mena JM, Kar D, Fan X, Ferreira F, Anand SN, Layton D, Clifton D, Joy M, Thakur A, Alessi A, Lee A, Mather L, de Lusignan S.Drug Saf. 2025 Oct;48(10):1161-1175. doi: 10.1007/s40264-025-01566-1. Epub 2025 Jul 31.PMID: 40745250

Knowledge, Attitude and Practice about Covid-19 among the Adult Population of a Sub-urban Community in Bangladesh.

Islam MM.Mymensingh Med J. 2025 Oct;34(4):1177-1184.PMID: 41024558

Modelling the spread of Salmonid Rickettsial Septicaemia and assessing regional control strategies for saltwater salmon farms in Aysén, Chile.

Lam CT, Ivanek R, Wada M, Rosanowski S, Nekouei O, Getchell R, St-Hilaire S.Prev Vet Med. 2025 Oct;243:106595. doi: 10.1016/j.prevetmed.2025.106595. Epub 2025 Jun 13.PMID: 40614531

The evolving burden of childhood meningitis in low- and middle-income countries, 1990-2021: a decomposition and frontier analysis.

Liu T, Chen Z, Ge J, Mei H, Shi L, Zheng J.Eur J Pediatr. 2025 Oct 12;184(11):679. doi: 10.1007/s00431-025-06516-8.PMID: 41076501

Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus.

Bolanos R, Araos R, Gonzalez C, Sepulveda D, Falconi JF, Averin A, Atwood M, Quinn E, Law AW, Mendes D.Expert Rev Vaccines. 2025 Dec;24(1):904-913. doi: 10.1080/14760584.2025.2562201. Epub 2025 Oct 2.PMID: 40958705

Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 - February 2022.

Miller EM, Boyce RM, Kipp AM, Newby LK, Woods CW, Cassidy CA, Gunderson AK, Lea CS, Neighbors CE, Shook-Sa BE, Sloane R, Starling AP, Wambui D, Wixted D, Fleischauer A, Aiello AE.PLoS One. 2025 Oct 8;20(10):e0332645. doi: 10.1371/journal.pone.0332645. eCollection 2025.PMID: 41060960

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Tetanus toxoid vaccination coverage and associated factors among pregnant women in East Africa: systematic review and meta-analysis.

Taye BA, Weldearegay BY, Yirsaw BG, Belete AK.BMC Public Health. 2025 Oct 3;25(1):3319. doi: 10.1186/s12889-025-24687-9.PMID: 41044529

Evaluating the Implementation of Public Health Strategies to Address COVID-19 Disparities in a Community Setting: A Qualitative Study Using the RE-AIM Framework.

McElrone M, Holden E, Brown C, Ballew J.Public Health Nurs. 2025 Oct 3. doi: 10.1111/phn.70021. Online ahead of print.PMID: 41042687

Impact of vaccination on SARS-CoV-2 infections and long COVID symptoms: a cross-sectional study in China.

Yan X, Zhao X, Wang H, Du Y, Liu L, Liu J, Wang Q, Wei S.BMC Infect Dis. 2025 Oct 10;25(1):1266. doi: 10.1186/s12879-025-11677-w.PMID: 41073932

Enhanced adenoviral reactivity in Guillain-Barré syndrome after SARS-CoV-2 infection and vaccination.

Bellanti R, Iserte AC, Johnson CB, Goodfellow J, Johnson M, Dejnirattisai W, Keddie S, Campo JJ, Screaton G, Goldblatt D, Lunn MP, Davies AJ, Rinaldi S.Brain. 2025 Oct 7:awaf376. doi: 10.1093/brain/awaf376. Online ahead of print.PMID: 41055073

Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study.

Sol O, Mermoud J, Hallikainen M, Kurl S, Rinne J, Dautzenberg P, Vijverberg EGB, Mummery C, Börjesson-Hanson A, Jonsson M, Ritchie C, Pennington C, Vukicevic M, Gollwitzer E, Fiorini E, Hickman DT, Hliva V, Gray J, Gerasymchuk V, Wagg J, Fournier N, Lê B, Kezic I, Steukers L, Triana-Baltzer G, Theunis C, Streffer J, Kosco-Vilbois M, Pfeifer A, Scheltens P.EBioMedicine. 2025 Oct;120:105940. doi: 10.1016/j.ebiom.2025.105940. Epub 2025 Sep 18.PMID: 40972226

Cycle threshold values and SARS-CoV-2 variant associations with breakthrough infections: a retrospective study in Accra, Ghana.

Aboagye FT, Annison L, Aidoo EK, Acquah ME, Ashong YA, Oppong BB, Osae-Nyarko L, Owusu-Frimpong I, Hackman HK, Annison S, Quarshie QD, Owusu-Senyah Enninful AK, Kuma NA, Egyam BC, Osei-Atweneboana MY.BMC Infect Dis. 2025 Oct 10;25(1):1269. doi: 10.1186/s12879-025-11732-6.PMID: 41073974

Knowledge, Attitudes, and Behaviors Regarding HPV Vaccination and Self-Sampling Among US Young Adults.

Hargis A, Berg CJ, Le D.J Cancer Educ. 2025 Oct 3. doi: 10.1007/s13187-025-02701-3. Online ahead of print.PMID: 41044442

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Immunization Coverage and Its Determinants Among Children Aged 12-23 Months in East Africa: A Bayesian Hierarchical Modeling Approach Based on DHS 2019-2022.

Endalamew SG, Gebeye E, Assefa SK, Geremew BM.Biomed Res Int. 2025 Oct 3;2025:6645541. doi: 10.1155/bmri/6645541. eCollection 2025.PMID: 41050846

Immunological profile of pregnant women with preconception immunity with or without vertical transmission of human cytomegalovirus to the fetus: a retrospective observational study.

Zelini P, d'Angelo P, Fornara C, Zavaglio F, Furione M, Arossa A, Achille C, Tassis B, Ronchi A, Pugni L, Ornaghi S, Cavoretto PI, Candiani M, Fabbri E, Locatelli A, Consonni S, Rutolo S, Miotto E, Savasi V, Di Giminiani M, Prefumo F, Pellegrinelli L, Pietrasanta C, Spinillo A, Lilleri D, Baldanti F.Lancet Microbe. 2025 Oct;6(10):101162. doi: 10.1016/j.lanmic.2025.101162. Epub 2025 Aug 18.PMID: 40840474

Advocacy to action for cervical cancer elimination in the state of Assam: a narrative review of the government policies and the latest report of NCDIR survey.

Barmon D, Nath A, Aparajita, Sharma JD, Kannan R, Alam S, Sharma A.BMC Health Serv Res. 2025 Oct 2;25(1):1291. doi: 10.1186/s12913-025-13475-1.PMID: 41039387

Feasibility, Safety, and Impact of the Probiotics Lactiplantibacillus plantarum and Bifidobacterium longum subspecies infantis in Papua New Guinean Infants: Protocol for a Randomized Controlled Trial.

Ford RL, Greenhill AR, Sapura J, Koata A, Dreyam M, Orami T, Jude J, Ong M, Kirarock W, Joseph D, Masiria G, Aho C, Pomat WS, van den Biggelaar AHJ, Richmond PC.JMIR Res Protoc. 2025 Oct 2;14:e73926. doi: 10.2196/73926.PMID: 41037809

Genital Graft-Versus-Host-Disease Predicts Decreased Sexual Function in Female Survivors of Allogeneic Hematopoietic Stem Cell Transplant.

Shanis D, Yang L, Bevans M, Scrivani C, Merideth MA, Childs RW, Battiwalla M, Stratton P.Transplant Cell Ther. 2025 Oct;31(10):834.e1-834.e11. doi: 10.1016/j.jtct.2025.06.021. Epub 2025 Jun 18.PMID: 40541681

Long COVID-19 in pregnancy: increased risk but modest incidence following mild Omicron infection in a boosted obstetric cohort during endemicity.

Tan YY, Loy EXH, Tan WZ, Tay AT, Lim JT, Chiew CJ, Choolani M, Lye DC, Tan KB, Wee LE.Am J Obstet Gynecol. 2025 Oct;233(4):323.e1-323.e12. doi: 10.1016/j.ajog.2025.03.004. Epub 2025 Mar 10.PMID: 40073919

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Patentes registradas en Patentscope

Estrategia de búqueda: *(Vaccine) AND DP:([01.10.2025 TO 12.10.2025]) 68 records.*

1.WO/2025/199993CHOLESTEROL-MODIFIED CATIONIC LIPOSOME TUMOR VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF

WO - 02.10.2025

Clasificación Internacional A61K 9/127Nº de solicitud PCT/CN2024/084956Solicitante SICHUAN UNIVERSITYInventor/a WEI, Xiawei

The present invention belongs to the technical field of cancer immunotherapy, and particularly relates to a cholesterol-modified cationic liposome tumor vaccine, a preparation method therefor, and use thereof. In order to solve the problems of poor targeting and strong side effects of TLR agonists in anti-tumor treatment, the present invention provides a cationic liposome prepared from a cholesterol-modified 1V209 molecule, a cationic lipid component, cholesterol, and DSPE-PEG2000, and then the cationic liposome and ovalbumin 5 form the tumor vaccine by electrostatic adsorption. Animal experiments show that the vaccine can induce antigen-specific CD8+ T cells, activate lymphocytes, and generate stronger antigen cross-presentation, more memory T cells, antibodies, and cytokines. Prophylactic inoculation with the vaccine can significantly delay the progression of mouse melanoma and lymphoma and prolong the survival of mice. The combination use of the vaccine and a PD-1 checkpoint inhibitor can further enhance the anti-tumor effect. Therefore, the vaccine is a promising cancer vaccine.

2.WO/2025/211492IMMUNE ADJUVANT COMPRISING IMIQUIMOD AND NOD2 RECEPTOR-STIMULATING COMPONENT OR BACTERIUM

WO - 09.10.2025

Clasificación Internacional A61K 39/39Nº de solicitud PCT/KR2024/006650Solicitante REPUBLIC OF KOREA(DEFENSE ACQUISITION PROGRAM ADMINISTRATION)Inventor/a KIM, Donghyun

The present invention relates to a vaccine immune adjuvant that utilizes the synergy between imiquimod and a Nod2 receptor-stimulating component or a Nod2 receptor-stimulating bacterium. According to one aspect of the present invention, a vaccine immune adjuvant composition comprising, as active ingredients, imiquimod and a Nod2 receptor-stimulating component or a Nod2 receptor-stimulating bacterium can enhance the efficacy of a vaccine to be greater than that of the administration of imiquimod alone, and thus can be effectively used as a complex immune adjuvant for increasing immune responses of various vaccines such as an SARS-CoV-2 virus vaccine, an influenza A virus vaccine and an anticancer vaccine against melanoma.

3.20250302932COMBINATION OF VACCINATION AND OX40 AGONISTS

US - 02.10.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18952886Solicitante CureVac SEInventor/a Mariola FOTIN-MLECZEK

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.

4.WO/2025/201659COMBINATION THERAPY COMPRISING THERAPEUTIC RNA CANCER VACCINES AND ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT

WO - 02.10.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2024/058693Solicitante BIONTECH SEInventor/a SAHIN, Ugur

The invention provides an RNA cancer vaccine and/or an anti-CTLA4 antibody for use in a method of treating cancer in a subject in need thereof, wherein the subject is administered a combination comprising the RNA cancer vaccine comprising at least one RNA and the anti- CTLA4 antibody. The invention further provides a compositions or kit of parts comprising the RNA cancer vaccine comprising the at least one RNA and the anti-CTLA4 antibody. The invention further provides methods of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject the RNA cancer vaccine comprising the at least one RNA and the anti-CTLA4 antibody. The invention further provides a combination of the RNA cancer vaccine comprising at least one RNA and the anti-CTLA4 antibody.

5.WO/2025/202495COMBINATION THERAPY COMPRISING THERAPEUTIC RNA CANCER VACCINES AND ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT

WO - 02.10.2025

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2025/058630Solicitante BioNTech SEInventor/a SAHIN, Ugur

The invention provides an RNA cancer vaccine and/or an anti-CTLA4 antibody for use in a method of treating cancer in a subject in need thereof, wherein the subject is administered a combination comprising the RNA cancer vaccine comprising at least one RNA and the anti- CTLA4 antibody. The invention further provides a compositions or kit of parts comprising the RNA cancer vaccine comprising the at least one RNA and the anti-CTLA4 antibody. The invention further provides methods of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject the RNA cancer vaccine comprising the at least one RNA and the anti-CTLA4 antibody. The invention further provides a combination of the RNA cancer vaccine comprising at least one RNA and the anti-CTLA4 antibody. The invention further provides a combination of the RNA cancer vaccine comprising at least one RNA and the anti-CTLA4 antibody for use as a medicament.

6.WO/2025/212705VACCINE TARGETING TO MUCOSAL LYMPHOID TISSUES IN THE GASTROINTESTINAL TRACT

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

WO - 09.10.2025

Clasificación Internacional A61K 9/10Nº de solicitud PCT/US2025/022620Solicitante MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventor/a IRVINE, Darrell, J.

Viruses, bacteria, and parasites frequently cause infections in the gastrointestinal (GI) tract, but traditional vaccination strategies typically elicit little or no mucosal antibody responses. Disclosed herein is a vaccine comprising a nanoemulsion and an immunogen non-covalently conjugated to the surface of the nanoemulsion by an amphiphilic linker, wherein the vaccine is suitable for inducing a mucosal antibody response in the gastrointestinal tract. Also disclosed are methods of using the vaccine to immunize a subject by intraperitoneal administration of an effective amount of the vaccine, alone or with an adjuvant.

7.20250314636METHOD OF PREPARING AND EXPANDING A POPULATION OF IMMUNE CELLS FOR CANCER THERAPY, POTENCY ASSAY FOR TUMOR RECOGNITION, BIOLOGICAL VACCINE PREPARATION AND EPITOPETARGET FOR ANTIBODIES

US - 09.10.2025

Clasificación Internacional G01N 33/50Nº de solicitud 18864625Solicitante FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD - CEInventor/a Carolina MENDONÇA GORGULHO

The present invention relates to a method of preparing and expanding a population of immune cells, a potency assay for tumor recognition, a biological vaccine preparation to provide anti-tumor response or an antiviral response for cancer therapy and epitopes targets for antibodies which are useful for the construction of chimeric antigen receptors.

The present invention is based on the fact that private or commonly shared tumor-associated antigens or private target antigens can be recognized by clinically relevant immune cells. Such target antigens could be used to prepare a biological vaccine preparation to provide anti-tumor response or an antiviral response by expanding a certain set of T-cells or B-cells and boosting the immune response in cancer therapy.

The present invention guides the selection of viable target antigens in designing an anti-tumor vaccine to remove potentially harmful autoimmune responses or pro-tumorigenic immune responses and aids to select the biologically and clinically most relevant set of immune cells specifically directed against cancer cells harvested from tumor infiltrating lymphocytes or from different anatomical sites for the active cellular therapy of patients with cancer.

8.20250312315CANCER VACCINE COMPOSITIONS AND METHODS OF USE THEREOF

US - 09.10.2025

Clasificación Internacional A61K 31/4178Nº de solicitud 19084504Solicitante Colorado State University Research FoundationInventor/a Terry OPGENORTH

The disclosure provides a cancer vaccine composition comprising inactivated cancer cells and an adjuvant, wherein the inactivated cancer cells are incapable of replication. Also provided is a method for producing a cancer vaccine composition, the method comprising contacting cancer cells with light (e.g., UV light) in the presence of a photosensitizer (e.g., riboflavin).

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

9.20250302939VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1

US - 02.10.2025

Clasificación Internacional A61K 39/21Nº de solicitud 18864213Solicitante The United States of America, as represented by the Secretary, Department of Health and HumanInventor/a Genoveffa Franchini

Provided herein is a nucleic acid-based vaccine for human T-cell leukemia virus type 1 (HTLV-1). In some aspects, the vaccine includes a combination of nucleic acid molecules encoding HTLV-1 gag protein and one or both of Type A HTLV-1 Envelope (Env) and Type C HTLV-1 Env. In some aspects, the vaccine includes a combination of nucleic acid molecules encoding HIV-1 gag protein and one or both of Type A HTLV-1 Envelope (Env) and Type C HTLV-1 Env. When administered to a subject, the Env and Gag proteins are expressed in the host and form HTLV-1 virus-like particles (VLPs) that are secreted from cells within the host and elicit an immune response that inhibits HTLV-1 infection.

10.4628166IMPFSTOFFADJUVANS UND HERSTELLUNGSVERFAHREN DAFÜR UND VERWENDUNG DAVON

EP - 08.10.2025

Clasificación Internacional A61P 35/00Nº de solicitud 25195745Solicitante CHENGDU MAXVAX BIOTECHNOLOGY LLCInventor/a CHEN DEXIANG

A vaccine adjuvant, and a preparation method therefor and a use thereof. The vaccine adjuvant is a MA105 immunologic adjuvant, and comprises (1) QS-21: 50 μg/ml to 300 μg/ml; (2) Poly I:C: 400 μg/mL to 3000 μg/mL; and (3) lipid molecules constituting a vector, the vector being a mixture of a cationic liposome and a neutral liposome.

11.WO/2025/199604RECOMBINANT VACCINE PROTEINS FOR THE PREVENTION OF AVIAN NECROTIC ENTERITIS

WO - 02.10.2025

Clasificación Internacional A61K 39/08Nº de solicitud PCT/CA2024/050383Solicitante UNIVERSITÉ DE MONTRÉALInventor/a GAUCHER, Marie-lou

Avian necrotic enteritis (NE) is a complex and multifactorial enteric disease of commercial chickens and turkeys that has major economic consequences on the poultry industry worldwide. There is thus a need for improved and efficient vaccines for the prevention of diseases associated to pathogenic Clostridium perfringens in the poultry industry. The present application discloses immunogenic polypeptides unique to pathogenic strains of Clostridium perfringens which causes avian NE, as well as vaccine compositions comprising one or more of the immunogenic polypeptides, immunogenic fragments thereof, or nucleic acids encoding such immunogenic polypeptides and fragments. Methods and uses of the vaccine compositions for inducing or eliciting an immune response against Clostridium perfringens, for preventing or treating infection by Clostridium perfringens, and/or for preventing or treating avian NE in an animal, such as a poultry, are also disclosed.

12.WO/2025/202803A PROCESS FOR PREPARING LACTOBACILLUS-BASED RECOMBINANT VACCINE CANDIDATE AGAINST MULTIPLE SALMONELLA SEROVAR IN POULTRY

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

WO - 02.10.2025

Clasificación Internacional C12N 15/74Nº de solicitud PCT/IB2025/052370Solicitante AHMAD, Syed MudasirInventor/a AHMAD, Syed Mudasir

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

13.202503124 33PROCESS FOR PRODUCING OF VACCINE FORMULATIONS WITH PRESERVATIVES

US - 09.10.2025

Clasificación Internacional A61K 39/09Nº de solicitud 18863176Solicitante PFIZER INC.Inventor/a Michael David BRUCHSALER

The present invention relates to a process for the production of a conjugate vaccine comprising a preservative. The invention relates in particular to a process for the production of a conjugate vaccine where the preservative is hydrophobic and viscous (such as 2-phenoxyethanol (2-PE)).

14.4628095FUSIONSPROTEIN UND GRANULIERTES ANTIGEN DAMIT

EP - 08.10.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23887963Solicitante UNIV XIAMENInventor/a LI SHAOWEI

Provided are a fusion protein and a composition, a kit, a granulated antigen, a vaccine, and a pharmaceutical composition comprising same. The present invention also relates to use of the fusion protein and the composition, the kit, and the granulated antigen comprising same in the preparation of a pharmaceutical composition or a vaccine. The granulated antigen is particularly suitable for the production and vaccination of a vaccine and has advantages in the prevention and/or treatment of viral infections.

15.WO/2025/206323CELL THERAPY

WO - 02.10.2025

Clasificación Internacional A61K 48/00Nº de solicitud PCT/JP2025/012812Solicitante OSAKA UNIVERSITYInventor/a ISHII, Hideshi

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The present disclosure provides a novel modality for a new target disease (e.g. pancreatic cancer). The present disclosure applies a mRNA CAR-T vaccine to CAR-T for a new target disease (e.g., pancreatic cancer). In the present disclosure, it has been revealed, by in vitro and in vivo experiments, that a mRNA CAR-T vaccine that targets FAP as an antigen can achieve a potent anti-tumor effect in in vivo editing. As for a mechanism for inhibiting the effect of a mRNA CAR-T vaccine, the pathways involving regulatory T cells and the like have also been revealed. As for a synergistic effect with an immune checkpoint agonist, a "condition" for achieving a potent anti-tumor effect in vivo has also been revealed through much trial and error.

16.4626574HERSTELLUNG UND HERSTELLUNG EINES FLAVIVIRUSIMPFSTOFFS IM GROSSMASSSTAB

EP - 08.10.2025

Clasificación Internacional B01D 15/36Nº de solicitud 23829266Solicitante TAKEDA VACCINES INCInventor/a SANTANGELO JOSEPH DAVID

The present invention provides methods for large-scale flaviviral vaccine production and manufacture. The methods provided herein are specifically contemplated for large-scale production and manufacture of live, attenuated flaviviral vaccines such as live, attenuated, dengue virus vaccines. Further, the methods provided herein pertain to formulation of live, attenuated, monovalent, divalent, trivalent, or tetravalent viral vaccine products.

17.WO/2025/210229AN IMMUNOGENIC OR VACCINE COMPOSITION COMPRISING A LIVE ATTENUATED AVIAN METAPNEUMOVIRUS (AMPV) FOR USE IN THE PREVENTION AND/OR TREATMENT OF AN AMPV INFECTION

WO - 09.10.2025

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2025/059289Solicitante HIPRA SCIENTIFIC, S.L.U.Inventor/a GUIRADO CACERES, Evelina

An immunogenic or vaccine composition comprising a live attenuated avian metapneumovirus (aMPV) for use in the prevention and/or treatment of an aMPV infection The present invention refers to an immunogenic or vaccine composition comprising a live attenuated avian metapneumovirus (aMPV) for use in the prevention and/or treatment of an aMPV infection, wherein said use comprises administering the composition to laying birds, or for use in active immunization of laying birds.

18.20250302896VESICULAR STOMATITIS VIRUS MARBURG VIRUS VACCINE

US - 02.10.2025

Clasificación Internacional A61K 35/76Nº de solicitud 19063559Solicitante International AIDS Vaccine Initiative, Inc.Inventor/a Christopher L. PARKS

The present invention relates to a vesicular stomatitis virus vaccine vector encoding a MARV glycoprotein (rVSVΔG-MARV-GP). Vaccination with as little as 200 plaque-forming units was 100% efficacious against MARV lethality and prevented development of viremia. rVSVΔG-MARV-GP vaccination induced MARV GP-specific serum IgG, and virus-neutralizing activity in serum was detectable in animals vaccinated with the highest doses.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

19.20250312428HETEROLOGOUS PRIME BOOST VACCINE

US - 09.10.2025

Clasificación Internacional A61K 39/00Nº de solicitud 19237140Solicitante BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor/a Guido WOLLMANN

The present invention pertains to the provision of a vaccine comprising a first component (K) and a second component (V), wherein the first component (K) comprises a complex in which a cell penetrating peptide, an antigenic domain and a TLR agonist are functionally linked and the second component (V) comprises an oncolytic recombinant vesicular stomatitis virus expressing an antigenic domain. The invention further pertains to the use of the inventive vaccine in the treatment of cancer. The invention also provides a recombinant vesicular stomatitis virus expressing an antigenic domain and its use in cancer vaccines.

20.4627580VERFAHREN ZUR BEWERTUNG DER AUFFÄLLIGKEIT EINES EPITOPS GEGENÜBER DEM REPERTOIRE VON T-ZELL-REZEPTOREN

EP - 08.10.2025

Clasificación Internacional G16B 20/00Nº de solicitud 23817365Solicitante IMMUNEWATCH BVInventor/a MEYSMAN PIETER

The current invention relates to a method of predicting T-cell response to a query epitope with a known epitope-TCR binding comprising calculating conspicuousness score of said epitope based on the number of known TCR sequences or TCR clusters responsive to said epitopes or by a centrality metric for each said epitopes in the epitope-TCR graph. The invention further relates to a second method to predict T- Cell response of any arbitrary epitopes using a machine learning algorithm. The T- cell response of epitopes can be used for the selection of molecules for vaccine and/or non-immunogenic compositions. The invention further relates to a third method for producing vaccine, to a vaccine, a biological and a data base.

21.4626405PNEUMOKOKKENKONJUGAT-IMPFSTOFFFORMULIERUNGEN

EP - 08.10.2025

Clasificación Internacional A61K 9/08Nº de solicitud 23817825Solicitante PFIZERInventor/a DIOP AWA

The present invention relates to new vaccine formulations comprising conjugated *Streptococcus pneumoniae* capsular saccharide antigens (glycoconjugates) and uses thereof. Vaccine formulations of the present invention will typically comprise at least one glycoconjugate from a *S. pneumoniae* serotype in a formulation designed to facilitate resuspension.

22.WO/2025/207938NUCLEIC ACID VACCINES AGAINST COCCIDIOIDOMYCOSIS

WO - 02.10.2025

Clasificación Internacional A61K 39/00Nº de solicitud PCT/US2025/021841Solicitante UNIVERSITY OF WASHINGTONInventor/a FULLER, James Thomas

A trivalent vaccine induces robust antibody and mucosal and systemic IFN-γ and Th17 T cell responses against Coccidioides and affords complete protection from fungal dissemination and disease. The combination of the three antigens of this trivalent vaccine can exert synergistic protection against lethality,

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

disease and fungal dissemination. These robust responses can be further enhanced by use of one or more additional antigens described herein.

23.202503124 34LIPOPOLYSACCHARIDE (LPS) DEFICIENT ACINETOBACTER BAUMANNII MULTIVALENT VACCINE

US - 09.10.2025

Clasificación Internacional A61K 39/104Nº de solicitud 18702767Solicitante VAXDYN S.L.Inventor/a Juan José INFANTE VIÑOLO

The invention refers to a composition comprising inactivated cells deficient in LPS from the genus *Acinetobacter* and/or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases caused by *K. pneumoniae, P. aeruginosa, E. coli*, and/or *A. pleuropneumoniae*, and optionally *A. baumannii.*

24.20250302941APPLICATION OF AN IMMUNOGENIC OR VACCINE COMPOSITION

US - 02.10.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18283067Solicitante EYE VACCInventor/a Joël Blomet

The present invention relates to an immunogenic or vaccine composition comprising a marker, for use thereof in prevention and/or treatment of an infection caused by at least one pathogen, characterized in that it is administered on the ocular mucosa and/or the urogenital mucosa.

25.WO/2025/200576RECOMBINANT RSV F PROTEIN AND USE THEREOF

WO - 02.10.2025

Clasificación Internacional C07K 19/00Nº de solicitud PCT/CN2024/137843Solicitante XIAMEN UNIVERSITYInventor/a ZHENG, Zizheng

Provided are a recombinant respiratory syncytial virus (RSV) fusion (F) protein, and a fusion protein, vaccine, immunogenic composition, kit and pharmaceutical composition comprising same. Further provided is a use of the recombinant RSV F protein, fusion protein, vaccine, immunogenic composition, kit and pharmaceutical composition in preventing and/or treating RSV infection or diseases and/or symptoms caused by RSV infection.

26.4622666ABGESCHWÄCHTES AFRIKANISCHES SCHWEINEPESTVIRUS UND VERWENDUNG DAVON IN IMPFSTOFFZUSAMMENSETZUNGEN

EP - 01.10.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23809585Solicitante INTERVET INT BVInventor/a VAN DEN BORN ERWIN

The present invention relates to African Swine Fever (ASF) attenuated viruses wherein the genes EP402R and EP153R have been inactivated, which can be used as a vaccine. The attenuated viruses protect pigs against subsequent challenge with virulent virus. The present invention also relates to the use of such attenuated viruses to treat and/or prevent ASF.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

27.WO/2025/213131RNA COMPOSITIONS FOR DELIVERY OF ORTHOPOX ANTIGENS AND RELATED METHODS

WO - 09.10.2025

Clasificación Internacional A61K 39/275Nº de solicitud PCT/US2025/023311Solicitante BIONTECH SEInventor/a ZUIANI, Adam

The present disclosure provides pharmaceutical compositions for delivery of orthopoxvirus antigens (e.g., mpox, variola, borealpox, ectromelia, cowpox, volepox, modified vaccinia virus Ankara, or vaccinia) and related technologies (e.g., components thereof and/or methods relating thereto). For example, the present disclosure provides polyribonucleotides encoding one or more mpox antigens, fragments, or fusions thereof.

28.WO/2025/202543A VACCINE COMPOSITION COMPRISING AN ADENOVIRAL VECTOR AND AN ADENOVIRAL VECTOR DELIVERY ENHANCING AGENT

WO - 02.10.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/FI2025/050148Solicitante ROKOTE LABORATORIES FINLAND OYInventor/a YLÄ-HERTTUALA, Seppo

The present invention is directed to a vaccine composition comprising i) an adenoviral vector delivery enhancing agent selected from the group consisting of SYN3, and SYN3 analogs, and ii) an adenoviral vector comprising, at an insertion site in the viral genome, a nucleic acid sequence encoding an immunogenic protein generating adaptive immune response upon exposure to a host organism. The present invention is also directed to a method for delivering an adenoviral vector to a mammalian subject, said method comprising a step of administering onto the nasal and/or oral mucosa of the subject a dose of a delivery enhancing agent selected from the group consisting of SYN3 and SYN3 analogs and a dose of an adenoviral vector, wherein the first dose of said delivery enhancing agent and the first dose of said adenoviral vector are administered simultaneously or sequentially.

29.20250302931COLORECTAL CANCER TUMOR CELL VACCINES

US - 02.10.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18947958Solicitante NEUVOGEN, INC.Inventor/a Bernadette Ferraro

The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing colorectal cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to driver mutations. Also provided herein are methods of making and preparing the colorectal cancer vaccine compositions and methods of use thereof.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

30.WO/2025/208217A RECOMBINANT BACTERIAL STRAIN AS TUBERCULOSIS VACCINE CANDIDATE, AND METHODS OF PRODUCING THEREOF

WO - 09.10.2025

Clasificación Internacional C12N 15/74Nº de solicitud PCT/CA2025/050473Solicitante UNIVERSITY OF SASKATCHEWANInventor/a CHEN, Jeffrey Matthew

The invention describes a recombinant Mycobacterium strain such as M. smegmatis that is recombinantly converted to express the M. tb complex ESX protein expression system, e.g. M. tb complex ESX-1 protein expression system. The recombinant strain exports virulence effector proteins (such as EspA, EspB, EspC, EsxA or EsxB) similar to M. tb, when administered to a subject, and is therefore useful as a potential tuberculosis vaccine candidate. The recombinant strain is non-pathogenic and the vaccinated subject does not give a false positive result when tested with any standard tuberculosis diagnostic test e.g. CCT, as the recombinant strain does not sensitize the vaccinated host to M. tb antigens or protein derivate of M. bovis.

31.4628096REKOMBINANTER EXPRESSIONSVEKTOR ZUR HERSTELLUNG VON VIRUSÄHNLICHEN PARTIKELN ODER NANOPARTIKELN DER FUSS- UND MUNDERKRANKUNG UND IMPFSTOFFZUSAMMENSETZUNG DAMIT

EP - 08.10.2025

Clasificación Internacional A61K 39/135Nº de solicitud 23895042Solicitante OPTIPHARM CO LTDInventor/a LEE JI HOON

The present invention relates to a recombinant expression vector for preparing foot-and-mouth disease virus-like particles or nanoparticles, and a vaccine composition using same. The present invention provides virus-like particles or nanoparticles, and a preparation method therefor, the particles or nanoparticles being produced by expressing, simultaneously, VP4 with VPI, VP2 and VP3 or expressing VP1, VP2 and VP3 while excluding VP4, from among FMDV structural proteins. The virus-like particles or nanoparticles, prepared according to the method of the present invention, can be effectively used in the prevention of diseases caused by foot-and-mouth disease viral infection.

32.WO/2025/202630HEMORRHAGIC FEVER VACCINES

WO - 02.10.2025

Clasificación Internacional C07K 14/005Nº de solicitud PCT/GB2025/050635Solicitante CAMBRIDGE ENTERPRISE LIMITEDInventor/a BILLMEIER, Martina

Designed polypeptide sequences are described, and their use as vaccines against pathogens which cause hemorrhagic fever, such as viruses of the Ebolavirus, Lassa Fever virus and Marburg virus families. The designed sequences include those which comprise the designed Tri-LEMvac vaccine, and the bivalent Lassa virus vaccine. Nucleic acid molecules encoding the polypeptides, as well as vectors, fusion proteins, pseudotyped virus particles, pharmaceutical compositions, combined preparations, cells, and their use as vaccines against viruses of the Ebolavirus, Lassa Fever virus and Marburg virus families are also described.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

33.WO/2025/200475SYSTEM AND METHOD FOR PREPARING OUTER MEMBRANE VESICLES WITH GUARANTEED IMMUNE EFFECTS

WO - 02.10.2025

Clasificación Internacional C12P 1/04Nº de solicitud PCT/CN2024/131238Solicitante HUBEI UNIVERSITY OF MEDICINEInventor/a HAO, Mingyue

Provided are a system and method for preparing outer membrane vesicles with guaranteed immune effects. The system comprises a strain acquisition module, a strain screening module, an outer membrane vesicle yield promotion module, an outer membrane vesicle extraction module, an outer membrane vesicle purification module, an immune efficacy evaluation module, and a yield evaluation module, wherein the strain acquisition module is connected to the strain screening module, the outer membrane vesicle yield promotion module, and the outer membrane vesicle extraction module, respectively. By means of a genetic modification operation, the alr gene of Brucella is knocked out, which in turn improves the yield and immune efficacy of the outer membrane vesicles. Moreover, by means of strictly controlling the Brucella culture conditions, an inducing environment is established to induce Brucella to secrete outer membrane vesicles, thereby further improving the yield of outer membrane vesicles, and in turn obtaining outer membrane vesicles with a high yield and good immune effects, which meets the requirements of large-scale vaccine production, and provides a high-quality vaccine adjuvant for the research into, development of and application of Brucella vaccines.

34.4628510CHIMÄRER MULTIANTIGEN-POXVIRUS-IMPFSTOFF UND VERWENDUNG DAVON

EP - 08.10.2025

Clasificación Internacional C07K 19/00Nº de solicitud 23896693Solicitante INST MICROBIOLOGY CASInventor/a GAO FU

The present application relates to a multi-immunogen chimeric or mixed antigen for a poxvirus, particularly monkeypox virus, related products, and preparation method and use thereof. The chimeric or mixed antigen of the present application comprises three immunogens: (1) a monkeypox virus A35R protein or an antigenic fragment thereof (or a peptide fragment derived therefrom), (2) a monkeypox virus M1R protein or an antigenic fragment thereof (or a peptide fragment derived therefrom), and (3) a monkeypox virus B6R protein or an antigenic fragment thereof (or a peptide fragment derived therefrom), and can elicit an immune response against two types of infectious virus particles, namely intracellular mature virus particles (IMV) and extracellular envelope virus particles (EEV), thereby efficiently inducing specific immunoprotective effects against the monkeypox virus. Moreover, the poxvirus vaccine of the present application features good safety, rapid response, and scalable production capacity, thus showing excellent clinical application prospects.

35.20250302942VACCINE COMPOSITION AGAINST CORONAVIRUS

US - 02.10.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18553042Solicitante LG CHEM, LTD.Inventor/a Yoon Ae NOH

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The present invention relates to: a conjugate in which a receptor-binding domain (RBD) of coronavirus and a hepatitis B surface antigen (HBsAg) are linked; virus-like particles including the conjugate; and a coronavirus vaccine composition containing the conjugate and/or virus-like particles.

36.4626470IMPFSTOFFE MIT NEUEN NANOPARTIKELGERÜSTEN

EP - 08.10.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23898663Solicitante SCRIPPS RESEARCH INSTInventor/a HE LINLING

The present invention provides novel engineered nanoparticle scaffold sequences that are derived from the 13-01 protein. Relative to the known 13-01 protein or variants thereof, the novel 13-01 derived scaffold sequences of the invention contain an extended N-terminal helix. Also provided in the invention are vaccine constructs that contain various immunogenic proteins displayed on the novel nanoparticle scaffold sequences described herein. The vaccine constructs of the invention include, e.g., nanoparticles displaying tandem repeats of influenza M2e proteins or HCV E2 core proteins.

37.20250302944COMBINATION OF EPITOPES AND USE THEREOF, VACCINE CONSTRUCT, METHOD OF INDUCING AN IMMUNE RESPONSE, METHOD FOR THE IDENTIFICATION OF EPITOPES

US - 02.10.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18850231Solicitante FUNDAÇÃO ZERBINIInventor/a Jorge Elias KALIL FILHO

COMBINATION OF EPITOPES AND USE THEREOF, VACCINE CONSTRUCT, METHOD OF INDUCING AN IMMUNE RESPONSE, METHOD FOR THE IDENTIFICATION OF EPITOPES The present invention refers to a combination of epitopes comprising at least eight T cell epitopes from the SARS-CoV-2, as well as the use of said combination (“set of epitopes”). Said epitopes are widely recognized by CD4+ T-lymphocytes of the overwhelming majority of COVID-19 convalescent individuals.

38.20250302935DETECTION OF A GENETIC FUSION OR DELETION THAT RESULTS IN EXPRESSION OF A NEOANTIGEN

US - 02.10.2025

Clasificación Internacional A61K 39/00Nº de solicitud 19067594Solicitante Flagship Pioneering Innovations VI, LLCInventor/a Anthony P. Shuber

The invention provides methods of detecting a sequence modification (e.g., a genetic fusion or deletion) associated with cancer development that results in expression of a neoantigen. The neoepitope serves as the basis for manufacture of a vaccine, which is administered to a subject to induce an immune response against those cells producing the neoantigen.

39.20250302938RECOMBINANT SUBUNIT BASED UNIVERSAL INFLUENZA AND RESPIRATORY VIRUS VACCINES

US - 02.10.2025

Clasificación Internacional A61K 39/145Nº de solicitud 18863015Solicitante GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventor/a Sang-Moo KANG

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure relates to universal influenza vaccines and methods of making the same. Also disclosed is method for vaccinating a subject for influenza A that involves administering a cross-protective influenza vaccine disclosed herein to a subject in need thereof by intranasal, intramuscular, subcutaneous, transdermal, or sublingual administration.

40.20250312427MRNA VACCINES COMPRISING IL-4 AND/OR IL-13 RNA AND USES THEREOF

US - 09.10.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18685004Solicitante NEOVACSInventor/a Beatrice DROUET

An mRNA vaccine including at least one RNA molecule that encodes at least one cytokine (preferably IL-4, IL-13 or fragments thereof) and at least one T cell epitope, for treating or preventing disorders associated with aberrant IL-4 and/or IL-13 expression or activity, in particular asthma, atopic dermatitis and allergic disorders.

41.20250312439VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION

US - 09.10.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18866792Solicitante PHION THERAPEUTICS LTDInventor/a Helen MCCARTHY

The present specification relates to vaccines comprising an mRNA polynucleotide encoding a coronavirus antigen; and an amphipathic cell penetrating RALA peptide.

42.WO/2025/207952MATERIALS AND METHODS FOR TREATMENT OF MELANOMAS AND OTHER CANCERS

WO - 02.10.2025

Clasificación Internacional A61K 39/09Nº de solicitud PCT/US2025/021863Solicitante TUHURA BIOSCIENCES, INC.Inventor/a LAWMAN, Michael J.P.

The present disclosure generally relates to DNA vaccine compositions and methods of use thereof to enhance an immune response against cancer, and in particular to methods of enhancing an immune response to immune checkpoint inhibitor resistant cancers and rendering the cancer susceptible to immune checkpoint inhibitor therapies.

43.20250312425COMPOSITIONS AND METHODS COMPRISING ADA-1 FOR WOUND HEALING AND VACCINE ENHANCEMENT

US - 09.10.2025

Clasificación Internacional A61K 38/50Nº de solicitud 19172548Solicitante Drexel UniversityInventor/a Kara Lorraine Spiller

Compositions and methods incorporating Adenosine deaminase-1 (ADA-1) as an adjuvant are provided. Polynucleotides encoding novel coding sequences, polypeptides, vectors containing same, and methods of use are provided. Compositions and methods incorporating Adenosine deaminase-1 (ADA-1) in a hydrogel are also provided. Compositions and methods comprising ADA-1 for treating wounds are also provided.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

44.WO/2025/211732LIPID NANOPARTICLES COMPRISING GINSENOSIDE OR DERIVATIVE THEREOF, AND USE THEREOF

WO - 09.10.2025

Clasificación Internacional A61K 9/51Nº de solicitud PCT/KR2025/004311Solicitante GENOMICTREE, INC.Inventor/a AN, Sungwhan

The present invention relates to lipid nanoparticles comprising ginsenoside or a derivative thereof, and use thereof, and, specifically, to: lipid nanoparticles containing vegetable ginsenoside or a derivative thereof included in ginseng or red ginseng, instead of animal cholesterol for the delivery of therapeutic or vaccine nucleic acids; gene-inorganic nanoparticles in which the corresponding lipid nanoparticles are encapsulated, and a preparation method therefor; and a nucleic acid delivery composition comprising same.

45.2639923SYSTEM AND METHOD FOR FORECASTING EFFECT OF PATHOGEN ON POPULATION

GB - 08.10.2025

Clasificación Internacional G16H 50/80Nº de solicitud 202404459Solicitante AIRFINITY LTDInventor/a MATTHEW DAVID LINLEY

A mathematical simulation model to the input data to generate output data providing a forecast indicative of an effect of the pathogen on the population, wherein the mathematical simulation model is configured to use at least a Susceptible-Infected-Recovered model (SIR model). The SIR model is applied to a historical part of the input data to generate an initial iteration of the output data, the SIR model trained on a recently-acquired part of the input data to improve an accuracy of the SIR model when generating a subsequent iteration of the output data. Vaccine forecast for mitigating pathogen impacts, Fourier computation and variations in infection rates over time may be used to predict epidemiological burden, hospital admissions and deaths. Input data may be acquired in part using sensor arrangements.

46.WO/2025/212898PRE-FUSION STABILIZED CCHFV GP38-GN-GC GLYCOPROTEIN COMPLEX

WO - 09.10.2025

Clasificación Internacional C07K 14/005Nº de solicitud PCT/US2025/022968Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor/a MCLELLAN, Jason

Provided herein are engineered proteins comprising engineered CCHFV glycoprotein ectodomain. Such engineered CCHFV glycoprotein ectodomains may exhibit improved conformational homogeneity and/or biophysical stability. The ectodomains may be incorporated into nanoparticles or virus-like particles. Methods are also provided for use of the engineered CCHFV glycoprotein ectodomains as diagnostics, in screening platforms, and/or in vaccine compositions.

47.20250302934SET DOMAIN-CONTAINING 2 (SETD2) VACCINE

US - 02.10.2025

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Clasificación Internacional A61K 39/00Nº de solicitud 18864271Solicitante INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCE CENTERInventor/a Philip ABBOSH

Pharmaceutical compositions comprising one or more peptides derived from aberrantly translated retained introns (ATaRIs), methods for treating cancer with the same, and methods of immunizing a subject against cancer or eliciting an immune response to one or more peptides derived from ATaRIs are provided herein.

48.202503124 36STABILIZATION OF VIRUS-BASED THERAPEUTIC AGENT

US - 09.10.2025

Clasificación Internacional A61K 39/205Nº de solicitud 19170865Solicitante ELAREX INC.Inventor/a Jeremy Andrew IWASHKIW

A virus-based active agent is mixed with trehalose and water and dried. The mixture may also contain one or more of carbohydrate, such as pullulan and albumin. The mixture may be dried to a moisture content of 0.1-10%. The drying may be under vacuum but optionally without producing a foam. Some or all of the drying may be at a temperature in the range of 15-400C, or at a temperature in the range of 1-15° C., or both. The active agent may be based on a vesicular stomatitis virus (VSV) or an adenovirus (AdV). The dried mixture may be stored at a temperature in the range of 1-55° C. A composition includes a virus, which may be a derived or modified form of a virus such as VSV or AdV. The composition may be used for a virus-based vaccine.

49.WO/2025/212893COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING LYME DISEASE

WO - 09.10.2025

Clasificación Internacional A61K 39/02Nº de solicitud PCT/US2025/022962Solicitante THE MEDICAL COLLEGE OF WISCONSIN, INC.Inventor/a LOCHHEAD, Robert Bruce

Disclosed herein are compositions and methods for treating, and for the preventative treatment of Lyme disease. The compositions can include a conjugate vaccine polypeptide.

50.4628897VERFAHREN, ZUSAMMENSETZUNGEN UND SYSTEME ZUM NACHWEIS VON CORONAVIRUSNEUTRALISIERENDEN ANTIKÖRPERN

EP - 08.10.2025

Clasificación Internacional G01N 33/68Nº de solicitud 25181055Solicitante LABORATORY CORP AMERICA HOLDINGSInventor/a PETROPOULOS CHRISTOS J

The present disclosure relates to methods, compositions, and systems for detecting whether a subject exposed to a coronavirus has developed a neutralizing antibody response. Also disclosed are methods for determining whether a patient infected by a coronavirus is likely to respond to treatment with an antibody preparation. Also disclosed are methods for detecting the level of neutralizing antibody response in a sample of serum from a subject exposed to a coronavirus or to a coronavirus vaccine.

51.4626469COXIELLA BURNETTI-IMPFSTOFF

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

EP - 08.10.2025

Clasificación Internacional A61K 39/02Nº de solicitud 23821335Solicitante MOREDUN RES INSTITUTEInventor/a MCNEILLY TOM

The disclosure provides a phase II Coxiella burnetii variant that can be used to raise protective immune responses. The disclosure further provides vaccines and compositions comprising the same as well as antigens and LPS derived therefrom, both of which may also be used to raise protective immune responses. The disclosure further relates to the treatment of disease and/or conditions caused or contributed to by Coxiella burnetii.

52.20250302943RE-FOCUSING PROTEIN BOOSTER IMMUNIZATION COMPOSITIONS AND METHODS OF USE THEREOF

US - 02.10.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18707713Solicitante King Abdullah University of Science and TechnologyInventor/a Magnus Albert Rueping

Booster immunization compositions and methods of use thereof, are provided. The disclosed compositions use adjuvanted proteins as a booster vaccine targeting functionally relevant pathogen B and T cell epitopes to re-focus a patient's adaptive antibody and cytotoxic T-cell response. The pharmaceutically active ingredient of the re-focusing boost vaccines include of one or several recombinant protein molecules in a full-length or truncated yet functional (meaning the overall antigenic tertiary structure is retained) version of disease-related protein or protein domain, a smaller subunit or specific or modified epitope or combination of shorter epitopes derived from that initial prime antigen sequence. Methods for re-focusing an immune response in a subject, to augment an existing (not sufficiently protective immune response) and effectively neutralize a pathogen of interest in a mammalian host organism include administering to a subject whose immune system has been primed by a previous infection/vaccination against the pathogen.

53.20250302837INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS

US - 02.10.2025

Clasificación Internacional A61K 31/513Nº de solicitud 18854816Solicitante SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.Inventor/a Pedro D'ORLÉANS-JUSTE

The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene)-2-sulfonamido derivatives of general formula (II) for manufacturing pharmaceutical compositions for the treatment or prophylaxis of stroke, pulmonary embolism, deep or superficial vein thrombosis, thrombotic microangiopathy, thrombotic microangiopathy in hypercoagulable states after infection, inflammation, transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, vascular access site thrombosis or occlusion.

54.3615005COMPOSITIONS AND METHODS FOR VACCINE DELIVERY

PL - 06.10.2025

Clasificación Internacional A61K 9/127Nº de solicitud 18791678SolicitanteInventor/a SHEETIJ DUTTA

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

55.20250312458FORMULATIONS FOR NEOPLASIA VACCINES

US - 09.10.2025

Clasificación Internacional A61K 47/12Nº de solicitud 19074044Solicitante The Broad Institute, Inc.Inventor/a EDWARD F. FRITSCH

The present invention relates to neoplasia vaccine or immunogenic composition formulation for the treatment or prevention of neoplasia in a subject.

56.WO/2025/210141DELIVERY SYSTEM USEFUL FOR TOPICAL ADMINISTRATION OF RNA

WO - 09.10.2025

Clasificación Internacional A61K 9/107Nº de solicitud PCT/EP2025/059116Solicitante BOEHRINGER INGELHEIM VETMEDICA GMBHInventor/a SIGOILLOT-CLAUDE, Cecile

The present invention relates to a composition useful for the topical administration of RNA, wherein the composition comprises (i) an aqueous phase containing RNA and (ii) an oil phase, which in one embodiment are in mixture with two specific surfactants. Particularly, the present invention pertains to the formulation of mRNA encoding for an antigenic protein of interest. More particular, a microemulsion to cross the skin barrier is provided, with allows for alternative routes for mRNA vaccine applications. The microemulsion may be applied topically and can go through the skin via the transfollicular route. Thereby a delivery system is enabled which allows to (1) avoid the use of needles for vaccination and (2) target more specifically the mucosal component of immunity.

57.20250302929TUMOR NEOANTIGENIC PEPTIDES

US - 02.10.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18549993Solicitante INSTITUT CURIEInventor/a Sebastian AMIGORENA

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

58.WO/2025/206402AFRICAN SWINE FEVER VACCINE-PRODUCING RECOMBINANT ERI SILKWORM AND USE THEREOF

WO - 02.10.2025

Clasificación Internacional A01K 67/60Nº de solicitud PCT/JP2025/013137Solicitante OKINAWA UKAMI SERICULTURE CO., LTD.Inventor/a MAEGAWA, Kenichi

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The purpose of the present invention is to provide a method for producing an ASF antigen protein, said method having low endotoxin contamination and reduced workload in comparison with conventional methods. This purpose is achieved by a method using a recombinant eri silkworm that expresses an African swine fever virus antigen protein, in particular a recombinant eri silkworm that expresses an African swine fever virus antigen protein such as EP402R, i177L, P30, P54, pp62 and P72.

59.20250304623PEPTIDES FOR INTRACELLULAR DELIVERY

US - 02.10.2025

Clasificación Internacional C07K 7/08Nº de solicitud 18876364Solicitante UNIVERSIDADE DE SANTIAGO DE COMPOSTELAInventor/a Javier MONTENEGRO GARCÍA

The present invention relates to short peptides or salts thereof which can be modified with appropriate hydrophobic tails to generate amphiphilic molecules useful for the intracellular delivery of molecules of biological interest. Thus, the invention also relates to the amphiphilic molecules and to the complexes between said amphiphilic molecules and the molecules of biological interest. In addition, the invention refers to the use of said peptides, said amphiphilic molecules and said complexes for the delivery of molecules of biological interest. The invention relates to said peptides or salts thereof, said amphiphilic molecules and said complexes for use in medicine, particularly for use as a vaccine. Methods for the preparation of the amphiphilic molecules and the complexes of the invention are also contemplated. Finally, the invention relates to novel amino acids useful in the synthesis of the peptides and molecules of the invention.

60.20250304995MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY

US - 02.10.2025

Clasificación Internacional C12N 15/86Nº de solicitud 18258502Solicitante PRIME VECTOR TECHNOLOGIES GMBHInventor/a Ralf AMANN

The present invention relates to a modified *Parapoxvirus*, preferably a *Parapoxvirus* vector, having an increased immunogenicity, a biological cell containing said modified *Parapoxvirus*, a pharmaceutical composition, preferably a vaccine, containing said modified *Parapoxvirus* vector and/or said cell, and a new use of said modified *Parapoxvirus.*

61.WO/2025/201437STING PROTEIN MUTANT, NUCLEIC ACID ENCODING STING PROTEIN MUTANT, AND USE OF STING PROTEIN MUTANT

WO - 02.10.2025

Clasificación Internacional C07K 14/47Nº de solicitud PCT/CN2025/085227Solicitante RINUAGENE BIOTECHNOLOGY CO., LTD.Inventor/a ZHANG, Weiguo

Provided are a STING mutant protein, a nucleic acid encoding the protein, a vector, a composition or vaccine comprising the protein or nucleic acid or vector, and a use of the protein in stimulating an immune response or treating cancer.

62.20250302933ATTENUATED YET IMMUNOGENICALLY POTENTIATED TUMOR EXTRACELLULAR VESICLE COMPOSITIONS AND USES THEREOF

US - 02.10.2025

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Clasificación Internacional A61K 39/00Nº de solicitud 19097584Solicitante KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventor/a In-San KIM

The present disclosure relates to attenuated yet immunogenically potentiated tumor-derived extracellular vesicle compositions and uses thereof. The present disclosure was completed by confirming that the extracellular vesicles secreted by tumor cells are attenuated yet immunogenically potentiated through a process of treating tumor cells with verteporfin, and the extracellular vesicles of the present disclosure can be used as a vaccine composition, etc.

63.20250302940PATHOGEN-LIKE ANTIGEN-BASED VACCINE AND PREPARATION METHOD THEREFOR

US - 02.10.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18267379Solicitante RONGSEN BIOTECHNOLOGY (BEIJING) CO., LTDInventor/a Baidong HOU

The present application relates to a pathogen-like antigen (PLA) complex, and a preparation method therefor and an application thereof. The PLA complex consists of structurally-modified *Escherichia coli* bacteriophage virus-like particles (VLPs) and antigens displayed thereon, and nucleic acids are encapsulated inside the VLPs.

64.WO/2025/209940EBV VACCINE AND ANTIBODIES

WO - 09.10.2025

Clasificación Internacional A61P 31/20Nº de solicitud PCT/EP2025/058562Solicitante HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventor/a HAMMERSCHMIDT, Wolfgang

The present invention relates, inter alia, to a composition comprising the BILF2 glycoprotein of Epstein-Barr-Virus (EBV), a nucleic acid encoding the BILF2 glycoprotein of EBV, or an extracellular vesicle (EV) or EB-virus-like particle (VLP) displaying at its surface the BILF2 glycoprotein of EBV, for use in a method of eliciting antibodies against said BILF2 glycoprotein which reduce infectivity of EBV for human epithelial cells. Preferably, said composition elicits antibodies that prevent infection of human epithelial cells by EBV.

65.20250316334NEOANTIGEN IDENTIFICATION, MANUFACTURE, AND USE

US - 09.10.2025

Clasificación Internacional G16B 20/30Nº de solicitud 18431595Solicitante GRITSTONE BIO, INC.Inventor/a Thomas Boucher

Disclosed herein is a system and methods for determining the alleles, neoantigens, and vaccine composition as determined on the basis of an individual's tumor mutations. Also disclosed are systems and methods for obtaining high quality sequencing data from a tumor. Further, described herein are systems and methods for identifying somatic changes in polymorphic genome data. Finally, described herein are unique cancer vaccines.

66.WO/2025/208014HAPTEN CONJUGATE VACCINE AGAINST XYLAZINE

WO - 02.10.2025

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Clasificación Internacional A61K 39/385Nº de solicitud PCT/US2025/021994Solicitante THE SCRIPPS RESEARCH INSTITUTEInventor/a JANDA, Kim, D.

The application discloses compositions comprising a xylazine hapten having the Formula (I). The application further discloses xylazine hapten compositions and vaccines against xylazine. The application further discloses methods of preventing xylazine overdose. The application further discloses methods of preventing use disorder of xylazine. The application further discloses methods of generating antibodies against xylazine. The application further discloses methods of treating consumption of a substance laced with xylazine.

67.20250312440CHEMICAL SCREEN OF MODULATORS FOR VACCINE ADJUVANTS

US - 09.10.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18869655Solicitante THE UNIVERSITY OF CHICAGOInventor/a Aaron ESSER-KAHN

The disclosure provides for methods and compositions that can be used for modulating an immune response. Described are methods comprising administering an effective amount of (a) an adjuvant; and (b) one or more of bafetinib (INNO-406), LY3009120, MK-8353 (SCH900353), amodiaquine, zanubrutinib (BOB-3111), Ku55933, Tucidinostat, PD318088, WNK463, and TRx0237 (LMTX) mesylate to a subject. The methods may he for the vaccination of subjects, or for the treatment or prevention of cancer, graft rejection, graft versus host disease, a bacterial infection, or a viral infection in a subject. The method may be for modulating an immune response in vivo, in vitro, or ex vivo. The methods also include immune activation of a population of immune cells in vitro or ex vivo. Also described is a method for identifying the efficacy of an adjuvant.

68.WO/2025/202674LANGERHANS CELLS TARGETING HIV-1 VACCINES

WO - 02.10.2025

Clasificación Internacional C07K 16/28Nº de solicitud PCT/IB2024/000163Solicitante INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALEInventor/a CARDINAUD, Sylvain

Developing an effective HIV-1 vaccine is contingent on generating protective antibodies (Abs). Novel antigen delivery methods are needed to enhance immune responses. One promising approach involves directing antigens to dendritic cells (DC) through fused monoclonal antibodies (mAbs) to amplify both cellular and humoral responses. Here, the inventors aimed to refine Langerhans cells (EC) targeting by designing three Env monochains instead of 2 (EC^3. Env^3) mimicking natural Env conformation. The inventors demonstrated that EC^3. Env^3 construct (i) elicited a rapid and potent Env-IgG response, (ii) enhanced the avidity of anti-Env IgG that was accompanied by a marked expansion of Tfh and GC B cells and (iii) swiftly induced the formation of structured germinal centers in dLN, indicative of a robust immune response. Finally, significant Tier-1 NeutAb induction was observed in rabbits immunized with the construct. In conclusion, HIV Env antigen can be adaptively targeted to LC as a timer, intensifying both the magnitude and quality of humoral responses. The present invention thus relates to the use of such a construct as LC targeting HIV-1 vaccines.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búqueda: *vaccine.ti. AND @PD>="20251001"<=20251012 33 records*

Document ID	Title	Inventor	Applicant Name
US 20250312458 A1	FORMULATIONS FOR NEOPLASIA VACCINES	FRITSCH; EDWARD F. et al.	The Broad Institute, Inc.
US 20250312315 A1	CANCER VACCINE COMPOSITIONS AND METHODS OF USE THEREOF	OPGENORTH; Terry et al.	Colorado State University Research Foundation
US 20250312442 A1	EPSTEIN-BARR VIRUS VACCINES	Ciaramella; Giuseppe et al.	ModernaTX, Inc.
US 20250312428 A1	Heterologous Prime Boost Vaccine	WOLLMANN; Guido et al.	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
US 20250312434 A1	LIPOPOLYSACCHARIDE (LPS) DEFICIENT ACINETOBACTER BAUMANNII MULTIVALENT VACCINE	INFANTE VIÑOLO; Juan José et al.	VAXDYN S.L.,INSTITUTO DE SALUD CARLOS III
US 20250313858 A1	SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES	DIAMOND; Don J. et al.	CITY OF HOPE
US 20250312429 A1	ANTI-GUCY2C VACCINES AND VACCINATION	Snook; Adam E et al.	THOMAS JEFFERSON UNIVERSITY
US 20250312439 A1	VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION	MCCARTHY; Helen et al.	PHION THERAPEUTICS LTD
US 20250312427 A1	mRNA VACCINES COMPRISING IL-4 AND/OR IL-13 RNA AND USES THEREOF	DROUET; Beatrice et al.	NEOVACS
US 20250312437 A1	CORONAVIRUS VACCINES	HEENEY; Jonathan Luke et al.	DIOSynVax Ltd,The Chancellor, Masters and Scholars of the University of Cambridge,Universitaet Regensburg
US 20250312433 A1	Process for Producing of Vaccine Formulations With Preservatives	BRUCHSALER; Michael David et al.	PFIZER INC.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

US 20250314636 A1	METHOD OF PREPARING AND EXPANDING A POPULATION OF IMMUNE CELLS FOR CANCER THERAPY, POTENCY ASSAY FOR TUMOR RECOGNITION, BIOLOGICAL VACCINE PREPARATION AND EPITOPETARGET FOR ANTIBODIES	MENDONÇA GORGULHO; Carolina et al.	FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD - CE,Human Cell Co.
US 20250312431 A1	VACCINES AGAINST MORITELLA VISCOSA	FUREVIK; Anette et al.	Zoetis Services LLC
US 20250312438 A1	HUMANIZED CONSTRUCTS, VACCINES, AND METHODS	Julien; Jean-Philippe et al.	THE HOSPITAL FOR SICK CHILDREN
US 20250312440 A1	CHEMICAL SCREEN OF MODULATORS FOR VACCINE ADJUVANTS	ESSER-KAHN; Aaron et al.	THE UNIVERSITY OF CHICAGO
US 20250312425 A1	COMPOSITIONS AND METHODS COMPRISING ADA-1 FOR WOUND HEALING AND VACCINE ENHANCEMENT	Spiller; Kara Lorraine et al.	Drexel University
US 12433944 B2	Vaccine composition	Biswas; Sumi et al.	SpyBiotech Limited
US 12433943 B2	Nanoparticle-based influenza virus vaccines and uses thereof	Kanekiyo; Masaru et al.	The USA, as represented by the Secretary, Department of Health and Human Services,Unversity of Washington
US 12433942 B2	Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof	Iyer; Arun et al.	Boehringer Ingelheim Vetmedica GmbH,Iowa State University Research Foundation, Inc.
US 12433941 B2	Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms	Gould; Stephen John et al.	The Johns Hopkins University,Capricor, Inc.
US 12435317 B2	Viral vaccines and methods of forming the same	Ramamoorthy; Sheela	NDSU Research Foundation
US 20250308710 A1	Systems and Methods for Designing Vaccines	Naik; Armaghan Waseem et al.	Sanofi Pasteur, Inc.
US 20250302931 A1	COLORECTAL CANCER TUMOR CELL VACCINES	Ferraro; Bernadette et al.	NEUVOGEN, INC.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

US 20250302941 A1	Application of an Immunogenic or Vaccine Composition	Blomet; Joël et al.	EYE VACC
US 20250302940 A1	PATHOGEN-LIKE ANTIGEN-BASED VACCINE AND PREPARATION METHOD THEREFOR	HOU; Baidong et al.	RONGSEN BIOTECHNOLOGY (BEIJING) CO., LTD,INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES
US 20250302942 A1	VACCINE COMPOSITION AGAINST CORONAVIRUS	NOH; Yoon Ae et al.	LG CHEM, LTD.
US 20250302936 A1	MULTIVALENT PNEUMOCOCCAL VACCINES	Besin; Gilles R. et al.	Affinivax, Inc.
US 20250304636 A1	DAP12 CONSTRUCTS AND THEIR USE TO ENHANCE DC VACCINES AND IMMUNOTHERAPIES	Eksioglu; Erika A.	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
US 20250302939 A1	VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1	Franchini; Genoveffa et al.	The United States of America, as represented by the Secretary, Department of Health and Human
US 20250302944 A1	COMBINATION OF EPITOPES AND USE THEREOF, VACCINE CONSTRUCT, METHOD OF INDUCING AN IMMUNE RESPONSE, METHOD FOR THE IDENTIFICATION OF EPITOPES	KALIL FILHO; Jorge Elias et al.	FUNDAÇÃO ZERBINI
US 20250302938 A1	RECOMBINANT SUBUNIT BASED UNIVERSAL INFLUENZA AND RESPIRATORY VIRUS VACCINES	KANG; Sang-Moo et al.	GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
US 20250302934 A1	SET DOMAIN-CONTAINING 2 (SETD2) VACCINE	ABBOSH; Philip et al.	INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCE CENTER
US 20250302896 A1	VESICULAR STOMATITIS VIRUS MARBURG VIRUS VACCINE	PARKS; Christopher L. et al.	International AIDS Vaccine Initiative, Inc.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS